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In order to understand common, complex disease it is necessary to consider not just
genetic risks and environmental risks, but also the interplay between them. This thesis
aims to develop methodology for the detection of gene-environment interactions
specifically; both by looking at the strengths and weaknesses of traditional approaches
and through the development and testing of a novel statistical method. Developments
in genotyping technology enable researchers to collect large volumes of
polymorphisms in human genes, yet very few statistical methods are able to handle
the volume, variation and complexity of this data, especially in combination with
environmental risk factors. Interactions between genes and the environment are often
subject to the curse of dimensionality, with each new variable increasing the potential
number of interactions exponentially, leading to low power and a high false positive
rate.
The Mixed Tree Method (MTM) exploits the differences between environmental and
genetic variables, by selecting the most appropriate features from conventional
methods (including recursive partitioning, random forests and logistic regression) and
combining them with new comparison algorithms which rank the genetic variables by
the likelihood that they interact with the environmental variable under study.
Results show the MTM to be as effective as the most successful current method for
identification of interactions, but maintaining a much lower false positive rate and
computational burden. As the number of SNPs in the dataset increases, the success of
MTM compared to other methods becomes greater while the comparator approaches
exhibit computational problems and rapidly increasing processing times. The MTM is
also applied to a colorectal cancer dataset to show its use in a practical setting. The
results together suggest that MTM could be a useful strategy for identifying gene-
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Epidemiology is the study of patterns and trends of disease in populations and the
factors that might influence these trends. The occurrence of a disease is compared by
time, place and person to try and quantify the difference in disease frequency over
time, between different geographical populations and between members of the same
population. The results from epidemiological work can be combined with other
disciplines to elucidate the aetiology of a disease or to try and develop public health
interventions to reduce the disease frequency.
The fundamental concepts of epidemiology originated from studying the
characteristics and trends of infectious diseases. However, many of the principles are
equally applicable to common, non infectious, complex diseases and conditions. The
field of epidemiology has now evolved to the point, in Western societies, where
lifestyle choices are an essential area of research – an arena far removed from the
infectious disease model.
Traditional epidemiology of transmissible disease is concerned with three main
factors: agent, host and environment and the interplay between them 1. The
relationships between these factors are also present between non-infectious
aetiological agents, hosts and environment. Examples of agents in complex disease
could be radiations, carcinogens or cholesterol. Host factors, also called intrinsic
factors, would be the same as for a complex disease as for an infectious disease.
Examples of host factors include genetics, age, ethnicity and physiological state.
Environmental factors, also called extrinsic factors, can affect the existence, exposure
and susceptibility of the agent or host. Environmental factors include human
population density, climate, socioeconomic factors and rare events such as floods or
earthquakes.
There are specific fields of scientific research concerned with each factor, or a
subgroup of a factor, individually. The task for epidemiology is to combine data from
a variety of disciplines in a way that attempts to explain the trends or causes of a
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disease. It is important to analyse how the environmental factors interact with the
agents and how both interact with the host.
Gene-environment interactions are relevant to such a model and to the analytical
methods associated with such a premise. In studying gene environment interactions,
this triangular model of interaction is always relevant and suitable analysis will
always take this into account. For example, in studying coronary heart disease,
cholesterol (an agent) is affected by both genetic (host) and dietary (environmental)
factors. It is important also to consider the interplay between the host and
environmental factors, for example the effect of diet on physiological characteristics.
There are different forms of interaction, involving a combination of main effects
enhanced or decreased by the presence of a different factor and interacting effects
only present as such.
In the 1970s there was a debate within the epidemiological community around the
definition of  interaction 2 and whether or not the terms interaction and synergy are
synonymous 3. However, in 1980, a paper by Kenneth J Rothman 4 found a
compromise by dividing the term interaction into four categories: statistical,
biological, public health and individual decision making. Therefore, it is important to
define the type of interaction being considered before commencing a study.
There has been a large volume of epidemiological research looking at the agent or
environmental risk factors, there has been genetic research looking directly at
candidate disease genes but there is potential to study how the two fields interact.
Understanding the interactions between genetics and the environment could both open
up new avenues of research through identifying novel genes only involved in
interactions or could help resolve some of the confusions where the same
environmental factor confers different risk to different populations.
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1.2 Public Health Implications of Gene-Environment
Interactions
“Some vegetarians with acceptable levels of cholesterol
suffer myocardial infarction in their 30s. Other individuals
seem to live forever despite personal stress, smoking and
poor adherence to a Heart Association approved diet”
R.A. Hegel (1992)
1.2.1 Historical Perspectives
The history of genetic epidemiology predates the recognition of genetics or
epidemiology as fields of scientific interest, as throughout history people have
observed similarities and differences among individuals, families, tribes and
communities. Genetics and evolution help us understand these differences; public
health techniques will help us extrapolate from these differences ways to improve
population health.
Documented examples of historic writing that unknowingly connects genetics with
public health include Plato, who in 360BC, in “The Republic” muses on mate choice
and the fact that people selecting mates similar to their own may cause them to lose
the “balancing characteristics” 5 reflects a similar sentiment to more recent work on
mate choice and the Major Histocompatibility Complex (MHC) 6. Many Victorian
authors connect people with fair complexion as being fragile and prone to fainting.
Phrases like “child bearing hips” have found their way into our everyday language
without many people genuinely considering there might be a relationship between
body shape and complications during childbirth.
The swing towards the scientific style of genetics we would recognise today began in
the 1860s with Francis Galton, who was Charles Darwin’s half cousin, creating the
statistical concepts of regression and correlation; he was the first to apply statistical
methods to the study of human differences. At the same time in Austria, Gregor
Mendel was developing his “Laws of Inheritance”. In the 1900s, Karl Landsteiner
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classified the blood groups ABO and in 1953, Watson and Crick proposed the double
stranded DNA helix as the unit of inheritance.
The progress of public health research, meanwhile, has been less consistent,
constantly adapting to new and varied health risks. The concepts of quarantine,
sanitation and medical interventions (albeit shaman and witch style interactions) have
been present in many past civilisations. Major advances in public health include
Girolamo Fracastoro proposing transferable infection in 1546, the development of the
smallpox vaccine in 1796 by Edward Jenner (heralding an age of preventable
medicine), and Louis Pasteur confirming germ theory in 1862.
It was not until the 1940s and 1950s, however, that programmes of epidemiological
research for genetic diseases were pioneered and that neonatal screening programmes
for inborn errors of metabolism, such as sickle cell anaemia or Tay-Sachs carrier
status, were established. This was the first example of a public health intervention
based on genetic epidemiology.
1.2.2 Opportunities in Public Health Genetics
Current focus in public health research is on environmental variables, however, there
are five main areas of research where genetics and public health research methods
could be used together for population benefit, these are: Ecogenetics,
pharmacogenetics, nutritional genetics, behavioural genetics and infectious disease
genetics. The more personalised medical treatments and screening, although primarily
aimed at improving individual health, could also have a knock on benefit on
population health. Although these areas are considered primarily genetic, the
theoretical basis is quite often a gene-environment interaction, with an assigned
environmental factor.
Ecogenetics
The term ecogenetics was introduced in 1971 by George Brewer as a wide-ranging
term for genes interacting with environmental factors 7. This area has since diverged
into more distinct fields for drugs and dietary variables with the term ecogenetics
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taking the more specific role of studying variables present in the environment,
including work environments. The National Research Council
(http://www.nationalacademies.org/nrc/) in America recommends that: “individual
variation be more carefully investigated and be used in standard setting and in risk
management to protect subgroups in the population”. Despite the tendency towards
smaller samples, being able to define those subgroups by their genetics would lead to
more accurate risk assessments and smaller confidence intervals as the within group
variance would be lower.
The regulatory agencies in America are interested in the prospect of being able to
create more accurate and case specific risk estimates to replace the current estimates,
that some find are so conservative that they limit other areas of industry 8. They are
also trying to change the current strategy where a single chemical or exposure is
studied separately and each health outcome in isolation 9. The tendency to study every
chemical individually is valuable for regulatory purposes but does not help with
analysis of subgroups that might be exposed to combinations of the same low risk
substances 10.
In the field of research there is a group called the Environmental Genome Project
(http://www.niehs.nih.gov/envgenom/home.htm), which is part of the National
Institute of Environment Health Sciences. It covers a large number of areas of
research including sequencing, mouse models, biostatistics and population based
modelling. The population based projects funded vary from the effects of air
pollutants and asbestos to susceptibility genes and cancer.
It is also recognised that risks may not only differ by genetic makeup but also by
stage of life, and therefore which genes are being expressed. This is of particular
concern regarding the protection of children or foetuses at crucial stages of
development. Understanding which genes are involved in teratogenesis may help
predict future health risks to newborns through environmental interaction.
A better understanding of how humans, as genetic beings, interact with their
surroundings would also help our understanding of the biological mechanisms of
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carcinogenic and neurotoxic agents with an aim to improving treatments and
identifying other harmful substances.
Pharmacogenetics
Pharmacogenetics is a specific area of genetic epidemiology where the exposure is
the drug dose and the aim is to measure how risk of adverse outcomes and levels of
benefit from treatment vary across strata defined by genotype and exposure 11. The
idea is then that pharmacological therapies are optimised based on the genetic
characteristics of the patient. It is also an important field for the development of
biological targets for interventions, such as drugs or vaccines 12.
Using pharmacogenetics it would be possible to better judge the correct
pharmaceutical treatment for subgroups of the population and to increase the
therapeutic margin for drugs. Advice is given to clinicians about tailoring treatment to
the patient but this currently involves using general doses adjusted by weight, age and
renal clearance only. These general drug dosages are normally recommended based
on their pharmacokinetics when being taken by a group of healthy people, with
normal drug metabolism levels 13. However, varying drug metabolism rates can lead
to some people developing clinically significant adverse side effects from dosages
that elicit no therapeutic response in others.
Currently, there are two sides of the problem of where to draw the line with licensing
a drug regarding side effects. A dose too high for some people is dangerous for them,
whereas recommending a drug at a low level, safe for this subgroup, may not be the
most effective treatment for the rest of the population. Drugs have been withdrawn
over side effects that could be predicted using genetic testing. For example, a test for
the CYP2D6 polymorphism that leads to a reduced ability to metabolise
debrisoquine, might have prevented the withdrawal of this drug from the market, thus
helping those less likely to suffer side effects 13 .
As well as differences in drug metabolism, pharmacogenetics also includes the study
of genes and mechanism of drug targets and the disease pathway. One such
pharmacogenetic result that has been well publicised is the breast cancer treatment
Herceptin, which is more effective for women who have the genetically determined
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immunophenotype HER2 14. Adverse drug reactions are estimated to be responsible
for 10,000 deaths per year in Britain 15. A better understanding of the causes of these
reactions would be beneficial, for example, even something as simple as a familial
trend would help establish if there was a potential genetic basis for the reaction.
Nutritional Genetics
Nutritional research has a strong emphasis on biochemical and metabolic
mechanisms, many of which are also areas of genetic research. Cholesterol fractions,
lipids and other fatty acids are risk factors for coronary heart disease, however,
individuals with cholesterol levels elevated to about the same level may require a
number of different dietary and pharmacological interventions 16. There is also
evidence to suggest both dietary vitamin D, the genetics of the Vitamin D receptor
and exposure to sunlight are associated with the incidence of Multiple Sclerosis 17.
One dietary variable that is required and processed differently in different people is
iron. Iron is needed in our diets for the manufacture of haemoglobin and other tissue
molecules, a deficiency of iron, anaemia, is the most widespread nutritional problem
around the world 18. It has been proposed in America that food should be fortified
with iron to ensure that those most at risk, children and pregnant women, do not
suffer the consequences of anaemia. However, such fortification would put a
subgroup of people, who suffer from iron overload, haemochromatosis, at risk.
Identifying people at risk could have a twofold effect. For example, the sufferers of
haemochromatosis could follow a special diet, receive regular health checks and
blood removal to reduce their iron levels. Also, it may reassure the people worried
about the side effects of food fortification with iron, if it were possible to identify the
at risk subgroup. Therefore some such foods, well labelled, could be introduced to the
market to make some progress towards reducing anaemia in the general population.
Careful studies of how people respond to different dietary and vitamin supplement




This is an extremely controversial area of genetic study due to the difficulties in
measuring human behavioural traits, such as personality and intelligence. The racial,
socio-economic and educational biases inherent in such measures are also a problem
for their analysis. Behavioural genetic studies both how human actions interact with
environmental factors to influence risk and how genetic factors might affect
behaviours.  The genes that influence the likelihood of someone partaking in an
unhealthy behaviour is sometimes called a “Gene Environment Correlation.” These
are hard to study as many families both share genes and are responsible for other
family members’ environmental exposures.  A gene environment interaction is
different from a correlation, as the increase in risk due to both genetic and
environmental factors acting together is far greater than the predicted increase from
either factor independently, but the factors are considered to be independent. Whereas
for a correlation, the effects are not independent of one another, the environmental
risk is related to the genetics and it is this relationship that provides the correlation.
Infectious Disease Genetics
Infectious diseases have influenced our genomes through natural selection for
thousands, if not millions, of years. Before the development of antibiotics and
vaccines, human populations were constantly battling diseases that led to the deaths
of the most susceptible or weakest people. Evolutionary pressure from infections
meant that the selective advantages of those carrying the haemoglobin variants S, C,
D and E, the thalassemias, or glucose-6-phosphate dehydrogenase deficiency in the
face of malaria 19 increased survival. Another possible example of a selection effect is
CCR5 homozygosity, thought to have evolved from cholera exposure, providing a
degree of resistance to HIV infection 20.
There are a number of ways that human genetics play a role in infectious disease
susceptibility and progression. Taking Chronic Hepatitis B virus (HBV) infection as
an example, human genetics plays a role in a number of categories, including:
mediation of the viral entry (binding, membrane fusion and transportation) into cells;
genes modulating the immune response to infection; the pathological alterations and
symptoms in tissue; the disease development, including control of mother to child
transmission and development of resistance to drug treatments 21.  It is also useful to
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be able to study the genomes of infectious organisms, the complete sequence of the
malaria parasite, Plasmodium falciparum, was finished in 2002 22, for example, which
can help to understand the organism and develop drug targets to fight it. Genetic
variation at all these levels provides potential for clinical interventions or preventative
strategies to benefit individuals and the population as a whole.
Screening
On a more personal health level, there are some highly penetrant genetic mutations
which account for disease clusters within families. These tend to be rare and account
for less than 5% of major cancers and coronary heart disease 23. Examples of some
well known, highly penetrant mutations include the LDL (low density lipoprotein)
receptor, where mutations can lead to large increases in cholesterol or heart disease
risk, or the BRCA1 and BRCA2 genes which confer an increased risk of breast
cancer. For the individuals affected, the health gains from early and successful
interventions are enormous. Although not targeted at the entire population, the
knowledge gained about biological mechanisms and outcomes from interventions can
benefit the population at large.
There are very successful screening programmes aimed at identifying diseases in
adults by identifying early stage symptoms, for example pre-cancerous cells.
However, these are a separate public health intervention from the genetic screening
for susceptibility and such success, or lack, does not necessarily translate to evidence
for or against genetic screening.
1.2.3 Are Genetic Studies Justified on a Public Health Basis?
There are two schools of thought that consider genetic epidemiology overrated and
that it should not be such a focus for future medical research. The first think that all
epidemiology is lacking in theory development and is not a progressive field of
research 24, 25. Then there are the epidemiologists who feel that environmental risk
factors should be prioritised over genetic ones; that it is not useful to concentrate on




Over the last fifteen years, the usefulness of risk factor epidemiology has been called
into question 27. The concern is that too much research is focused on methodology
and data manipulation and not enough on theory development, which might actually
advance our field of knowledge. It is thought that new studies into the effects of
smoking, drinking and obesity will add little to guidelines for public health policy.
There are already interventions in place to try to reduce these risk factors and there is
no requirement for additional evidence that they are unhealthy. Also, epidemiology is
only relevant to the time the studies are carried out and can therefore not justify
research for its own sake in the way of other scientific disciplines 25.
There are also problems inherent to risk factor epidemiology. The ecological fallacy
means erroneously making assumptions about an individual based on the risk of the
group or groups he belongs to. Measurement of environmental variables, usually done
retrospectively, may have substantial amounts of error. If it is the desire of
epidemiology to predict future outcomes, will the risks being measured be relevant
and have similar effects in the future. There is a strong publication bias in favour of
positive results, multiple potential confounders and the possibility that any results are
the product of chance. All of which combined makes epidemiological studies hard
work for small reward.
Such arguments can be even more forcefully applied to the field of genetic
epidemiology where interventions, if possible at all, will take years of further research
following the identification of a gene.
Genetic Epidemiology
“If causes can be removed, then susceptibility ceases to matter”
-   Geoffrey Rose
Within the epidemiological community, there are people that consider genetic
research not to be worth the time, funding and prominence that it is given.
Environmental risk factors are more easily modified and there is considerably more
evidence of their importance.
12
Epidemiology and human genetics gained authority through efficient and successful
identification of Mendelian diseases, infectious disease vectors and environmental
risks. These discoveries were easily converted to public health recommendations in
the form of prenatal testing, workplace regulations, vaccinations and other
preventative measures. However, the lack of success of genetic studies to identify
causes of complex common disease to date is seen by many as evidence that it is not a
fruitful area of research. It has been proposed that statistical empiricism and
epidemiology are not working and what is needed is a molecular based approach to
understanding the biological mechanism of disease 26. This does not include further
genetic studies, as the nature of complex disease means they are susceptible to the
same problems as basic epidemiological studies.
The Nature of Complex Disease
Any complex disease has multiple genetic and environmental components and
pathways, the relevance of which is normally confined to the discussion section of
research articles. The methods currently being employed were designed to detect risk
factors with large effects, whereas complex diseases tend to have multiple risk
factors, mostly with fairly weak effects.
One of the complications that arise from working with complex disease is phenotypic
and genotypic heterogeneity. Phenotypic heterogeneity is when the definition of the
disease is hard to classify and even a biologically specific definition can have
different disease outcomes. Genotypic heterogeneity is when a variety of different
alleles lead to the same disease outcome. This is relatively common as evolution acts
on the phenotype of traits and not their genotypes, so a number of different
components of a biological pathway could be under the same selective pressure. Even
if some of the causal components are known, trying to relate the other potential risk
factors to the web of causality and interactions is extremely difficult.
Population Risk
Even assuming genetic factors could be useful indicators of individual risk, it does
not follow that they are informative regarding population risk 28. It is extremely
difficult to gather data from individuals, extrapolate from it conclusions about a
population, and then from these conclusions apply interventions aimed at individuals.
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Other than pharmacogenetics, it can been argued that targeted interventions based on
genetics may have less impact than an intervention targeted at the whole population
29. Interventions aimed at high risk groups have not been as effective at improving
population health as general interventions, based in part on the fact that those in high
risk groups find it more difficult to adapt their behaviours away from those of the
general population.
Another reason it is difficult to make conclusions about population health is that
genetic heterogeneity is greater within populations than between populations, the
opposite of environmental risk factors. It is impossible to identify environmental
exposures as risk factors if they are uniform across the study populations (i.e. if
everyone smoked the same number of cigarettes every day, variation in lung cancer
incidence would be mostly explained by genetics). This explains why people who
emigrate tend to have similar disease rates to the country they moved to 30. This
problem is compounded when isolated populations are studied as the range of
exposure variables, both genetic and environmental, is extremely limited, compared
to an outbred population.
In terms of screening, there is some debate on whether genetic testing for complex
diseases actually adds anything to current methodologies. It has been argued that if
genetic profiling is to be considered as a public health intervention then the screening
programmes should be evaluated by the same criteria as current programmes 31 The
majority of genetic screening would fail by these standards as the excess risk
identified is too low or the knowledge of the excess risk does not influence an already
supported disease management strategy 28.
Even some of the more promising genetic studies are based on biologically plausible
theories from epidemiological analysis and do not add any information with direct
public health benefit. For example, the polymorphisms involved in oestrogen
synthesis and metabolism could identify a prognostic index for breast cancer based on
the accumulated risk of the different genotypes 32. This however, is no more useful
than measuring serum levels of oestrogen and may even be less useful as it does not
account for known environmental risk factors, such as contraception. Genetic
epidemiology does not need to prove that it could be useful in a world of research
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where nothing is known. It needs to prove that it can add to or improve current
methodologies.
Importance of Genetic Studies
When faced with trying to understand the epidemiology for a disease associated with
both environmental and genetic risk, the environmental variables are more easily
altered and more tangible. Why then investigate the genetic factors? It is because
there is no alternative 33. Many years have been spent making claims about
macroscopic risk factors and refuting such claims. The inconsistency and instability
of many claims may be due to the interplay of many more proximal factors: to study
such factors would assist the research into environmental risks, not be in competition
with it. Traditional risk factors, like smoking, obesity and diet, are composed of
hundreds or thousands of very heterogeneous factors. The benefit associated with
eating fruit results from a very complex mechanism involving taste, digestion, gut
flora, antioxidants, oxidants, fibre and many more factors. The current measure, also
fairly inaccurate, of portions per day is proving an insufficient measure. First fruit and
vegetables were found to reduce breast cancer risk 34, 35, more recently large cohorts
have found there to be no effect at all 36 claiming the results could be due to poor
controls or confounding.
In a number of studies, it is implied that the population attributable risk (the
percentage of the disease incidence that would be reduced if the risk factor was
eliminated) is entirely dictated by the risk factor in question. This is quite often not
the case; the attributable risks for a complex disease can add up to considerably more
than 100%. This is a result of the interactions amongst the various risk factors. For
example, it may be the case that both a gene and environmental factor are required for
disease symptoms, both with 100% attributable risk, leading to 200% of the risk
being accounted for. For phenylketonuria both the genetic mutation and a diet
containing phenylalanine are necessary for the disease and could eliminate the disease
if removed.
There are accusations that genetic epidemiology has not lived up to its expectations
and that such slow progression is evidence that there is not much progress to be
made. This is considered to be the weakness of epidemiology and not a sign of how
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high expectations are set for any field of research with potential. Is the twelve years
that has elapsed since the completed human genome mapping project a reasonable
timeframe within which to expect unequivocal results 37?  Normally these
expectations are set by people with only a token understanding of the area and should
be treated with caution or specialists that are exaggerating the potential of their
research to secure funding. Areas of research involving human subjects do not often
live up to the preceding hype, humans are complex and complicated and often the
most desirable research academically would be the most awful ethically. Providing a
cure is not the sole target of epidemiology, showing cause can also alleviate blame.
To imply that all mental health epidemiology has been useless because it cannot now
cure everybody would be a ridiculous claim, yet more than 150 years have passed in
which to find cures compared to the 6 years that passed between the completion of
the human genome sequence and the first criticisms of genetic epidemiology. We are
also in a very different research climate, where conclusions are now reached more
slowly but more carefully. This may add to the impression that genetic research is not
progressing as fast as other areas did. It is not slower, just more tentative.
There is also the argument that current environmental interventions are proving
inadequate: for example, obesity levels are still rising despite campaigns for
awareness of obesity related risks. Often a single contradiction to the published
evidence is enough to negate the effect of a health promotion intervention. For
example, smoking in teenage girls is often justified by them knowing someone or
knowing of someone who smoked and is not sick 38. Explaining that there may be a
genetic reason that that person is not sick may remove this line of argument and add
weight to the intervention, even if it is in some way conjecture.
Many of the arguments that are being used against genetic epidemiology do not prove
that the area of research is useless but rather that we have to approach it slightly
differently. Many models and statistical methods employed for genetic epidemiology
are perfect for analysing Mendelian traits or single gene disorders, but are not
appropriate for conditions where many variables have small effects, like complex
diseases.
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There are a number of factors that contribute to the inconsistency in gene
identification studies, making genetic effects seem less reliable or even non-existent.
Small study designs make it hard to identify effects within a sufficiently narrow
confidence interval and occasionally inappropriate controls are used, for example,
younger family members when studying a late onset condition, so their case status
cannot be accurately determined. Publication bias towards positive results may
encourage publication before verification. Most importantly though, most studies fail
to collect data on environmental variables that might modify the relationship between
genotype and disease status, meaning an association between gene and disease in one
study would not necessarily show up in a study where the population have different
environmental exposures. Instead of being contradictory, these differences may
provide new study opportunities.
1.2.4 Conclusions
The public health implications of gene environment interactions may be important in
the field of genetic epidemiology. Looking for interactions alongside gene
identification studies could help elucidate some of the contradictions and residual
variation that currently complicate genetic studies. Gaining knowledge about the
interactions between risk factors would make studies and risk estimates more accurate
and increase our understanding of the underlying biology, which in turn could benefit
the health of the population. Studying one field, whether genetic, environmental or
behavioural without acknowledging the others and possible interplay between the two
is scientific bad practice. The best way to approach complex problems is to work
together and not in competition.
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1.3 Dimensionality and Power
The number of variables in gene-environmental interaction studies can lead to low
power and a high error rate. Statistically, it is not possible to use traditional parametric
methods, such as logistic regression, for data with as many exposure variables as
genome wide association scans (GWAS). If there are insufficient outcome events
relative to the number of independent variables being analysed, many multivariable
methods, including logistic regression, produce problematic results 39. In studying
interactions, it is not simply the number of variables that are being studied but each
possible pairing of these variables.
Therefore one of the most common problems in studying interactions between
variables is the dimensionality of the problem. Every new variable added to the model
adds a dimension, with the potential interaction terms increasing the hypothesis space
exponentially. This adding of dimensions to a mathematical space can mean that the
space is enormous and the data are sparse. This is often referred to by statisticians as
the curse of dimensionality.
Taken together, the number of variables present in a GWAS and the further increase
introduced by studying interactions, there is a need to be aware of the potential false
positive rate or bias introduced through multiple testing. Initally the results from
GWAS were intended to suggest candidates for further study 40. However, the
exceedingly large multiple testing used in these studies can also miss gene variants
with small effects 41.
With such large volumes of data, an efficient and straightforward way to explore the
data sets prior to statistical analysis would be beneficial both in saving time and
preserving the value of the data.
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1.4 Research Problem
1.4.1 Definitions and Key Assumptions
The definition of “novel” with respect to the method being developed can incorporate
functions and theory from traditional methods, as long as the application and
combination is new in some way. The computer code for the overall method will be
unique to this project and thoroughly tested. The different definitions of interaction
are covered and discussed throughout.
1.4.2 Aims
The overarching aim of this thesis is to develop a novel statistical method of exploring
genetic data and identifying gene-environment interactions, given the high number of
dimensions. In order to achieve this, there are three core research components
addressing different aspects of the problem: the current methods, developing a new
method and ensuring such a method can be used, or adjusted to be used, across a
variety of data types gathered from different study designs. A final aim involves using
the method on a real dataset to identify any gene-environment interactions present.
i) Assessment of methods currently used to identify gene-environment
interactions
The first aim is to undertake a systematic literature review on the statistical techniques
commonly used on data with many dimensions. This includes papers focused on
gene-environment and gene-gene interactions, statistical theory of high dimensions,
identification studies looking for interactions and papers discussing the public health
implications of such research. This review can be found in Chapter 2, with
background on colorectal cancer and potential public health benefits in Chapter 3.
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ii) Development of Novel Method
Identifying interactions with statistically significant effects in large data sets, using a
single traditional method, would require either an enormous sample or an unrealistic
effect size. Exploring the data in order to generate hypotheses, then testing these
hypothesis, would increase the chances of an interaction being found. Exploratory
data analysis, also known as data mining, can take a number of forms including both
visualisation and machine learning methods.
There are a group of data mining methods called tree based methods, elements of
which have been combined within the novel method being proposed in this thesis. The
primary tree method is Classification And Regression Trees (CART), which search
the hypothesis space for the variable that, when dividing the data by that variable,
creates the greatest difference between subsets. Another important tree based method
is the random forests approach, which uses tree methodology, cross validation and
boot strapping to grow large numbers of decision trees (hence the term forest) to
identify the most significant variables.
These current tree methods enter all the data simultaneously and often the main
effects of the environmental variables dominate the higher splits in the tree. However,
if looking specifically for interactions between the genes and the environment, it is
possible effectively to plant the environmental variable as the tree root and enter only
the genetic data to build the tree from that root. Trees can be built from all the
different environmental variable roots and the branches analysed. The position of a
variable in a subtree and the comparison of variable positions between different
subtrees can be quantitatively assessed. Once the computer programme has run trees
for each of the environmental variables, it can assess which genetic variables show the
least consistency in branch position and identify them as potentially interacting
variables. A quantitative measure of association, such as logistic regression can then
be used to determine the risk estimates.
Another aim is to compare the novel method with the traditional methods using
identical artificial data sets with known effects sizes and a variety of underlying
interaction models. Such comparison forms the basis of Chapter 7.
20
iii) Adapting the Method to Different Data Types
The artificial data will be used to assess the performance of the method for different
data containing different characteristics and underlying, complex effects, before real
data are analysed. The aim is for the model to be flexible, or able to be adjusted prior
to analysis, for a variety of study and data types, explored in Chapter 6.
Case control data are the simplest to analyse with binary outcomes being well suited
to the tree theory. Another advantage, for most statistical analysis, is the similar
proportions of cases to controls. However, different case-control ratios will be tested
and potential adaptations for data type explored.
Continuous outcomes variables can either be stratified by cut off points or a
regression model can be fitted to the leaf of the branches. For a variable like BMI
where there are well recognised categories, it may be suitable to group the outcomes
into categories: underweight, healthy weight, overweight and obese. Such grouping in
advance is a weakness of the tree methods and may lead to a loss of information.
Therefore in this study both pre-determined and data driven cut-off points will be
explored.
iv) Application to Real Data
Once the method has been developed and its performance maximised by identifying
the parameters best suited to the real data set, an analysis of a genuine example is run.
The results can be found in Chapter 8 are compared to the relevant literature and
examined in a wider genetic epidemiological context.
The real data are from the epidemiological case control study of colorectal cancer:
Study of Colorectal Cancer in Scotland (SOCCS). The aim was prospective
recruitment of all incident cases, in people aged 16-79, of colon or rectal carcinoma in
Scottish hospitals. In order to minimise survivor bias recruitment was as close as
possible to the first admission. There were certain exclusions: patient death before
recruitment or severe illness during participation; the cancer being recurrent; and the
patient being unable to give informed consent – either due to illness or learning
difficulties. The controls were matched for age, gender and geographical region and
drawn randomly from a population based register.
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The SOCCS study was not designed with this analysis in mind and therefore is
perhaps not the way sampling would have been done if gene-environment interactions
were the primary aim. For example, matching is not the ideal approach for non
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2.1 Introduction
Many complex, chronic, human diseases are the result of numerous genetic and
environmental factors and interactions between the two. In the last ten years, there
have been rapid developments in genomics, molecular biology, population genetics
and genotyping technology. We now have large data sets available to study, yet the
analysis of these data sets has been slow to yield results and rarely replicated. The
genetic influences on many common, chronic diseases are extremely complex, they
have a pattern of family history, yet do not follow the rules of simple Mendelian
models of inheritance 42. There is often no clear autosomal, X-linked, dominant or
negative model. This could be due to the presence of the recognised, but yet
unclassified, interplay between genetics and environmental factors.
2.1.1 Aims of Literature Review
There are a number of important aims to be considered in the review of the literature
including: defining the question, reviewing previous work, the applications of such
work and the role of new research in a wider context. In order to properly define the
research question, the different possible interpretations of interaction- in terms of
biology, statistics and gene-environment interactions- were explored. The main area
of this review is an in-depth summary of current statistical methods for detecting
gene-environment interactions, both to identify their strengths and weaknesses and to
evaluate how appropriate they were for use as comparators for the methodology
reported in this work. This section is the background to the method development stage
of the project.
2.1.2 Definition of Interaction
To understand the definitions of interaction, also called synergy, it is first necessary to
understand the definition of causality. A cause which inevitably produces an effect is
termed a sufficient cause. A sufficient cause can be made up of a number of
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component causes, where the lack of any component renders the remaining
components insufficient. For example, the bacterium Vibrio Cholerae is the cause of
cholera, whereas a sufficient cause might involve lack of immunity, poor sanitation,
contaminated water or even blood group 43. A necessary cause is one without which
the disease would not happen, in the case of cholera, this would be exposure to the
bacteria.
There are both biological and statistical definitions for gene-environment interactions,
sometimes referred to as “plastic reaction norms”. Biologically, an interaction is a
situation where the qualitative nature of the action mechanism of a factor is affected
by the presence or absence of another. The model underpinning the theory of
biological definitions is additive, with interaction being suspected if the disease rates
of the joint effect exceed the sum of the separate effects. If two risk factors are
involved in the same sufficient cause, i.e. there is one pathway that confers disease
risk in which both risk factors are required, they can be said to interact biologically.
Statistically, a gene environment interaction is defined in two ways, as: “a different
effect of an environmental exposure on disease risk in persons with different
genotypes,” or “a different effect of genotype on disease risk of persons with different
environmental exposures.” For two risk factors to interact, they must not agree with
the stipulations of conditional independence: that the relationship between two factors
is the same across strata defined by a third factor. Assessing the effect of a genetic
and environmental risk factor, G and E respectively, on disease risk would involve
looking for Conditional Independence. This would mean that the effect of G on
disease risk would be the same across a range of strata defined by E. If these
conditions are not met and the effect of G on disease risk varies depending on E, an
interaction can be said to exist.
A statistical interaction would imply that for the model to fit the data well it should
include an interaction term. In simple linear regression, the non additive nature of
adding an interaction term complies well with the biological definition. However, a
logistic regression model is implicitly exponential and therefore multiplicative (only
additive following logarithmic transformation). Therefore, including an interaction
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term in a logistic regression model would imply that the interaction between the
variables is non multiplicative 44.
Some epidemiologists use the term “Public Health Interaction” to denote the
relevance of risk factors to the health of a population. In this case, if the disease rate is
not dependent on two risk factors occurring together, they are considered independent
from each other 4. If the rate at which the two risk factors occur together is higher than
expected, it is considered to be an interaction. This is very similar in definition to the
biological definition and often has a basis in biological and statistical studies with
results extrapolated to the entire population.
2.1.2.1 Biological Theories of Interaction
The magnitude and prevalence of interactions or joint actions of multiple factors in
biology is still unknown. Canalisation, first identified in the 1930s, is the genetic
capacity to buffer developmental pathways against mutational or environmental
perturbations. More recent work has indicated that “cryptic” interactions or
decanalisation may be the more common types of interaction 45, 46. The possible
mechanisms of interactions could include a number of possibilities. It is possible that
the interaction is an inherent property of a network system and that the gene effect is
context dependent, one example would be enzyme saturation in a multi step biological
pathway. The second possibility is that there is a large network of interaction
mechanisms, with positive and negative feedback regulation.
2.1.2.2 Biological Models of Interaction
There are five different biologically plausible models for how a risk genotype and an




Model A: The genotype produces or increases the
expression of an environmental risk factor, which





2.1.2.3 Gene-Environment Interactions on Disease Risk
Statisticians and epidemiologists may not regard the first model as an interaction
effect; however the other four models match up with the recognised epidemiological
definitions of gene-environment interactions, shown in table 2.1.
Model B: The genotype increases the effect of the





Model C: The genotype has an independent
effect, which is exacerbated by the environmental






Model D: Both the genotype and the exposure are






Model E: Both the genotype and the
environmental variable have independent effects
on the risk of disease. The overall effect is greater


















Absent Absent 1.0 1.0 1.0 1.0
Present Absent 1.0 1.0 Modest/High Modest
Absent Present 1.0 Modest/High 1.0 Modest
Present Present Very High Very High Very High Very High
Biologically Plausible Model D B C E
Example of a condition PKU Podoconiosis VP COPD
The first type of gene-environment interaction to be considered is that in which both
the environmental and the gene variant are necessary for the disease symptoms, either
on its own will have no effect (Model 1/Model D). A well known example of this type
of condition is Phenylketonuria (PKU), an autosomal recessive disorder that prevents
the sufferer from being able to convert phenylalanine to tyrosine. Both the genetic
variant and the presence of phenylalanine in the diet are necessary for the symptoms;
if either is absent the person is asymptomatic. There is a small subgroup that are the
exception to this rule and that is the children born to mothers with PKU, who are not
themselves genetically predisposed to PKU, who have been exposed to high levels of
phenylalanine in the blood due to their mothers enzyme deficiency. However, this can
be prevented by the mother following an phenylalanine restricted diet 47.
A second type of model for a gene-environment interaction (Model 2/Model B) is
when there is an established environmental risk, enhanced by the presence of
particular genotypes, which, on their own confer no increase in risk. An example of
this is podoconiosis, also know as non-filarial elephantiasis, which is a chronic and
debilitating disorder endemic in regions where people are exposed to red clay soil
derived from volcanic rock. The main symptoms are oedema of the foot and lower
leg, caused by silica particles absorbed through the foot, causing an inflammatory
reaction and destruction of the vessel lumen 48. Only a small proportion of people
exposed to red clay develop podoconiosis and that the disease tends to cluster in
families 49. Following a segregation analysis, they found that the most likely
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explanation was that of an autosomal co-dominant gene, with age as a significant co-
variate and wearing shoes having a protective effect 50. This model fitted the data
better than a model based entirely on environmental risks.
Another condition where the environmental risk is amplified by different genotypes is
xeroderma pigmentosum (XP). Exposure to ultraviolet light is a risk factor for
developing skin cancer. In combination with XP mutation, the risk becomes very
high. Although not possible in practice, if an individual with the XP mutation avoided
UV light altogether, they would have a similar skin cancer risk to the background risk
51.
In the third model (Model 3), a gene confers an increase in risk, yet the risk is
enhanced or changed in some way depending on the environmental factors. An
example of this is porphyria variegata, also known as variegate porphyria, (VP) an
autosomal dominant disorder whose symptoms include abdominal pain,
neuropsychiatric manifestations, sun sensitivity and blistering easily. Exposure to
barbiturates, which is harmless for most people, for people with VP can lead to
paralysis or even death 52. The symptoms are caused by a partial deficiency of
protoporphyrinogen oxidase (PPOX), PPOX is a mitochondrial enzyme involved in
the haem biosynthetic pathway 53. Mutations in the gene coding for this enzyme lead
its deficiency and the resultant symptoms. The symptoms are worsened considerably
on exposure to barbiturates.
Similarly a gene mutation might behave differently and develop new associated risks
when exposed to different environmental variables. There are some genes involved in
repair or oxidation pathways that might be a risk factor for a number of different
cancers, including the CYP1A1 gene, with reported independent association with lung
cancer risk 54. Some studies have reported a relationship between coffee consumption
and ovarian cancer risk 55, 56 and others have dismissed such claims completely 57.
However one study has documented a gene-environment interaction involving coffee
and a variant of the CYP1A1 gene 58. The study have found that having the gene
variant alone does not increase risk of ovarian cancer, yet if people with this variant
drink above median levels of caffeine, their risk of developing ovarian cancer is
significantly higher.
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Finally, if both a gene on its own and the environmental risk alone are associated with
an increase in risk, but together the risk is significantly higher than the additive risk of
both independent risks, this is a model of gene-environment interaction (Model 4). An
example of this is Chronic Obstructive Pulmonary Disease (COPD), expected to be
the fifth leading cause of disability by the year 2020 59. The most established
environmental risk factor for COPD is smoking 60, 61. There are other important
environmental risk factors including childhood infections, air pollution and
occupational exposure. However, there are also indications of a genetic component,
one that may interact with the environmental variables 62. For example, severe α1-
antitrypsin (AAT) deficiency, normally the result of a PI ZZ or PI Znull genotype,
combined with smoking leads to more severe pulmonary impairment at an earlier age
63. There are also reported variants of the CYP1A1 gene reported to interact in this
way 64. Further studies are needed to help clarify their finding as the segregation and
linkage analysis approach used by Janus in 1985 assumes no interactions.
2.1.3 Variables
In the search for interaction effects, care must be taken when selecting each variable,
whether environmental, genetic or outcome. The environmental exposure can be
physical, chemical, biological, behavioural or a life event.  When quantifying an
environmental risk factor, it is important to consider how purely environmental a
variable is.  Usually gender and age are considered in the environmental exposure
category, when both could also be considered genetically determined. Other factors
that are classed as environmental may also be influenced by genetics, obesity, for
example or even alcohol consumption.  Thus it is important to investigate and think
about each environmental exposure prior to analysis.
2.1.4 Studies and Analysis
For each new hypothesis or exploratory study it is also necessary to plan the most
appropriate study and analysis method in advance. Often, the study to identify
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interactions follows from a gene identification study or an environmental risk factor
study that has shown unexpected results. More recently there have been studies
primarily aimed at identifying interactions and methods adapted appropriately.
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2.2 Search Strategy for Reviewing Literature
2.2.1 Search Tools
Initial searches were done using MEDLINE (National Library of Medicine), with the
saved searches repeated in EMBASE (Excerpta Medica). After the results from the
initial searches had been analysed, the references from relevant articles, or articles
with a relevant section, were searched through and entered into an EndNote database.
Once an article had identified a research group with a relevant interest, PubMed and
Google Scholar were searched by author name for further articles from the same
group. If an article was a basic introduction to a concept, a cited search was used to
find any more recent articles that had cited the work. When back referencing from
articles, Google scholar proved the fastest and most efficient way of finding the
required article. When searching for specific articles, the other articles identified as
most similar were also briefly read and assessed for relevance.
2.2.2 Basic search
There were two basic searches that were repeated for most of the subheadings. As the
literature review was concerned with both genetic research in general and the more
specific studies for gene-environment interactions, the first search looked for general
papers on genetic studies. If any interaction studies are found from the basic searches,
they were categorised as such and efforts were made in the search for gene-
environment studies to ensure the same studies are identified by the criteria.
2.2.3 Inclusion/Exclusion criteria
For an article to be included, it needed to come from a credible scientific source. All
types of paper were considered; whether reviews, commentary, specific studies or
meta-analysis. They needed to focus on either a particular gene or genetic studies.
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A study was excluded if the evidence was primarily lab based or methodological or if
the primary study aim was not for humans. Studies with small sample sizes would
only be used anecdotally if there were no other, more suitable, articles.
2.2.4 Search Methodology
In place of a second independent researcher repeating the search for inconsistencies,
the entire search was discussed with the medical librarian, who crafted the search to
maximise the results from the search engines involved. This was considered a suitable
subsititute considering the timescale of repeated searches and the complexity of the
subject matter.
There were common search terms used throughout, shown below. In each case the
search was limited to humans and a variety of genetic and interaction synonyms were
used.
An initial list of statistical methods was obtained through reading the “methods”
sections of the papers that had been useful in defining interactions. This was followed
by a search based on synonyms of “method” or “methodology,” before specific
searches for each of the methods identified, using both their full names and acronyms.
The initial descriptive paper for each method was tracked down, even if it was not
directly relevant to gene-environment interactions. Papers comparing methodologies
in high dimension data or for interactions were considered the most relevant. Possible
bias of papers proving the superiority of a single method was taken into account and
additional papers identified.
The basic search is shown below, with steps 5 and 6 only used when additional papers
were needed, usually for specific examples where the environmental variable would
be described as “BMI” or “eating carrots” without using the term “environment” or
“exposure”
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1. (1polymorphism$ or allel$ or genotyp$ or phenotype$ or isoform$ or
mutation$ or gene or genes or genet$).mp. [mp=title, original title, abstract,
name of substance word, subject heading word]
2. Limit 1 to humans
3. (environment$ or exposure).mp. [mp=title, original title, abstract, name of
substance word, subject heading word]
4. 1 and 3 and interact$.mp. [mp=title, original title, abstract, name of substance
word, subject heading word]
5. 1 and interact$.mp. [mp=title, original title, abstract, name of substance word,
subject heading word]
6. 5 not 4
Abstracts were read and relevant papers selected, followed by citation searches using
both back referencing, the citation tracker application and extracting relevant
references from said selected papers.
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2.3 Review of Statistical Methods
2.3.1 Introduction to Statistical Methods
There are a variety of statistical methods which have been developed to analyse the
relationships between large numbers of genetic and environmental variables and
disease status. Given the complexity and variety of gene environment interactions,
there is no single, straightforward, statistical method that can accurately identify all
possible types of interaction in all possible datasets. The following chapter discusses
the strengths and weaknesses of the available statistical methods, including gene
identification methods; epidemiological methods that can incorporate interaction
terms; and methods that are designed to tackle a specific type of interaction between
variables. It is important to first cover what is being measured, the data and the
sources of the data in order to understand the methods themselves.
Significance and Estimation
When using conventional statistical/epidemiological methods to test for association
between exposure and disease, there is a difference between significance testing and
estimation; over the last fifteen years, there has been a move away from pure
significance testing towards estimations or presentation of both 65.  Significance is
testing whether or any differences in the data could have been produced by chance
from variation during sampling and is normally in the form of a p-value (a value
representing the likelihood of these results occurring by chance). p-values do not
describe the magnitude of the relationship nor the statistical uncertainty surrounding
the results 66. Estimation involves quantitatively measuring the magnitude of an
association producing a point estimate and a confidence interval around that estimate.
This gives more information about the relationship between an exposure and an
outcome and allows better assessments of its implications for interventions or further
studies. In studies where non-statistically significant results are found, having a point
estimate and confidence interval for an odds ratio instead of a p-value can help
interpret the findings appropriately. For example, if the confidence interval is very
wide, but only includes a value of close to 1.0 at one extremity of this interval, this
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may indicate that the sample size was too small to yield statistically significant
results.
Covariance
Statistical measures such as standard deviation and variance only work on data of a
single dimension. As disease phenotype and gene-environment interactions
incorporate multi-dimensions, the measure used to assess how much the dimensions
vary from the mean, with respect to each other, is called covariance. Covariance is a
statistical measure of the variance of two random variables, observed or measured in
the same mean time period, that tend to vary together; when one of them is above its
expected value, then the other variable tends to be above its expected value too. In
this case the covariance between the two variables will be positive. The covariance
would be negative when one variable is above and the other below their respective
expected values.
Additive and Multiplicative Models
An additive model is one in which the effect of a risk factor or treatment will
correspond to an absolute change in the outcome variable for all the members of the
population under study. In a multiplicative model, the change will be proportional
based on the previous values of the study population. For example an additive model
will increase disease risk for every member exposed by 10%, so someone with 20%
risk from other factors would now have 30% and someone with 60%, 70%. A
multiplicative model increasing risk by 10% would increase the first risk from 20% to
22% and the second from 60% to 66%.
Accuracy Estimation Methods
It is important, especially when mining large data sets, to ensure that hypotheses
suggested by the data are not being tested by the same data (sometimes referred to as
Type III errors) 67. To prevent this, different subsets of the data from those used for
the model building or hypothesis generation can be used to validate findings and these
are called accuracy estimation methods. A number of different exploratory methods
being reviewed incorporate this approach.
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The most commonly used method for estimating accuracy of results is cross
validation, also known as rotation estimation. The data is randomly split into x
approximately sized, mutually exclusive subsets. The method being validated is then
trained (using data minus a subset) and tested (using the subset) x times and the
accuracy estimated by dividing the number of correctly classified outcomes by the
total number of outcomes 68. The way cross validation is normally integrated into a
study is shown in Figure 2.1. However, cross-validation may be wasteful of the data,
with splitting the data leading to a smaller derivation set. In studies requiring a large
sample size other methods should be considered.
One more efficient method in terms of sample size is bootstrapping 69, where the
properties of an estimator are estimated by sampling from an approximate
distribution. To generate an approximate distribution, the original dataset is randomly
sampled and some members of the data are replaced by repetitions of other members.
There is also “leave one out” validation, where one variable is removed at a time and








Validate using 10x cross validation
Select Best
Figure 2.1 Cross Validation in Practice
38
2.3.2 Data
All the data is of the traditional DNA variety, using genetic code variations from the
four bases (A, G, T and C). This corresponds to the real dataset under analysis but
does not consider epigenetic or copy number variations. Aside from these more
molecular based genetic markers, there are a number of quantitative genetic data types
used for analysis. These include: Variable number of tandem repeats; microsatellite
polymorphisms; Candidate SNPs; Haplotypes and Genome Wide Scans.
Variable Number of Tandem Repeats
Some studies identify variable numbers of tandem repeats, patterns of two or more
nucleotides repeated directly adjacent to each other. Two nucleotides is a dinucleotide
repeat, three is a trinucleotide repeat and a group of more than ten nucleotide repeats
is considered a minisatellite.
Microsatellite Polymorphisms
Microsatellites are simple sequence repeats (SSQ) between 1-6 base pairs in length
that, when polymorphic (ie vary between individuals) can be used as markers in
genetic studies.
SNPs
Single Nucleotide Polymorphisms (SNPs) are DNA sequence variations in which a
single nucleotide differs between individuals. Within a population, SNPs are assigned
a minor allele frequency that describes the frequency of the least common allele at
that locus. This can vary by population or ethnic group. Traditionally, sequence
variants with a minor allele frequency greater than 1% were considered SNPs 71.
SNPs can lie anywhere on the genome: within non coding regions, coding regions or
intergenic regions between genes. SNPs in non-coding or intergenic regions may still
have an effect on phenotype as these regions can be involved in the regulation of
transcription. Those in coding regions are divided into two groups, synonymous and
non-synonymous, depending on whether the nucleotide change results in a different
amino acid in the translated protein chain. The non-synonymous changes can result in
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stop codon (a Nonsense, Ns, mutation) or a different amino acid (a missense
mutation). NsSNPs, together with SNPs in regulatory regions, are believed to have the
highest impact on phenotype 72.
SNPs are widely used in genetic epidemiological studies as markers of genetic
variation, there are databases: GenBank, dbSNP and a number of disease studies that
collate SNP data.
Haplotypes
In genetic analysis, a haplotype is a set of SNPs at multiple loci, transmitted together
on one chromatid. For example, a first locus with the alleles G and C has the possible
genotypes GG, GC and CC. A second locus has A and T, has the combinations AA,
AT and TT. Therefore, across these two loci, there are nine possible genotypes. If a
person is homozygous at one or both loci, for example genotype AGAC or AGAG, it
can be deduced that the haplotypes are AA, GC and AA, GG respectively. Haplotypes
are more complex when the person is heterozygous at both loci. There is collaboration
among scientists worldwide working together to develop a haplotype map of the
human genome. This is called the International HapMap Project
(http://www.hapmap.org).
Genome Wide Scans
A genome wide scan (GWS) involves the genotyping of a large number of markers
across the entire genome. The first genome wide association study (GWAS) was
published in 2002 73. There have been many other studies since, including two
studying Age Related Macular Degeneration (AMD) that complement each other and
are therefore encouraging regarding the consistency of such a blanket approach 74, 75.
Although using such large numbers of genetic markers with traditional
epidemiological statistical methods reduces the power for detecting interactions and
increases the problems associated with multiple testing, the combination of GWS data
and hypothesis driven research may aid advances in interaction research by having the




The environmental variables in many disease studies are measured as part of the
research, through either biological measurements (weight, blood chemistry); through
questionnaires; from clinical records or observations taken by the researcher. There
are a number of different methods for collating and measuring environmental
variables for use in an epidemiological study. The methods of data collection and
analysis are decided at the start of the study and take into account the most
appropriate design for the study questions, time, cost and feasibility.
2.3.3 Statistical Methods for Gene Identification and Detection of
Interactions
There are a number of different approaches attempting to describe gene-environment
interactions. In some cases the idea of interactions is only explored when there is a
prior hypothesis of interaction effects, either following a gene identification study or
when biologically plausible.
There are also methods which attempt to visualise the data and integrate human skills
into the data exploration process, through distorted overview displays and dense pixel
displays 78 using human perception abilities to draw conclusions. This is intuitive,
requires no understanding of complex mathematics or statistics and deals well with
complex data. It is also possible to use clustering of parallel co-ordinates 79 or
principal components 80. Although, these methods may provide an invaluable method
of generating a testable hypothesis for further study, they are not on their own a
statistical method which can be consistently verified or compared and are therefore
not useful in the context of this study.
2.3.4 Evaluation of Searching Methods
It is generally accepted that the influence of a particular gene is dependent on the
context defined by other genes and by the environment. However, much of the
literature, even when acknowledging this complexity, tends to focus on identifying
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and characterising the effects of a single locus and the effects of the loci on
variability. Such analysis is based on the assumption that interacting loci can be
identified individually by their independent, marginal contributions to variability
within a phenotype. This approach does not consider the possibility that the role of
multi-locus functional genetic units is larger than that of single locus effects in
influencing trait variation 81. Single locus methods are only useful for studying single
gene disorders or disorders caused by a single locus within a gene, but cannot detect
complex patterns 82. Single locus methods are not appropriate for studying complex
disease as many genes may have marginal or non existent independent effects but
contribute to a complex disease through their interactions with other genes 83.
2.3.5 Areas of Interest in Identifying Gene-Environment Interactions
Given the problems associated with large data sets and trying to identify interactions
between variables within such large volumes of data, there are seven main areas in
which the methods of analysis can be assessed and compared.
Dimensionality
The first problem in analysing data looking for gene-environment interactions is the
dimensionality of interaction datasets. It is difficult to use many methods of analysis
on data with so many variables, as the number of potential interactions increases
exponentially as effects are added to the model. At such high dimensions, the data
across numerous combinations of factors will become very sparse, with many cells in
a contingency table containing little or no data: the curse of dimensionality. Any
parameter estimates obtained would therefore have very large standard errors, which
would increase the likelihood of type 1 errors 84.
Interactions
The second criteria for assessing the methods is how well they can detect interactions
specifically, even for variables that have no, or marginal, main effects. A number of
methods may detect interactions if they confer additional risk on top of the risk of the
combined main effects, but would completely miss variables whose effect was
dependent on interactions.
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Power and the Effect of Sample Size
For every tested locus, there is the possibility of a type I error; therefore the power
can be very low even when studying large data sets. Adjusting for multiple testing,
using Bonferroni correction or False Discovery Rate (FDR), also leads to a decrease
in power. Therefore, for a method to identify interactions successfully from a large
data set, it must make some attempts to preserve power.
The problem of power is exacerbated by modest sample sizes, as considerably larger
sample sizes are required to identify interactions than to detect main effects. If the
numbers of events, or cases of a disease, are too few relative to the number of risk
factors being tested, many methods are unable to accurately identify even the
variables related to disease risk, ie the main effects, and will certainly not be able to
identify interactions. This is quite closely related to the curse of dimensionality, yet
would yield slightly different problems for parametric and non-parametric methods.
Marginal Effects
The fourth limitation of many methods in analysing genetic data is that many genes
for complex common diseases have fairly small effect sizes. The ability of a method
to identify risk factors where the relative risk is lower than 2 is an important criterion
for effective analysis of genetic data.
Different Genetic Models
There are a number of different genetic models: dominant, partial dominance,
dominant negative, recessive and co-dominant. There are also a number of ways that
genetic factors behave differently than traditional environmental variables when
related to disease risk. For example, genetic heterogeneity, where a single disorder or
condition can be caused by different allelic or non -allelic mutations.
Computational Intensity
Another factor that can inhibit a statistical methodology is computational intensity.
Although many modern computers can handle large data sets, the software may not
translate well between systems and understanding the output can be time consuming




Finally, some methods deal so exclusively with theoretical statistics and the
hypothesis space that the results cannot be translated to be of practical use. It is
therefore important that any results gained from a method can be directly applied to a
study population.
So in summary, the seven areas of interest to this review are:
1. Dimensionality
2. Interactions
3. Power and the effect of sample size
4. Marginal Effects
5. Different genetic models; dominant, co-dominant etc.
6. Computational Intensity
7. Applicability of Results
To these ends there is an assortment of statistical methods that fill a number of the
above criteria and are worth investigation into their suitability for identifying gene-
environment interactions in large data sets. The statistical methods under
consideration in this review are summarised in Table 2.2:
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Table 2.2 Summary of Statistical Methods for Interaction Analysis
Linkage AnalysisBasic Gene Only
Methods Association Studies
Multiple Regression
Logistic Regression with Stepwise Selection
ANOVA/ MANOVA
Truncated Product of P-values
Hotelling’s T2 test
Multivariate Adaptive Regression Splines (MARS)
Conditional
Methods
Generalised Additive Models (GAM)
Feed Forward/ Back Propagation NN
Parameter Decreasing Method (PDM)/ Parameter
Increasing Method (PIM)










Approaches Multiallelic Set Association (MSA)
Singular Value Decomposition (SVD)Spectral Methods
Principal Components Analysis (PCA)
Combinatorial Partitioning Method (CPM)
Restricted Partitioning Method (RPM)
Combinatorial Searching Method (CSM)
Multifactor Dimensionality Reduction (MDR)
Generalised MDR (GMDR)
Odds Ratio MDR (ORMDR)
Combinatorial
Methods
Focused Interaction Testing Framework (FITF)
Patterning and Recursive Partitioning (PRP)







2.3.5.1 Basic, Gene-only Methods: Linkage and Association
Both linkage and association identify disease genes as being in the vicinity of a
marker locus 85. However there is a fundamental difference between a “necessary”
disease allele with a penetrance between 90 and 95% and a “susceptibility” allele
which confers an increase in risk but is neither necessary nor sufficient 86.
One approach to mapping disease genes involves scanning the entire genome for
genes related to disease, in a hypothesis independent manner, by looking for regions
that have been passed down through the generations largely intact from the founders
of a population. Evidence for the ancestral segments looks for sections of DNA that
are more commonly shared than would be expected from the relatedness of subjects,
this difference is called “linkage disequilibrium”(LD). This parameter is also used to
detect the presence of variants near or in disease genes 85. If the presence of the allele
is necessary for the disease to occur, the disease locus may be separate from the
marker locus and in linkage disequilibrium with it, unless the association is complete.
Although predominantly used for case-control studies, LD can be observed in samples
of affected sib-pairs that are independent from one another. The level of linkage
disequilibrium is influenced by genetic linkage, mutation rate, recombination rate,
random drift, non-random mating and population structure.
Association between genetic polymorphisms occurs when, due to genetic linkage, the
association of the marker and disease alleles is non random. This occurs as a result of
their proximity on the same chromosome and the fact that they are more likely to be
inherited together.
Association studies can be direct or indirect 87 but are always based on the hypothesis
that genetic variants affect disease susceptibility, even if they are neither necessary
nor sufficient for disease to occur. Direct association studies catalogue all common
variants and try and identify the disease susceptibility genes directly from the sample.
Indirect studies use a smaller number of markers and incorporate LD measures to
identify genes in the vicinity of a marker gene.
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A large part of the rationale for searching for complex disease genes within families is
the observation that having a parent with the disease confers an increase on risk in the
offspring. These similarities between offspring and parents are attributable to the
additive rather than the interactive effects of genes 88. It could be argued that parents
and offspring may share environmental exposures, however these are at such widely
different times (childhood compared to adulthood) that the shared effects would not
necessarily be expected to have the same effects. Statistically, a simple genotypic or
allelic association with a dichotomous trait can be measured using a chi-squared test
for significance.
It is extremely difficult for an association study to detect interaction effects as
association approaches are designed to identify main effects. Interactions can affect
power to detect genetic effects and limit the scope for replication in other studies 89.
2.3.5.2 Parametric Methods
Conditional Methods
Most traditional, conditional methods fall into the category called Generalised Linear
Models (GLM), which use least squares regression to study the relationships between
independent variables and outcome. This involves combining the model parameters,
or regression co-efficients, to create a regression equation of the standard form:
Y = β0 + β1X1 + β2X2…. βnXn + ε
The category of generalised linear models includes linear regression, logistic
regression, log-linear regression, ANOVA and Poisson regression. Logistic regression
is the most commonly used, especially for case control studies. However, all these
methods have a great deal in common.
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Linear Regression
Linear, or multiple, regression develops a model that uses a combination of values
from continuous explanatory variables to predict the continuous value of a dependent
variable.
Logistic Regression
Logistic regression relates a discrete outcome variable, for example case or control
status, following a binomial distribution 90, to a set of explanatory variables, that can
be discrete, continuous, binary or a selection of data types. The logistic function is
used for such varied data as it can convert any value as an input value and use it to
compute a value between 0 and 1. This prevents the calculation of impossible
probabilities in cases where risk is combined or stratified in more complex analyses.
The actually methodology for logistic regression is different that the straightforward
calculation in linear regression. The process is iterative, repeating cycles of
calculation of maximum likelihood. It is possible to start with all the variables in the
model and remove the least significant variables sequentially (backward selection), or
start with an empty model and add in the most significant (forward selection). It is
also possible to select the variables using a combination of forwards and backwards
steps, called stepwise regression. Stepwise regression can have different, pre-
determined starting points, depending on previous knowledge. It is also possible to
start with variables known to have strong effects. After the first round of variable
selection, the method can implement a stepwise procedure and work forwards and
backwards to find the best model.
Analysis of Variance (ANOVA)
ANOVA is a branch of statistics originally devised by Fisher 91, and describes a
collection of statistical methods where observed variance is partitioned into
components using categorical explanatory variables. It is possible to use regression to
fit an ANOVA model and use ANOVA to examine complex regression models, as it
partitions the sum of squares variance into between group variance and within group
variance.
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As complex diseases have, by definition, several dependent variables, the ANOVA
model most suited to investigation of the association between exposures and outcome
is Multivariate ANOVA, or MANOVA. This technique attempts to identify the
interactions among the independent variables and the association among dependent
variables where there is more than one (correlated) dependent variable and the
dependent variables cannot be combined. However, as each variable adds another
degree of freedom, this technique is used in conjunction with a prior hypothesis.
Regarding gene-environment interactions, there are at least three problem areas in
using ANOVA for analysis 92. Firstly, there is always less power for detecting
interactions than main effects as interactions are measured using sub-groups of the
data and therefore smaller sample sizes and their detection is dependent on the size of
their main effects. Secondly, estimates of main effects are inconsistent when
interactions are present and this unreliability is increased in the presence of an
unbalanced study design. Thirdly, as the gene frequencies are often unknown, their
estimated effects are difficult to estimate making it difficult to apply results from an
ANOVA study to other populations. Logistic regression, on the other hand, using
contiuous explanatory variables, makes it possible to obtain a risk estimate directly
from the regression co-efficient.
Other Conditional methods
There are a number of other statistical methods that rely on prior knowledge, a
testable hypothesis or on good evidence for a loci or set of loci. They all have been
developed to combine evidence from individual markers to test an overall null
hypothesis that there is no association between the markers and the disease
phenotype. In order to extend such a method to incorporate interaction effects would
rely on specifying the potential interactions before analysis. One method that focuses
on differences between populations, instead of within population is line cross analysis
(LCA) 93. There is the standard Hotelling’s T2 test 94, considered for genetic data by
Xiong et al 95 or an adapted version of Hotelling’s T2 test to deal with haplotype data
96.
Other methods include multivariate adaptive regression splines (MARS) 97, truncated
product of p-values 98, Generalised Additive Models and the global U statistic, which
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combines univariate U statistics using generalised least squares 99. These methods are
not specifically designed to identify interactions, especially for variables with small or
no main effect.
Some examples of practical uses where such methods have touched on interactions
include using MARS to study multiple genetic contributions to hypertension 100, 101.
Hotelling’s T2 test is mainly used to study data on serum or microarray markers 102,
103.
Evaluation of Conditional Methods
Regarding the seven areas on which these methods are being assessed, logistic
regression performs poorly in high dimensions, due to a high rate of false positives
104, which may be helped using stepwise selection. If the least absolute shrinkage and
selection operator (LASSO), which minimises the residual sum of squares using
penalty terms and structure detection, is applied, the co-efficients of the predictors
with marginal effects is recoded as zero 105. This allows a subset to be selected from
the larger set for further analysis. As conditional methods rely on a prior hypothesis or
candidate variables, they are not designed for mining large data sets.
In identifying interactions, logistic regression is not particularly effective unless the
specific interaction is entered as an interaction effect, which would require a prior
hypothesis. Using forward selection, only variables with a significant independent
effect would be fitted and tested for interaction effects. This approach would miss any
gene variations with interaction only effects. This could be overcome using
backwards or stepwise selection, but then there will be an unmanageable number of
degrees of freedom. The lasso shrinkage would also lose any interaction dependent
risk factors and would therefore be inappropriate for detecting interactions.
Backwards selection also does not work if the ratio of cases to possible predictors is
too low and is therefore not practical with small sample sizes. Stepwise selection
could be used but has a tendency to be over optimistic with results and, although
technically possible, is not recommended for such high variables to case ratios 106.
To ensure sufficient power, conditional methods require a reasonable case: variable
ratio, with estimates for the minimum number of events per variable ranging from 10
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to 20. ANOVA in particular is very sensitive to noise or error and could therefore
have trouble identifying marginal effects, although no conditional method would find
a significant, yet small, effect when there were a high number of variables under
study.
Also, the scale used to measure clinical variables may not correspond well to the scale
on which genetic and environmental variables act. Transforming the scale, for
example changing the scale to logarithmic, which is useful for many analytical
approaches, assumes the absence of gene-environment interactions on the original
scale. Such changes to the scale might actually make it more difficult to identify
interactions 107.
As logistic regression models the relationship between predictors and disease risk for
each individual, it cannot recognise subgroups with different gene to disease
relationships. Therefore it cannot handle genetic heterogeneity well. The manner in
which the data were entered would dictate if different dominance effects could be
identified. The markers could be entered, with each variation as a positive or negative
for a dummy variable, or they could be entered as haplotypes.
Given how high the degrees of freedom are when dealing with complex disease
variables, none of these methods would be powerful enough to identify an interaction
even in a large data set.
One advantage of both logistic regression and ANOVA is the ease with which widely
available software can compute them and the large number of packages available
which can be used to analyse data in this way. The greatest strength however, is that
the results obtained from a conditional methods approach would be widely applicable
to the population from which the sample was obtained.
Neural Networks
Artificial neural networks, often simply referred to as neural networks (NN), are non-
linear statistical data modelling tools. They are not specifically a parametric or non
parametric method as they provide large but not unlimited numbers of parameters.
They were developed for tasks involving pattern recognition, signal filtering and data
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classification 108. They are based on the complex pattern of connections and processes
used by our brains and are used in biology for analysis that is too complex and
computationally intensive for traditional methods. Neural networks can be used to
distinguish loci that are involved in an interaction, but have no main effect, from those
that have no effect on the disease.
A neural network consists of an input layer, an output layer and one or more hidden
layers. All the layers are composed of neurons (also known as units or nodes) and
work in parallel with each other. The neurons of one layer are connected to the
neurons of the next layer, with weights assigned to these connections. The weighting
is the number of connections, for example in a case with 8 input neurons, 4 neurons
on the hidden layer and a single output node, the weight would be (8*4) + (4*1) = 36.
The number of input and output nodes is determined by the nature of the data, but the
number of hidden layers, the parameters and configurations of the connections can be
adjusted to optimise the analysis.
The process of developing a neural network involves splitting the data into a training
set, used to calibrate the parameters of the network, and a testing set from which real
results can be established. There are a number of different processes that take a
network from a useless, basic premise with no set parameters to a useful data mining
tool. However, only three are particularly suitable for the data type and study of gene-
environment interactions: feed forward network (FFN), genetic programming
optimised neural network (GPNN) and the parameter decreasing method.
Feed Forward Network (FFN)
The most commonly used type of neural network is the “feed forward” network
(FFN), also known as the “back propagation” network (BPNN). This is the simplest
neural network developed as the information only moves in one direction, forward,
and there are no hidden loops or cycles in the network. In a feed forward structure, the
information flows from the input layer, through the neurons of the hidden layers to the
neurons of the output layer 109.
The earliest and most basic neural network is also referred to as a single layer
perceptron, where the inputs are fed directly to the inputs via a selection of weights.
52
Each node calculates the sum of the input and the products of the weights and if it
reaches a certain threshold, fires and assigns itself an activated value. The activated
value is usually 1 and the deactivated value -1. A multi-layered perceptron consists of
multiple layers and neurons, with each neuron in one layer having directed
connections to the neurons of the next layer.
The appeal of neural networks is that they can learn from the training set of data and
reduce the error (the difference between the calculated output and the expected
output) through a series of repetitions. The most commonly used learning technique is
called back propagation, where the error is fed back through the network to adjust the
weights of each connection. This is repeated until the error is small and the network
can be said to have learned the target function.
There are a few problems with this method, the main one being that the network may
overfit the training data and fail to capture the true statistical process generating the
data. Stopping the process early, after a pre-assigned number of repetitions can
minimise this problem, as can ensuring there are a large enough number of cases in
the training set.
Other types of neural network that are extensions of the feed forward network but not
suitable for this study include: the Radial Basis Function (RBF) which works best in a
small hypothesis space; the computationally intensive Kohonen self-organising
methods; the Stochastic neural networks, most useful for studies in which some
variables are unknown; and the modular neural networks, which separate the network
into several small networks.
Feed forward neural networks have been used extensively in genetic epidemiology
from basic testing of the method 110, 111 to gene identification studies for outcomes of
interest 112-114. Neural networks have been shown to reliably select SNP combinations
that are associated with a multifactorial disease, childhood asthma 115. However,
neural networks have shown most promise in combination with other methods or
variable selection procedures.
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Parameter Decreasing Method (PDM)
A parameter decreasing method (PDM) can be used to select the important SNPs from
a large sample of SNPs, before entering them into a neural network 115. This is done
by deleting one SNP and creating a model from the other SNPs, then replacing that
SNP and deleting another one before making a model with the then remaining SNPs.
This is repeated for all the SNPs and the models are compared. The missing SNP that
correlates with the model with the lowest misclassification error is removed from the
sample and the process repeated, deleting all the SNPs one by one. This is repeated
until there is only one SNP left, the most important SNP. Then the other SNPs are put
in order of importance. A model containing the 10 most important SNPs had the same
prediction accuracy as a model containing all 25 SNPs in an experiment 116. A
permutation test can determine whether one of the selected SNPs is associated with
the disease 117.
The PDM – neural network combination has been used to identify SNP combinations
associated with childhood allergic asthma 115, and to select a set of ten important
variables in postprandial lipaemia as a risk for cardiovascular disease 118.
Parameter Increasing Method (PIM)
The parameter increasing method (PIM) is the reverse of the PDM, starting with each
single variable and selecting the best model before adding all the other possible SNPs
individually and selecting the best model again 119. PIM has been used in conjunction
with neural networks to identify SNP combinations related to H. pylori susceptibility
119.
Genetic Programming Optimised Neural Network (GPNN)
One method that attempts to optimise the neural network architecture by using a
machine learning approach called genetic programming (GP), is called genetic
programming optimised neural network (GPNN) first proposed in 1991 120. The
premise of GP is based on the principles of natural selection, with the fittest models
and their offspring surviving to the next generation. As well as optimising the
weights, GPNN employs a set of inputs selected from a larger set of predictors. The
method was developed in 2003 with a view to identifying gene-gene interactions 121.
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A sample of all the possible GPNN models is generated, each with a random selection
of predictors taken from the larger set. The initial GPNN models may vary from one
another in size. The models are assigned a fitness value proportional to its
performance and resultant error rate. This fitness value informs the next set of models,
so a predefined proportion of the best models are a subset of the next generation,
sometimes referred to as their offspring. Other new models are produced by
exchanging model parts between these models to make another subset of best models,
the offspring of the best models. Then these subsets are grouped into a single group,
the same size as the previous generation and replace the previous generation of
models. The cycles then starts again to improve upon this generation, producing a set
of models with even lower error values. This cycle continues to a pre-specified point,
either when error reaches zero or negligible, or through a predefined number of
generations. Then the model of the final generation with the lowest error is selected as
the best model.
In a study looking for gene-gene interactions comparing traditional feed forward/back
propagation neural networks (BPNN) with GPNN using artificial data, the GPNN
showed improved prediction error and improved power. It can therefore be considered
an improvement on BPNN when looking for gene-gene interactions 121. BPNN has a
tendency to overfit the data when non functional SNPs are present and therefore has a
higher classification error than GPNN, which is more adaptable to new observations.
GPNN has been shown to have high power at detecting relatively small effects (2-3%
heritability) in data sets containing 2 or 3 locus interaction 122. It also compares
favourably, showing an increase in power, against logistic regression, 123 and stand
alone GP 124. GPNN has been used to identify a two locus interaction which confers
an increase in risk for Parkinson’s disease 125. GPNN has been useful for selecting and
modelling important predictors, but has not been tested for its efficiency in selecting
the best predictors amongst a large number of variables.
Grammatical Evolution Neural Networks (GENN)
However, there are limitations to using the genetic programming algorithm: The
implementation involves binary splits with each node attached to two nodes on the
level below it. Although this was sufficient for small datasets, more complex datasets
require more than two nodes. Similarly, there is a limit to the number of levels the
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network can contain which may be problematic in more complex situations. It is also
time consuming and restrictive to alter and recompile the source code for every
alteration of GPNN.
In order to tackle these problems a similar model was proposed that uses the
Grammatical Evolution (GE) learning algorithm 126 in place of the Genetic
Programming method. This is similar to GPNN as it uses a machine learning approach
to optimise the inputs from a pool of variables, weights and possible network
architecture. The main advantages that the GE algorithm has over GP are based on
flexibility. GE uses a linear genome and maps from the genome using grammatical
rules similar to the DAN transcription rules to form mRNA. This is equivalent to
comparing evolutionary changes at a chromosomal level, whereas GP is at the
phenotypic level. GENN is therefore less computationally intensive than GPNN.
In comparisons using simulated epistatic genetic models, both GPNN and GENN
performed better than the simple BPNN. Both GPNN and GENN reached the upper
limit of power. It was suggested that simulated data is not the best test sample for the
differences between the two methods as such artificial data do not generally contain
much noise. Although not proven, this is the area in which GENN was designed to
perform better than GPNN.
Neural Network Evaluation
Both the feed forward network and the parameter decreasing method can only handle
a limited number of events per variable and are therefore not an efficient method for
handling large data sets. However, neither GPNN nor GENN are affected by the curse
of dimensionality as they only use a random sample of variables to build the first
round of models and it is during the repetitions of the process that the most important
variables are selected 127.
If there is an interaction present, it can be detected in a predictive sense by PDM. If
one part of the interaction pair, or triplet, is removed it does influence the accuracy of
the model predictions 115. GPNN and GENN are the most powerful at detecting
interactions between genes and the environment, although more work needs to be
done to assess the limitations and parameters of these approaches and to compare
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them. It is also not possible to isolate individual interactions from the larger predictive
model.
When there is only a small sample, there is a neural network method called Radial
Basis Function (RBF) that can be used 128. The GPNN is designed specifically to
work in a large hypothesis space but can be used on smaller samples of data.
Although neural networks are successful at identifying small effects, as part of a
group dynamic, in complex models 122, there is still work required in isolating these
effects to look at them independently.
The neural network methods are effective in cases of genetic heterogeneity and in the
presence of correlated markers. In power studies, GPNN has performed better than
other similar methods. GPNN is not overly computationally intensive, and GENN is
even less so. Neither GPNN nor GENN have open source code. If a practical stopping
point is pre-assigned and over fitting is not allowed to happen. It is also a method
where the results can be applied to the population; the figures are not a theoretical
indicator but a practical one. However, such an application is likely to be as a
predictive model not information on independent or two variable interaction effects.
Neural Networks are an interesting field with a very different approach to gene
environment interactions and may be a useful comparison method. However the
results are in the format of a predictive model, not easily divided into its constituent




There are some studies where a two step approach is used, with a non parametric
method used to reduce the number of variables and then modelling this group of
selected variables for interactions. For identifying gene-environment interactions, the
first step would be applied to the large genetic data set and the environmental factors
would be introduced at the second step. The second step can be a logistic regression
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129 using forward selection to create the model and backwards selection to remove the
interactions that are not significant.
Set Association Approach
As a first stage of a two stage approach, the set association approach was developed
by Hoh et al 130, and then improved to the current methodology a year later 131 as a
non parametric method that could handle large numbers of predictor variables. It
selects a subset of important markers, which can be either categorical or quantitative,
from a large data set. It does this by evaluating sets of SNP markers at various
positions in the genome, performing a simultaneous significance test on several sets
of loci, whilst ensuring the type I error rate stays low.
The initial step of the set association approach is to determine a test statistic for each
marker individually, which is a combination of measures of allelic association (AA)
and deviation from the Hardy Weinberg equilibrium (HWE), with information
included to try and minimise the effects of genotyping errors. The measure of
association used is normally the χ2 statistic, but other measures can be used. Although
moderately high levels of deviation from HWE can indicate association with a risk
locus, extremely high levels can indicate genotyping errors 132. Therefore the statistics
are “trimmed” to remove the top 1 percentile of Hardy-Weinberg Disequilibrium
(HWD)
For the next step, a number of these informative SNPs from different genomic regions
contribute to form a sum statistic of single marker statistics. The trait association
statistic is chosen for each marker and the sets of statistics are summed. Finally, a
permutation test is used to calculate significance. A limitation of the set association
approach is that it deals only with bi-allelic loci as the χ2 statistic would have different
numbers of degrees of freedom for markers with different numbers of alleles. The set
association approach also requires more research into the power and type I error rate.
Multiallelic Set Association (MSA)
MSA is an extension of the set association approach, which can be used on multi
allelic markers 133. MSA trims the markers using the same extreme HWD limitations
as the bi-allelic set association on the higher values. However, the MSA also removes
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a pre-specified (d) proportion of the smallest HWD p-values, along with their
corresponding p-value for allelic association. This approach can theoretically be
applied to any reasonable score function at each locus, allowing different data types to
be combined and thus increasing the power of the analysis.
Set Association Evaluation
Regarding the curse of dimensionality, the set association approach reduces the large
number of markers to a smaller set of important markers. However, a disadvantage is
that interactions are only tested for between the markers that are selected as important.
This would mean that important interactions with small independent effects might be
missed, so the set association approach would not be a particularly strong method for
identifying gene environment interactions.
Under a simulated multilocus inheritance model, Ott and Hoh found that a rather
small number of case and control individuals can be sufficient to detect at least one
disease locus of the three they simulated 134.
Despite being affected by genetic heterogeneity and correlation, the power of the set
association approach in high dimensions is fairly high, and is better than if the
Bonferonni correction or False Discovery Rate (FDR) procedures are used 135. A sum
statistic is the combined value of marker main effects and therefore performs better
than methods that test each marker independently. For a meaningful power calculation
the computer simulation should be carried out under a pre-specified, reasonable,
multilocus inheritance model. The power can decrease considerably if prevalence of
the disease gene increases or the heritability decreases. This can be explained by the
oligogenic threshold model 136 as when prevalence is high and heritability is low, a
small number of susceptibility alleles is sufficient for the disease to be expressed.
However, in situations where neither interacting variable has a main effect, an
exhaustive pairwise search of the genome was found to be more powerful than a two
step selecting approach 137.
This method is also weak at detecting marginal effects and can be affected by genetic
heterogeneity as the method tests the association between markers and disease for the
whole sample. If there are different loci resulting in the same outcome, this will
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decrease the association between each of the markers and the outcome and reduce the
overall power. Correlated markers are also problematic as risk associated markers
correlated with loci that do not influence disease will lead to an overrepresentation of
these non susceptibility loci and thus reduce the power of the method. There has been
an adjustment procedure developed to adjust the test statistic of a marker for
correlation with other markers in the sum 135. This negates the effects of correlation
on power.
This method is easily implemented in a computer algorithm. There is open source
software available in a programme called SunStat 138. Results gained from the set
association approach can be applied to the study population and can be fairly easily
interpreted.
Examples of studies that have used the set association approach include looking for
genetic variation relating to glucocorticoid excess in early onset Alzheimer’s disease
139, gene-gene interactions in late onset Alzheimer’s 140, susceptibility genes in head
and neck cancers 141 and the occurrence of coronary artery restenosis following
percutaneous transluminal coronary angioplasty (PTCA) 142.
2.3.5.4 Non-Parametric Approaches
Spectral Methods
Spectral methods are based on the analysis of eigenvalues, or singular values of a
matrix, and attempt to solve differential equations using a series of known, smooth
functions. They constitute a variety of methods that can be used in a number of
applications including clustering, recognition and graph partitioning 143-146. The most
relevant spectral method for attempting to identify gene-environment interactions is
singular value decomposition (SVD) which is applied in principal components
analysis (PCA). SVD and PCA are common techniques for analysis of multivariate
data and are now occasionally used in gene expression studies 145, 147.
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Singular Value Decomposition/ Principal Components Analysis
SVD is a  powerful technique dealing with sets of equations or matrices that are either
singular or numerically very close to singular and is a factorisation procedure of
rectangular, real or complex matrices. A number of methods other than PCA employ
SVD; including fitting the data by least squares 148, computing the pseudo inverse 149
and matrix approximation 150. SVD can both identify and offer solutions to the
problems in a given matrix.
Taking a standard n×m matrix A, its first singular vector , normally called v1, is
defined as the unit vector that stretches the most under the action of A, maximising
||Av1||2. In the subspace containing all the rows of A, the most stretched vector will
also come from that subspace and therefore characterise it.
It is possible to construct trees using the basic tool from singular value decomposition
(SVD) 151, however this is mainly used to develop phylogenetic trees, not statistical
(classification, regression or decision) trees.
PCA is closely related to singular value decomposition; it is effectively applying SVD
to the covariance matrix of the data. PCA is also known as the Karhunen-Loève
transformation, the Hotelling Transformation or Proper orthogonal decomposition
(POD) and is used as a tool in exploratory data analysis and for making predictive
models.
PCA is defined in mathematics as an orthogonal linear transformation that transforms
the data to a new co-ordinate system such that the greatest variance by any projection
of the data comes to lie on the first coordinate (the principal component), the second
greatest variance on the second co-ordinate and so on. PCA reduces dimensionality by
selecting and keeping the characteristics that contribute the most to the variance.
Effectively PCA is rotating the co-ordinates so the transformed axes are aligned with
the direction of maximum variance. PCA gives optimal results when a single source
of information is corrupted with Gaussian noise and when the multidimensional
scatter plot of the data forms a hyper elliptic shape 152.
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There are a number of assumptions needed to be made in the process of PCA, so in
order to obtain a result the applications become limited. These assumptions include:
linearity of the data set and that the principal components are orthogonal with each
other. There have been methods developed to work with PCA to avoid making these
assumptions, kernel PCA and Independent Components Analysis (ICA), respectively
153, 154.There is also the assumption that large variance indicates importance. This
would be the case if there was a high signal: noise ratio with the larger effects being
an interesting dynamic and the smaller effects being noise. However, in genetic
studies this is unlikely to be the case, as many genes only have marginal effects or
work within a network of other genes and environmental variables. It is also a
drawback that for PCA, variables under analysis need to be continuous.
 PCA is used to try and identify and eliminate population stratification in genome
wide association studies 155. This works as an axis can be created that spans from
Northwest to Southeast Europe and the PCs for each country are more genetically
similar when physical proximity is closer 156.
Evaluation of Spectral Methods
PCA has been tried in a number of different genetic studies in an attempt to reduce
dimensionality. Regarding gene-environment interactions, it may be possible to use
PCA for some exposure variables. One example being sunlight exposure, and possible
interactions with vitamin D receptor genes, as sunlight varies in a constant way from
South-North and could be treated as a cline (a scale of continuous gradation). For
SNP data, there could be false results from PCA where, from a sample of 20 SNPs, a
group of correlated SNPs appears to have a bigger effect than the real effect of one
SNP. As PCA does not identify the SNPs individually, it would be difficult to explain
away confounding effects.
Identifying effects successfully in a study with a low ratio of cases to variables and
the identification of marginal effects both depend on the variable being in trend (on a
cline) with other variables. A cumulative, gradual difference may be detected where
an inconsistent or isolated larger effect may be missed.
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Compared to other popular gene identification techniques, PCA has been shown using
simulations to be more powerful than other methods 157. Computationally, PCA has to
weigh up keeping the subspace that has largest variance against the computational
intensity of analysing such a large space.
However, as PCA can only tell you the association between the phenotype and the
SNPs included in the model as a whole, not the relationship with individual SNPs, it
is impossible to extrapolate meaningful conclusions from results of a pure PCA.
However, PCA can be used to eliminate SNPs that are in high LD from linkage
analysis, thus reducing the dimensionality 158.
Combinatorial Approaches
Recently a number of approaches have been developed as tools specifically for
detecting gene-gene and gene-environment interactions. These approaches give more
insight into combinations and patterns for sets of genetic and/or environmental risk
factors. They can be used for either binary or continuous outcome variables and were
developed to explore high dimensional genotype space to try and predict the variation
in quantitative traits in the general population
There are a number of related approaches that work on the basis that combining
similar data into a single group reduces the dimensionality making the data more
manageable and analysis of such data more efficient.
These methods include Combinatorial Partitioning Methods (CPM), Restricted
Partition Method (RPM), Multi Dimension Reduction (MDR), Generalised Multi
Dimensionality Reduction (GMDR) and the MDR extension Odds Ratio MDR
(ORMDR). There is also a more generalised Combinatorial Approach which
incorporates elements from the other methods.
Combinatorial Partitioning Method (CPM)
CPM was one of the first partitioning methods developed to try and analyse the large
data sets being produced in genetic risk factor studies 159 and in response to the
increasing burden and realised complexity of chronic, complex disease. The goal of
CPM is to find a way to divide the multilocus genotypes into subgroups in such a way
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that the overall trait variation can be explained by the characteristics of how the genes
are grouped. There is no pre-specified genetic model required prior to analysis. CPM
is used to study the effects of combinations of risk factors on a quantitative
phenotype, and is therefore a suitable method for studying complex disease risk
factors.
Traditionally, when testing if a locus has an effect on the phenotype, it is possible to
use ANOVA as it tests the overall difference between the mean outcome values of
different genotypes. It is difficult then, however, to determine the significance level
without the problems of multiple testing. CPM however, determines the combinations
of genotypes that influence the quantitative phenotype at the same time as defining
groups of loci with similar phenotypic means.
There are three steps to combinatorial partitioning. The first step takes a subgroup of
loci from the whole sample and combines the genotypes with the same outcome (case
or control) into partitions. The set of partitions is evaluated, calculating the similarity
within the partitions to the dissimilarity of partition means to assess how much
variation can be accounted for. A group will be selected that predicts a pre-specified
level of variance. The selection criteria can be the amount of disease explained by the
identified group, or set, or the number of individuals in the identified group. A set
with a small number of individuals can produce false positive results 159.
The second step is multi fold (usually ten fold) cross validation. The data is divided
randomly into ten subgroups approximately equal in size. All the groups except one
are used to estimate the mean of the genotype partitions of a set. The remaining one is
used to compute the within partition sum of squares. Once the prediction error for this
one group is calculated, the process is repeated for the other groups and then the
average prediction error is calculated 160.
The third step is to identify the sets of loci that are most predictive of the variance and
analyse what information they provide about loci combinations and relationships with
disease risk. Selecting more than one set and comparing them increases information
gain.
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The main limitation of CPM is that the method is limited to studying pairs of variable
loci (or other discrete variables) and cannot therefore fully capture all the epistatic or
gene-environment effects. Extending to partitions of higher dimensions may be
prohibitive in terms of the number of partitions to be examined. It is also unclear as to
what capacity CPM has to detect additive effects of polymorphisms 161.
Examples of studies that have used CPM in interactions studies, though mainly gene-
gene interaction, include a study of the genetic effects on  plasma triglyceride levels
159 and the effect of metabolic pathway genes 162.
Restricted Partitioning Method (RPM)
RPM was designed by Culverhouse et al to try and reduce the burden of
computational intensity of CPM, most of which can be considered unnecessary 163. It
is a form of recursive partitioning, similar to CPM but restricts the search, removing
the partitions that only explain small amounts of variation.
In practice, the difference between RPM and CPM are the selection criteria, which
consist of three steps. The first is a multiple comparison test to measure which groups
have significantly different mean quantitative trait values. If all groups are equivalent,
the process stops at this step. The second step is ranking pairs of genotype groups
according to the difference between their genotypic means and merging the pair with
the smallest difference into a single group. The algorithm then returns to the first step
and repeats the process until the second step does not find significantly different
means between the groups. If there are nine genotypes, as would be the case for two
biallelic loci, the final partition will be found after no more than eight repeats of the
process followed by an R2 computation. For initial n genotypes, the algorithm will
always stop after no more than n-1 repeats.
Compared to CPM, this is much less computationally intensive: the same scenario
which takes RPM 8 iterations and one R2 calculation, would take CPM 21,146 R2
calculations. This difference in computational intensity is even more pronounced for
three way interactions with a maximum of 26 iterations for RPM to identify the most
significant partition and 1021 partitions evaluated under CPM.
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However, when studying large numbers of locus sets, each locus set needs several
tests and each test needs a permutation test to calculate the p-value, so RPM can still
be very computationally intensive. It also uses the Bonferonni correction to calculate
the overall p-value from the individual p-values. The Bonferonni correction may be
overly conservative, given the nature of the correlated locus sets.
RPM has been used in studies of cardiovascular disease risk factors 164, gene-gene
interactions associated with autism 165 and behavioural reactions in different people
following exposure to caffeine or nicotine 166, 167.
Combinatorial Searching Method (CSM)
The combinatorial searching method (CSM) was developed by Sha et al 168 and is
similar to RPM in that it is an extension of CPM with the potential partitions being
assessed for importance before analysis. Applying CSM to a data set filters all the
possible sets of loci to retain the candidate locus sets for evaluation, using a new
objective function based on cross-validation and partitioning. There are three steps to
CSM as outlined in the Figure 2.2 below (Figure form Sha et al 2006).
Figure 2.2 Combinatorial Searching Method
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Step 1 involves searching every single locus set, two locus sets, three locus sets
through to (pre-specified) L locus sets and retaining those that explain a significant
amount of trait variability. The second step validates the locus sets that have been
retained using two fold cross validation and assigns each locus set a value of the
objective function. The higher the value, the more reliable and more predictable the
locus set. Step 3 uses a permutation test to assess the statistical significance and
calculate a p-value for the association between the locus set and the phenotype.
CSM has been used by Sha to study the variations of the angiotensin-converting
enzyme (ACE) gene contributing to the ACE level and is being considered by a group
studying genetic susceptibility to cancer 169.
Multifactor Dimensionality Reduction (MDR)
MDR can be used to analyse either genetic, environmental or a combination of
genetic and environmental variables on a dichotomous outcome, such as case/ control
status. It was first developed by Ritchie et al in 2001 in a study to identify high order
interactions in sporadic breast cancer 170, however the theory and applications of the
method are far reaching.
MDR is a variation of the combinatorial partitioning method, which is a method that
involves collapsing high dimensionality data into a single dimension. In theory this
allows interactions to be detected in relatively small sample sizes. The MDR
algorithm looks for the strongest associations between variables and disease status. It
only requires the input of two parameters; the numbers of variables to be selected at
one time (N) and a threshold (T), guided by the goals of the study, as to what ratio of
affected: unaffected distinguishes high risk genotypes from low risk. To find main
effects, the N value can be set to 1.
MDR then incorporates a cross validation step. This paper uses ten fold cross
validation which is the process where the data are divided into a training set (9/10ths
of the data) and an independent testing set (the other 1/10).
One of the drawbacks of MDR is that it is necessary to pre-specify the number of
interacting factors prior to analysis, so a three way interaction will go undetected in a
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study into two way interactions. However, MDR can be adapted for use in case
control, discordant sib-pairs and family based designs 84, 171, 172.
The majority of the work on interactions analysed using combinatorial methods has
been done on gene-gene interactions. MDR has been used to identify multi locus
interactions in a number of cancers including prostate cancer 173, bladder cancer 174
and sporadic breast cancer 170. Other medical conditions where MDR has been used to
identify gene-gene interactions include degenerative conditions such as familial
amyloid polyneuropathy 175, Alzheimer’s disease 176 and multiple sclerosis 177,
common complex disease such as type 2 diabetes 178, asthma 179, 180, hypertension 181,
182, and myocardial infarction 183, 184, atrial fibrillation 185-188, autism 189, 190 and
schizophrenia 191.
Generalised MDR (GMDR)
GMDR has a similar framework to MDR but has a wider application. Unlike CPM,
RPM and MDR, GMDR allows adjustment for covariates, can handle both
dichotomous and quantitative phenotypes. and can be applied to a number of different
population based study designs 192. GMDR uses the same data reduction strategy as
the MDR method but changes the way the cells in the table are classified. Instead of
describing the cells high risk or low risk based on their ratio of cases to controls, the
GMDR uses a scoring method to classify cells.
The scoring method used in GMDR is a log-prospective likelihood of independent
observations, with the predictor-variable vectors conditioned. The first stage in
scoring the cells is to calculate Maximum Likelihood Estimations (MLEs) and scores
for all individuals under the null hypothesis. Since the null hypothesis assumes no
individual effects and no interaction effects, the score will be the same across all the
cells. Then the cumulative score value is calculated for each cell. High risk cells have
a score that is equal to or exceeds a pre-assigned threshold; low risk cells have a score
below the threshold. The validity only depends on the availability of an appropriate
statistic that can measure association between risk factors and the phenotype.
Therefore, GMDR (like MDR) can be considered model free. GMDR can do
everything MDR can do and more, including handling quantitative traits and
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covariates. Compared to MDR, GMDR can improve prediction accuracy when the
trait is influenced by covariates, even for complex and rare interaction models.
Although the GMDR approach can reduce some of the complications of MDR, it still
uses high dimensionality computing. This is problematic when more than ten factors
are used, and it has been suggested that combining this approach with knowledge
about biological plausibility to select the factors may be more effective.
Odds Ratio MDR (ORMDR)
Instead of classifying multilocus genotypes into binary, high and low risk sub-groups
based on case-control ratio, which can lead to a high false positive rate, ORMDR uses
a variation on the Odds Ratio (OR) as a quantitative measure of disease risk 193. This
allows the genotype combinations to be ordered both by effect size, using the
ORMDR measure, and by importance, using the confidence intervals.
ORMDR is the version of MDR that so far shows the most potential for identifying
gene-environment interactions. It has successfully been used, alongside other
methods, to identify a gene-gene interaction in Achilles tendinopathy 194.
Focused Interaction Testing Framework (FITF)
The Interaction Testing Framework (ITF) performs likelihood ratio tests in stages,
performing joint tests of main and interaction effects conditional on lower order
effects, so that the complexity of the test increases with the order of interaction
considered. The joint tests of interaction are performed conditional on significant
lower level effects 180.
Using ITF on its own in the presence of a large number of marginal effects, involves
such a large number of tests that the type I error rate has to be adjusted and power is
lost. Therefore the gene combinations are pre-screened using a goodness of fit χ2
statistic that is dependent on association among the candidate genes in a pooled case
control group. By controlling the false discovery rate in this way, the adjustments for
multiple testing are not necessary.
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The differences in performance between MDR and FITF depend on the genetic
effects. MDR performs better when identifying a set of high risk multilocus genotypes
for genes with little or no marginal effects. However, FITF performs better when the
interactions involve additive, dominant or recessive genes. This difference is due to
modelling assumptions, with MDR effectively the parametric method dependent on a
susceptibility pattern and FITF as the non parametric method 180.
However, the testing on FITF used a sample of candidate genes found in literature,
previous work and pathway genetics. It is unlikely that such an approach would
perform so well in GWA without a prior hypothesis, where the number of
comparisons, and therefore the number of tests, will be much greater 137.
FITF was used to identify a significant multilocus effect associating a group of three
genes with childhood asthma 180.
Evaluation of Combinatorial Methods
The different combinatorial methods have different strengths and weaknesses in
identifying gene-environment interactions. Without incorporating a filter or selection
method prior to the combinatorial method, none of the approaches can handle very
large data sets 186.
A very strong advantage of combinatorial methods is that they can all identify
interactions without the variables having an independent main effect 163. However, it
is difficult to reach genome wide significance, for example - with the application of
CPM to genes for coronary heart disease, the overall significance of the identified risk
genes was 0.14 159. This is not considered a significant level,
Apart from the effects on power from genetic variability, combinatorial methods
maintain their power well in the presence of errors, missing data or noise. The main
advantage of using combinatorial methods is that they maintain their power to identify
interactions when there is no main effect present 90. The power of MDR for detecting
gene-gene interactions actually increases when environmental variables are added to
the model, as environmental variables may indicate subgroup differences.
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Different genetic models can affect the power of combinatorial methods; with genetic
heterogeneity and phenocopy (where a phenotype, under a certain environmental
condition, is identical to a genotype determined phenotype) reducing the power and
efficiency as different groups reaching the same outcome would decrease the variance
of case: control ratio between partition groups. This decreases the prediction accuracy
and the consistency of the model cross validation 160. However, combinatorial
methods are appropriate way to identify the dominance effects at the same time as
identifying the risk locus. If there is a phenotype influenced by diallelic variation at
locus A, a combinatorial method would identify locus A at the same time as
separating the possible genotypes into genotypic partitions, for example: (AA, Aa)
and (aa) in the case of dominance 159. FITF has proved particularly effective at
identifying genes with dominance, additive or recessive effects 76.
CPM, MDR and ORMDR are very computationally intensive, with RPM and GMDR
designed to alleviate this problem to some degree. The results gained from a
combinatorial approach can be applied to populations and the results are interpretable
and useful in studies of disease risk.
Given the evaluation criteria, ORMDR is one of the most efficient methods currently
available in the search for gene-environment interactions. Comparison of any novel
method should be compared to ORMDR to justify any claims of success, or indeed
failure.
Table 2.3 shows a summary of the different advantages or disadvantages of the
methods assessed so far.
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Table 2.3 Summary of the Strengths and Weaknesses of Different Methods
Feature Success
Conditional Methods
Dimensionality Poor in high dimensions, high false positive rate
Interactions Strong when interaction is pre-specified only
Power Requires high case: variable ratio
Marginal Effects Poor, made worse with transformation and loss of information
Genetic Models Can be adapted if known in advance
Computational Intensity Highly intensive
Applicability Very Applicable, especially logistic regression
Neural Networks
Dimensionality Poor unless combined with a prior selection step
Interactions Strong in predictive sense, hard to isolate individually
Power Prior adaptation required
Marginal Effects Cannot isolate individual effects
Genetic Models Strong in a predictive sense
Computational Intensity Intensity depends on adaptations, no open source code
Applicability Applicable only as an entire model
Two Step Approaches
Dimensionality Reasonable if interacting variables have independent effects
Interactions Only for interactions where variables have main effects
Power Strong
Marginal Effects Weak, especially weak interactions
Genetic Models Affected by genetic heterogeneity
Computational Intensity Relatively low computational intensity
Applicability Applicable
Spectral Methods
Dimensionality Not appropriate for enough variable to assess
Interactions Identification is dependent on trend not individual effects
Power Powerful in correct circumstances
Marginal Effects Cannot isolate individual effects
Genetic Models Not possible to gauge, inappropriate
Computational Intensity Not possible to gauge, inappropriate
Applicability Not possible to gauge, inappropriate
Combined Approaches




Genetic Models Possible to draw conclusions on underlying model from results
Computational Intensity Very computationally intensive
Applicability Results interpretable
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Recursive Partitioning (RP) Methods
Recursive partitioning methods are non parametric methods that divide the total
dataset into smaller, more homogeneous subsets according to a set of predictor
variables. This produces a regression or classification tree for continuous or
categorical outcome variables respectively. Classification and regression trees were
developed by Breiman, Freidman, Olshen and Stone in the early 80s 195. The principal
is that each object can be defined by its properties into a set of classes. The basic
functions of a decision tree are to completely search an entire hypothesis space, select
the best attributes and to decide if each branch can be justified. For the first division,
the tree root, each attribute is statistically evaluated to see how well it fits the data.
There are two different criteria for choosing the best attribute: ID3 trees, commonly
used in machine learning, use information theory and gauge the best attribute as that
which maximises the information gain ratio; Classification and Regression Trees
(CART), more often used by statisticians, look for the decision that minimises
classification error 195.
Similarly to neural networks, the tree components are referred to as “nodes,” with the
primary split the “root node” containing the total sample. The root node is split into
two nodes which best improve the homogeneity of the case and control groups
compared to the root node. Also, similarly to neural networks, cross validation is
often used to create an optimal tree.
There are a number of advantages and disadvantages to recursive partitioning
methods compared to other multivariate models. In some, but not all, cases there is an
increase in accuracy using RP compared to other methods, 196, 197. Despite performing
similarly to logistic regression in predicting cognitive impairment, RP methods tend
to be easier to explain and more intuitive, without involving any complex
mathematics 198, which makes them a more useful tool in a clinical, as opposed to a
statistical, setting. Sensitivity and specificity can be balanced during the selection
process through prioritising and assigning  misclassification penalties 199. They do not
make any implicit assumptions about the form of the underlying relationships
between factors and outcome variables and can therefore identify synergistic
interactions between factors and non linear relationships.
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However, RP methods are not as effective when continuous variables are used 200 and
are more susceptible to the problems of multiple testing and overfitting the data 199.
They are also perform poorly compared to logistic regression in identifying additive
models 201 which is important for many clinical prediction models. However, these
limitations mostly describe scenarios in which logistic regression can be used
effectively.
There has also been work done combining logistic regression and recursive
partitioning, which found that the combination was particularly effective at
identifying at risk subgroups, with the RP methods identifying interactions that had
previously gone undetected 202.
There are variations of recursive partitioning, including Cox linear recursive
partitioning 199 which has been found to have better predictive accuracy than Cox
linear modeling and simple recursive partitioning 200.
Recursive Partitioning in Combination
Combining RP with a different dimensionality reduction technique can reduce the
number of terminal nodes and cross validated error rate 203. Combining patterning (P)
or Clustering (C) with RP, give acronyms PRP and CRP respectively.
PRP is an extension of CART that has been applied to genotype-phenotype
association data, originally devised for viral genetics and later used for SNP
association data. It assigns people to genotype groups based on their multi locus
genotypes and then use this classification, or pattern, as a predictor in RP. MDR is
effectively a special case of PRP where the tree is restricted to a single split and the
misclassification error is used to measure impurity 204. Therefore these two methods
tend to give similar results, with only slight differences in accuracy estimates.
Compared to RP, both PRP and CRP reduced the error rate and PRP reduced both the
false positive and false negative rates 203, with CRP reducing only the false positive.
74
Random Forests
The random forests approach uses a group of tree based models and identifies the
class that is the mode of the classes from the different trees. The algorithm was
developed by Breiman and Cutler 205 and combines models based on a random subset
of the data to select important predictor variables. More important predictors will
more successfully distinguish between cases and controls and will therefore be
present in most of the trees and closer to the root node. Less important predictors will
be present in less trees and nearer the terminal nodes 206.
There are two features that distinguish the random forest trees from those grown in a
traditional deterministic manner: Firstly, the subsets used for growing the trees are
generated using bootstrapping, repeating individuals within a sample to ensure the
sample size is the same as the study sample. Secondly, the individuals not included in
tree building are used to measure the prediction accuracy by the proportion of
correctly and incorrectly classed individuals.
The majority of the large volume of research involving RP methods is in predicting
patient specific probabilities of adverse outcomes or death. Such an approach can
identify an interaction unrelated to main effects 202, 207, 208. Recursive partitioning can
be used for tissue classification using gene expression data 209 and was found to be
more accurate in distinguishing distinct colon cancer tissues 210, although in some
situations other methods perform better 211. PRP was used to assign HIV medications
to appropriate strains of the virus 203.
Evaluation of Recursive Partitioning Methods
RP methods perform well in high dimensions and are well designed to detect
interactions between predictor variables. The random forest approach circumvents the
dimensionality problem by selecting the most important predictors but does not have a
cut off level at which a predictor is considered important 212. However, the same study
found that random forests could identify interactions where there were little or no
main effects.
However this ability to identify interactions is affected by the sample size and the
relative number of interactions present compared to the main effects. With a small
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sample size, there are fewer learning and test samples and therefore greater
uncertainty. In this situation a localised test can be used to balance the needs of
validating the results and retaining the larger number of observations 213.
Recursive partitioning methods are used often in identifying marginal effect sizes,
which was found to be justifiable using analytical and numerical arguments 214.
RP methods are able to identify genetic heterogeneity 212, 215 as different models are
fitted to the data defined by early splits in the tree, effectively dividing the
subpopulations into separate branches. Correlated markers can be a problem for
random forests as the importance of risk SNPs can be underestimated. When disease
risk is determined by haplotypes, RP can still identify candidate SNPs 214.
In large data sets, RP methods are less affected by the problems of multiple testing
compared to more traditional methods as variables are identified by their relationship
with the data instead of pre-defined thresholds. Combining RP with a patterning
reduction technique (PRP) reduces the false negative rate and therefore increases the
power of RP.
Given the cross validation and number of comparative splits, RP methods can be
computationally intensive. This is reduced by incorporating a dimensionality
reduction method prior to analysis. However the software is openly available and any
results gained from RP methods can be applied to the population from which they are
drawn. The use of RP methods in conjunction with other steps is an area of statistical
development that has potential.
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2.4 Summary of Findings
It has been suggested that, as many of the methods have different strengths and
weaknesses, the best approach might be to use a number of different methods on the
same data to try and identify the most important genes and understand the interaction
patterns. Heidema et al suggest that the set association approach, MDR and random
forests is a good combination 216. However, the characteristics of the data set should
be taken into account when deciding the most appropriate set of methods.
The two most successful current methods for identifying gene-environment
interactions are stepwise regression and the Odds Ratio Multifactor Dimensionality
Reduction (ORMDR) method. Both show successful results at identifying gene-gene
interactions and are being used to investigate gene-environment interactions.
However, the recursive partitioning methods show more potential for manipulation
and are as yet relatively untested on gene environment interactions. Any changes
made to ORMDR would be fine tuning an already good method, whereas the concepts
of recursive partitioning have much more scope for further, more novel, development.
Recursive partitioning, therefore, forms the basis of the novel method developed by




Methods that consider or exploit interactions between genes and the environment are
of growing importance in the dissection of risk factors of complex disease. Even
though methods have not yet been fully developed to deal with this complexity, it is
essential that future genetic studies should gather information on behavioural and
environmental factors. This will allow appropriate analysis to take place and ensure
the data collection is not wasted.
The field of gene-environment interactions is an area of study both relevant and
necessary to fully understand the nature of complex, chronic diseases. Development
of a statistical tool that aids the identification of such interactions could have both
clinical and public health benefits. Current methodologies are not wholly appropriate
for the large volumes of data now available and the complexities of different potential
disease models, but each has strength in a particular problem area. There is the
potential to combine the methods or develop a new method using some of the same
basic statistical theory
With techniques for molecular biology making such rapid advancements, it is
becoming more common to analyse the entire genomes of study populations. In these
gene identification studies, many environmental variables are also measured as
potential confounders. Therefore data sets suitable for studying gene-environment
interactions are becoming more common. The problems of power and dimensionality
inherent in having so many variables are being tackled to some degree for gene
identification studies, any resolution of which will also benefit interaction studies,
though need further work. As a variety of studies of isolated populations are doing
similar work on different populations, there may be differences in the genes identified
depending on the environment of the population. If this happens to a number of genes,









The main aim of this review is to establish the research status of colorectal cancer.
This identified potential genetic, environmental and interacting risk factors associated
with disease risk, which informs the later practical application of the method.
3.1.2 Search Strategy
The colorectal cancer section used information from different sources including
journals, reputable health information sites and health service reports. The search
criteria were extended with clinical understanding of the condition, for example
inclusion of the word “adenoma.” A more detailed version of the search criteria is
shown below, again enhanced by back referencing, citation tracker and papers from
other sections where relevant.
1. colorectal or colon or rectum or "large bowel" or "large intestine").mp
2. cancer or adenoma or carcinoma
Dietary variables: Diet$ or food$ or nutriti$ or mineral$ (or specific term, e.g
Retinol)
Genetic: polymorphism$ or allel$ or genotyp$ or phenotype$ or
isoform$ or mutation$ or gene or genes or genet$).mp.
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3.2 Epidemiology of Colorectal Cancer
Incidence
Across the UK, colorectal cancer (CRC) is the third most common cancer in both men
and women behind prostate and lung for men and breast and lung for women. The one
exception was England in 2006, when there were slightly more colorectal cancers





There were approximately 36,700 cases of CRC in the UK in 2006, which is on
average 100 new diagnoses every day.
Worldwide, the incidence rates of CRC vary by country, with developed countries
having an incidence rate four times higher than developing countries 217. At the
population level there is a relationship with sex, with CRC more common in males
than in females, with incidence in both sexes increasing as age increases. In fact, the
majority of cancer occurs in older people 218. Given the increasing age of the
population in developed countries, this suggests not only a current public health
problem but one whose importance may be set to increase.
Mortality
Despite an increase in incidence, there is a definite downward trend of deaths from
colorectal cancer, even in recent years, as shown in table 3.1. Figure 3.1 shows the
trend of deaths from colorectal cancer in the UK, the data from 2008 onwards is not
yet available. It is worth noting the y-axis begins at 17 cases per 100,000 and that
CRC is not close to being eradicated, as an initial reading may suggest.
Figures and graphs taken from the European Mortality Database:
http://data.euro.who.int/hfamdb/
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Table 3.1 UK deaths from Colorectal Cancer
2002 2003 2004 2005 2006 2007
SDR: Malignant neoplasm
of colon, rectum and anus,
per 100,000
19.13 18.91 18.62 18.31 17.91 17.74
Figure 3.1  Mortality Rate from Colorectal Cancer from 1980 to Present Day
Genetic Screening and Prevention
There are a number of different approaches possible to try and reduce the mortality
and morbidity of colorectal cancer, which can be broadly categorised into three
groups: primary prevention, secondary prevention and chemoprevention.
Primary prevention involves identifying risk factors and promoting their avoidance in
people’s lifestyles so as to reduce colorectal cancer incidence 219. The promotion of
healthy diets, maintaining a healthy body weight and increased exercise would be
considered primary prevention. Secondary prevention would involve screening people
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for early signs of disease, in the case of CRC this would be the pre-neoplastic lesions
and early stage tumours. Given the length of the latent period of tumorigenesis before
the development of a symptomatic tumour, colorectal cancer is an ideal candidate for
screening in this way.  Chemoprevention is the use of drug compounds to reduce
incidence of a disease, in the case of CRC this would involve non steroidal anti
inflammatory drugs (NSAIDs) such as aspirin 220-224. Fortifying a diet with calcium
has also been shown to have a preventative effect 225 although other studies have
found no effect 226 and some suggest that the effect is conditional on vitamin D status
227.
Colorectal Cancer Screening
The UK National Screening Committee has a set of criteria based on the condition,
the test and the treatment proposed 228. The condition should be an important health
problem, be well understood, have incorporated practical primary prevention
strategies and be understandable to those whom test positive. Colorectal cancer is
therefore an ideal condition for screening. The tests should be simple, safe, precise,
validated and acceptable to the general population with result thresholds agreed
beforehand. There are a number of different possible screening mechanisms for CRC:
Faecal Occult Blood Testing, colonoscopy, flexible sigmoidoscopies, double contrast
barium enema and virtual colonoscopy. The suitability of these methods, especially
their acceptability to the general population, does vary but a balance or combination
can be used depending on the patient. The guidelines regarding treatment insist that a
treatment is possible and that the policies regarding the treatment be well supported
and agreed. The treatments for CRC do fit these criteria. Once these conditions are
met, there are a number of conditions placed on the proposed treatment programme,
finding the most suitable is an area under constant investigation 229-233.
Recently Scotland has introduced a nationwide screening programme using Guaiac
Faecal Occult Blood Testing (GFOBT). The pilot involved three rounds of biennial
GFOBT, between 2000 and 2007 for all people aged between 50 and 69 resident in
Grampian, Tayside and Fife234. This pilot was based on evidence from other studies
showing that regular FOBT can reduce mortalty from colorectal cancer 235, 236. The
pilot demonstrated that population-based colorectal cancer screening is feasible in
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Scotland and should lead to a comparable reduction in disease-specific mortality;
therefore a nationwide screening programme was introduced.
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3.3 Clinical Characteristics of Colorectal Cancer
In general terms, cells following malignant transformation include the following
characteristics 237:
1. Self sufficiency in growth signalling, able to produce their own growth factors
and self stimulate
2. Lack of sensitivity to agent that restrict growth
3. Evasion of apoptosis (programmed cell death)
4. Unlimited ability to replicate
5. Sustained angiogenesis, blood flow to tumour site
6. Ability to invade other tissues and metastasise
The combination of the rapid turnover of epithelial cells in the gastrointestinal tract
and the hostile environment to which the cells are exposed has meant that
gastrointestinal epithelium is an important tissue in cancer research. That colon cancer
takes 10-15 years to develop and the progress through parallel histological and
molecular changes has permitted extensive study of the development pathway. There
are three main established, well recognised, characteristics: that there is a multipstep
progression at the molecular level, that many inherited familial cancer syndromes
correspond to key defects and the loss of genomic stability identified in tumours.
Colorectal carcinogenesis is a multi-step process involving global DNA methylation
changes, hyperproliferation, adenoma formation and growth, specific somatic
changes, and malignant transformation 238. The development of colorectal cancer
along these key stages has been standardised into a recognised process called the
adenoma-adenocarcinoma sequence, a stepwise pattern of loss of methyl groups in
DNA, mutational activation of oncogenes, for example K-ras, and inactivation of
tumour suppressor genes, for example p53, 239, shown in Figure 3.2. There is
epidemiological, clinicopathological and genetic evidence supporting the adenoma-
adenocarcinoma sequence 240.
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More generally, the development of tumours follows the “two-hit” principle proposed
by Knudson 241. The “first hit” is the disruption of the normal epithelium, via
hyperproliferation, to form Aberrant Crypt Foci, which can turn into adenomatous or
non-adenomatous polyps. Adenomatous polyps occur fairly regularly in the general
population and often do not develop any further. However, if the “second hit” occurs,
they undergo malignant transformation to become colorectal carcinomas. The
development of colorectal cancer is a slow process, with the adenoma-
adenocarcinoma sequence taking 10-15 years 242.
Figure 3.2 The Adenoma-adenocarcinoma Sequence, from Bronsens et al, 2005
The left side of the bowel is affected by cancer more often than the right: tumours in
the sigmoid colon, rectosigmoid junction and the rectum together account more than
half of all diagnoses. Figure 3.3 shows the percentage distribution of the different
sites in the colorectal tract 243.
Figure 3.3: Percentage Distribution of Cases by Site within the Large Bowel, England
1997-2000 243
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3.4 Environmental Variables Influencing Colorectal Cancer
Risk
The hypothesis that colorectal cancer is influenced by environmental factors is
supported by a number of different observations: the incidence of CRC is distinctly
different in different countries 244, 245, migrant groups soon adapt to the risk estimates
of their new country, often within a single generation of arrival 245, 246 and the sharp
increase in the rate of colorectal cancer in Japan following the second world war 247.
A number of exposure variables are the same as those seen in other medical
conditions, particularly cancer. Eating a healthy well balanced diet, not smoking or
drinking and taking physical exercise a number of times a week are standard health
recommendations, which will also help reduce your risk of CRC. For CRC
specifically, it is plausible that dietary variables are a particularly important exposure
variable as the large bowel has prolonged contact with digested food. In fact it has
been suggested that following an optimal dietary approach, population wide, could
reduce incidence of colorectal cancer by 70% 248.
BMI
Despite being a risk factor for so many health complications and disease, associations
between BMI and colorectal cancer can usually be explained by accounting for
dietary variables and physical activity 245.
Related Conditions
Inflammatory Bowel Disease (IBD) is a group of inflammatory conditions of the
intestinal tract, the main two of which are Crohn’s disease and ulcerative colitis (UC).
The differences between these two conditions are the location and the nature of the
inflammation, with Crohn’s affecting the whole intestinal tract and UC being
restricted to the colon and rectum.
Together with Familial Adenomatous Polyposis (FAP) and Hereditary Non Polyposis
Colorectal Cancer (HNPCC), discussed later, ulcerative colitis (UC) is one of the top
three high risk conditions for developing colorectal cancer with sufferers having a risk
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an order of magnitude higher than those without it 249. However, although FAP and
HNPCC both have a well understood genetic basis, it is the chronic inflammation of
UC that underlies the development of colorectal cancers 250. People receiving
treatment for UC are screened more regularly than the general public, so despite an
increase in incidence, mortality rates are generally lower. Similarly, Crohn’s disease
increases the chance of developing colorectal cancer, especially those who develop
Crohn’s at a younger age, under 30 and patients with colitis (Crohn’s inflammation in
nature but presenting in the colon) 251.
A relationship between history of diabetes, and a higher fasting blood glucose, and
risk of colorectal cancer has been found in women 252 but not in men. There is past
evidence for a link, with some studies finding no difference between the sexes 253, 254
and some inconsistency regarding position of the tumours. A meta analysis fund that
diabetes was a risk factor for colorectal cancer, with no significant differences
between the sexes or position of tumour 255.
Another study found a significant decrease in incidence of hypertension, heart
disease, stroke, chronic chest disease and chronic arthritis in people who developed
colorectal cancer compared to controls 256. They also found a significant association
with haemorrhoids.
NSAIDs
Results from epidemiological, clinical and animal based studies have found some Non
Steroidal Anti Inflammatory Drugs (NSAIDs), salicylate derivatives (including
aspirin) and COX-2 inhibitors to have a preventative effect on CRC 257. Even a low
dose of aspirin has been shown to have a chemopreventative effect on adenomas in
the colon 220.
There is both biological and epidemiological evidence for a protective role of
NSAIDs in CRC risk. The painkilling mechanism of NSAIDs works by inhibiting
both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), catalytic enzymes
involved in the synthesis of prostaglandins, through irreversible acetylation and
competitive inhibition respectively 258. COX-2 is an enzyme which is elevated in
colorectal cancer tissues but not in normal colonic epithelial tissue 259, 260.
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Epidemiological studies in a variety of populations and of different designs have
found associations between NSAID intake and a decrease in incidence of colorectal
neoplasms 261, 262. However, randomised controls trials have had less success 263, 264.
One successful study split patients who had received treatment for CRC into an
aspirin and placebo group. The aspirin group had lower levels of adenomas (17% to
27%) although there was no difference in adenoma size 223. Interestingly a study of
patients who had had adenomas removed found that low dose aspirin was associated
with a reduced risk but higher dose aspirin was not 220. Other studies have shown
positive results after 20 years of continuous use 265-267.
Given the moderate effects of aspirin on CRC, it is not a suitable substitute for good
screening, nor does the intention to treat analysis (1250 people for 10-20 years)
indicate that population wide aspirin will reduce CRC incidence 261.
Smoking
Carcinogenic particles from tobacco could enter the cells in the colorectal mucosa
either through the alimentary tract or the circulatory system. Nearly all recent research
into the relationship between tobacco consumption and colorectal cancer has found a
positive association between increase in consumption and increased risk 268. Earlier
studies, in the 1950s and 1960s, that found no associated risk, can be explained by the
reduced timescale of smoking of the participants compared to more recent years. This
association is also backed up by changes in trends in smoking between the sexes, with
women becoming long term smokers later than men and their colorectal cancer
incidence reflecting this. Chewing tobacco has been found to interact with particular
genotypes to increase oral cancer risk 269.
Physical Activity
Physical activity has been one of the most consistent factors associated with a reduced
risk of colon cancer. Early studies found that men with physical jobs had less colon
cancer and more recent studies shows that increased amounts of exercise in leisure
time can reduce risk 270. Recent studies have found the effects on risk of rectal cancer
to be equivalent to colon cancer 271. This is backed up by cohort studies showing there
is epidemiological evidence that men with high levels of either occupational or
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recreational physical activity are at lower risk of developing colorectal cancer 245, an
association that remains when diet and BMI are accounted for. However, research in
Norway has found this association only to apply to males 252, though this could in part
be explained by misclassification, with the physical activity level of housework being
differently perceived.
Evidence has also been found to support an exercise based intervention with a control
trial finding that middle aged or older people who took an hours exercise a day, six
days a week had reduced colon crypt cell proliferation 272.
Deprivation
Comparing colorectal cancer incidence and survival against the Carstairs index, where
1 represents the least deprived category and 7 the most deprived, found that incidence
varies little with deprivation but that survival increases with decreasing deprivation
245. Men have a higher incidence than women across all seven deprivation categories.
However, further research which adjusted for prognostic factors found the
relationship between CRC and CRC associated death to be insignificant 273 but that
death from other causes and co-morbidity were significantly higher in lower
socioeconomic groups. One important factor is the lower acceptance to screening
programmes in lower socioeconomic groups 274.
Female Hormones
A possible role of female hormone treatments in the progression of colorectal cancer
was first suggested when an excess of colorectal cancer was found in nuns, who do
not take contraception or fall pregnant 275. When postmenopausal hormone treatments
were less commonly used, the disease pattern of colorectal cancer varied between
men and women, with more females than males developing cancer in the proximal
colon, especially under 50 years of age. However, males over 65 have a similar excess
compared to other cancers 276. Males of all ages have a higher colorectal adenoma
prevalence 277. Therefore, without hormone supplementation, progression from
adenoma to carcinoma in the proximal colon must be more common in women under
65 and may be related to female hormones. Biologically this is supported by mRNA
for oestrogen and progesterone receptor proteins that has been found in the large
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bowel 278, the expression of which decreases as carcinoma cells become more
differentiated 279.
Over the last 25 years, the mortality from CRC has decreased slightly in men but
much more drastically in women 280. One possible explanation for this is the increased
use of hormone replacement therapy (HRT) in postmenopausal women. Oestrogen
could have an affect on CRC in a number of ways: by decreasing bile acid production,
by decreasing the production of insulin-growth factor 1, by directly effecting the
colorectal epithelium, or a combination of mechanisms early in the neoplastic process
281.
Most early studies found a relative risk of CRC and HRT either around or below zero
282. A more recent meta analysis of 18 published observational studies 283 found there
to be a 20% decrease of colorectal cancer between those who had never used HRT
and those who had ever used it. This decrease was 34% for current users versus never
users.
In studies of HRT use, other female only variables were identified that reduce
colorectal cancer risk including number of children, with the risk decreasing for each
additional child; breast feeding; the use of oral contraceptives; and BMI 284. None of
these factors were associated with HRT use.
Similarly, the oral contraceptive has been found to have a protective effect against
CRC, probably due to the inhibitory effects of oestrogen on colon cancer cells 285. A
meta-analysis of 8 case control studies and 4 cohort studies found an 18% decrease in
risk 286.
It is important to remember that the women receiving HRT are not a cross section of
the general population but a group of women receiving treatment based on perceived
need 277. Any protective effect therefore may not extend to the general population.
Given the decrease in mortality since the advent of HRT, it is unlikely that the
medical problems for which HRT treatment is used are themselves providing some
sort of protective effect and confounding the results. It is therefore more likely,
assuming that behavioural factors such as social class have been adjusted for, that
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case-control studies of HRT use may be underestimating the true protective effect
conferred on the women who will benefit most from the treatment by comparing them
to a lower risk control group.
It is also important to note that oral contraception has been associated with an increase
in risk for a number of other cancers: breast, cervical and liver 285. Therefore neither
HRT nor the combined pill should be considered as a public health recommendation





Traditionally known as roughage, an association between high levels of fibre
consumption and low incidence of colorectal cancer was first studied scientifically by
Burkitt in Africa, more than 35 years ago 287. Since then fibre has been one of the
most well researched, and most controversial, factors thought to affect colorectal
cancer risk. Despite there being both biological and epidemiological evidence
underlying the hypothesis, the limitations of different study designs have led to
conflicting results across epidemiological, intervention and animal studies.
The biological evidence is based on the fact that fibre increases stool weight, which
increases transit speed through the colon and reduces constipation, thus diluting the
contents of the colon and stimulating the bacterial anaerobic fermentation 288. The
increased speed and fermentation reduce the contact between the intestine contents
and the mucosa, leading to the production of short chain fatty acids, acetate,
propionate and butyrate 289. Butyrate reduces the pH of the colon and the production
of secondary bile acids through primary bile acid binding.
Butyrate is also a major source of energy and helps reduce cell proliferation and
induce apoptosis, which reduces the level of transformation of cells from colonic
epithelium to carcinoma. It is possible that butyrate works by blocking the induced
signalling events of IL6 and the IL6 receptor, an autocrine loop that promotes the
development of many tumours 290. It is also possible that butyrate modules the
expression of glutathione S-transferases genes, thus enhancing toxicological defence
in primary, adenoma and tumour human colon cells 291.
Epidemiologically, a strong associations was found in one of the largest prospective
studies, a collaborative project of ten European countries, called the European
Prospective Investigation of Cancer and Nutrition (EPIC) 292. The collaborative study
has an advantage over smaller studies, not just in sample size but in ensuring that
homogenous eating habits do not increase measurement error to the level that it
obscures all but the largest effects. In 2003, they found a significant association
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between fibre consumption and reduced colon cancer risk, reported as both a hazard
ratio between the highest and lowest fibre consumption quintile, and as a test for trend
across all five quintiles. The Prostate, Lung, Colorectal and Ovarian Cancer Screening
project team (PLCO) used sigmoidoscopies to screen and compared the dietary habits
of the 33,971 people that were free of polyps in their large bowel to the eating habits
of the 3,591 that has at least one adenoma in their colon 293. They found that increased
fibre from grains, cereals and fruits was associated with a decrease in CRC risk, but
that there was no association for fibres from legumes or vegetables. A different study
in Sweden found the benefits of fibre to come from fruit and vegetable consumption,
with no protective effect from eating high level of cereal fibre 294.
However, a number of randomised clinical trials have failed to find any association
between an increase in fibre consumption and adenoma recurrence. The Polyp
Prevention Trial (PPT) tested a dietary intervention after four years 295 and then after a
further four years follow up 296 finding that people could follow interventions
successfully but that there was no effect on polyp recurrence. Other trials that show
no effect include a study of wheat bran supplementation 297 and a high fibre, low fat
intervention 298. It has also been noted that the death rates from CRC are the same in
vegetarians as non-vegetarians 299.
The sheer volume of confounding factors between people with a diet high in fibre and
those with low levels can be make analysis difficult. One successful retrospective
study adjusted for the higher fibre group being older, more likely to be female, better
educated, exercised more, ate less red meat, lower levels of smoking, less alcohol
consumption, more aspirin, higher consumption of folate and calcium. Pooled
analysis of all the observational studies found the inverse association between fibre
and colorectal cancer became insignificant when all other dietary variables were
adjusted for 300. Given that different sources of fibre may have different affects on
risk, it is possible that fibre is in fact acting as a marker for an unmeasured substance
that occurs jointly with fibre 293. This substance could be glucosinolates 301,
caratanoids, or beta-cryptoxanthin 302.
It is unlikely, given how large the sample sizes were, that the contradictory findings
are the result of chance. However, treating dietary fibre as a variable that can be
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accurately measured and characterised may be misleading and result in contradictory
results. Dietary fibre is neither simple in structure nor simple to analyse 303. Dietary
fibre was first described in 1975 as the complex carbohydrates in the diet from plant
sources that escape small bowel digestion and therefore reach the colon 304. It was
later defined as the plant cell walls that are resistant to digestive enzymes, however
these vary greatly depending on species and cell type 305 and these different
components may have differing effects on cancer risk, with some types of fibre even
enhancing risk 306.
The intervention studies may have found no protective effect from additional fibre as
the intervention level of fibre was too low 303 and there was no way to verify that
people followed the recommended eating patters 296. Similarly the nurses’ study may
have found no association as the nurses consumed low levels of fibre from cereals,
and in the study by Mai et al 307, the 90th percentile of dietary fibre intake only
consumed 18.2 g of fibre, well below the recommended amount. The same applies to
the NIH-AARP Diet and Health Study, with the the 90th percentile eating only 15.9g
of fibre a day 308. Both the EPIC study and PLCO covered a much more varied range
of eating habits and may therefore be comparing heterogeneous eating patterns
including the beneficial fibres.
The timescale of the clinical trials may also be too short to be conclusive, with most
lasting 3-4 years 309 and colorectal carcinogenesis in humans estimated to take 10-40
years to develop 310.
In conclusion, the results suggest that fibre, consumed at high enough levels, does
have a protective effect but that further analysis subdividing the categories of fibre
could show more consistent and verifiable results. Such work has been explored in
animal models 311, 312 and although such data may be difficult to collect in humans, it
may make comparisons between different studies more valid and useful.
Folate
Folate is micronutrient found abundantly in fruit and vegetables. It has been suggested
that some of the inconsistencies between studies of fibre could be explained by the
protective effects of fibre in European populations being confounded by folate intake,
96
whereas those in North America, where cereals are fortified with folic acid, are
adjusted for possible confounding by folate 313. However, increasing the sample size
and adjusting for folate did not alter the association the EPIC study found between
fibre and a reduction in risk 314, it did however suggest that the positive association
between folate and reduced colorectal cancer incidence could be confounded by fibre
intake 315.
Biologically, folate plays an important role in DNA synthesis and replication 316 with
anti-folate agents used as chemotherapeutic treatments of cancer, as reduced folate
inhibits cancer cell growth. Folate blocking drugs work as fast growing tissues,
including cancers, require more folate for nucleotide synthesis and therefore up-
regulate their folate receptors. Other possible mechanisms include altered DNA
methylation or a relationship to the methylenetetrahydrofolate reductase (MTHFR)
gene 317, which is involved in folate metabolism 318 although research does not
indicate that these methods are likely in CRC progression 319. However, there are also
biologically plausible mechanisms by which a deficiency of folate could increase
incidence of cancer, by reducing DNA repair efficiency. It is one vitamin where low
levels can plausibly lead to an increase or a decrease of carcinogenesis.
A number of studies and meta analyses have shown an inverse relationship between
folate intake and risk of developing CRC 320-322. Although there is a protective effect
of eating a folate rich diet, the degree of benefit seems to be greater for those that take
a folate supplement 257. However, there are also biological and epidemiological
studies that show that increased folate can enhance the progression of tumours,
increasing the risk of advanced lesions 323, 324. It therefore seems likely that the timing
of folate administration is important. Folate administration prior to the development
of the first pre-neoplastic lesions can prevent initial tumour development, whereas
increased folate after early lesions are established increases tumorigenesis 325.
Meat and Fat
One of the specific components of the western diet that has been proposed as a
possible risk factors for CRC is increased intake of both animal fat and saturated fat
326. A meta analysis of studies over the 1973-1999 period found that a high intake of
red meat, especially processed meat, was associated with a moderate but significant
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increase in CRC risk. Total meat consumption is not associated with risk but the risk
is higher in regions where red meat composes a higher proportion of the diet. It was
concluded that reducing red meat intake to 70g/week in these areas would decrease
the risk of colorectal cancer for the population by 7-24% 327.
Other Dietary Variables
Other dietary variables that have been associated with CRC risk include calcium and
vitamin D (both separately and in combination), alcohol, flavanoids and antioxidants.
Epidemiological studies have found an inverse association between consumption of
dairy products and hypertension, stroke and colorectal cancer 328. Increased
consumption of calcium may have a protective effect by binding with bile and fatty
acids and by direct inhibition of colonic epithelial-cell proliferation 257. Pooled
analysis of ten prospective studies found the protective effect of milk consumption
was limited to tumours in the distal colon and rectum 329. Most retrospective studies
have also found an inverse correlation between calcium intake and CRC risk, though
not always reaching significance. The main limitations of these studies is accurately
measuring calcium intake and confounding from other dietary variables. One
advantage to calcium supplementation, compared to other methods of
chemoprevention, is that the preventative effect begins in a relatively short space of
time, within a year of starting supplementation 225.
Alcohol has been associated with colorectal cancer risk both independently and as a
negating factor for other protective dietary variables. The associated risk seems to be
more consistent for proximal colon, distal colon and rectum 330. Pooled analysis of a
number of different studies found that a single determination of alcohol intake
correlated with a slight elevation in CRC rate, an effect more pronounced for higher
levels of alcohol consumption 331.
Despite being most widely known for their antioxidant activity, flavanoids may also
use other mechanisms to provide health benefits. Flavanoids are found in plants and
can be subdivided by chemistry into ten different subgroups. One category of
flavanoid and three individual compounds have been associated with reduced risk of
colorectal cancer 332. This has been backed up by a randomised dietary intervention
98
trial which found that flavonols were associated with decreased risk of advanced
adenoma recurrence, but not total flavanoid consumption 333. However in a both meta
analysis and a review other antioxidants have been shown to have either no effects or
detrimental effects on the risk of different cancers of the gastrointestinal tract 334, 335.
Whatever the specific reasons, eating a diet rich in a variety of plant foods, including
fruit, vegetables and wholegrains, remains the best option for reduction of colorectal
cancer risk and for general good health.
99
3.6 Genetic Susceptibility to Colorectal Cancer
Similarly to other conditions with a genetic risk component, the inherited risk of
colorectal cancer was initially identified by its tendency towards familial aggregation.
Familial colorectal cancer is a public health issue due to its relatively high frequency,
with 15-20% of colorectal cancers being familial 336. Some twin studies have found
that as many as 35% (95%CI of 10 - 48%) of cases of colorectal cancer have a genetic
component 337. The genetic risk factors involved in colorectal cancer are not yet fully
understood and include genes with different dominance patterns, pathogenic
mutations with low penetrance and gene-gene and gene-environment interactions.
Persistent genomic instability, which contributes to the accumulation of mutations in
tumour suppressor genes and oncogenes, is essential for all colorectal cancers. The
instability can arise through two separate distinct pathways those with microsatellite
instability (MSI) and those that show chromosomal instability (CIN) 338, with both
occurring after adenoma formation but before malignancy 339. MSI mutations are
recessive, with cancers occurring more frequently in the right hand side of the colon,
having diploid DNA and behaving indolently. CIN mutations are dominant, the
resulting cancers tend to be on the left hand side, show aneuploid DNA and behave
aggressively 336. Both types of instability can be characterised by associated
mutations.
Cancer Syndromes
There are two autosomally inherited cancer syndromes that account for a significant
minority of colorectal cancer cases and confer large increases in risk to those with
such a family history: FAP and HNPCC.
The first, called Familial Adenomatous Polyposis (FAP), an autosomal dominant
precancerous condition of the entire colorectal tract, characterised by the appearance
of large numbers (>100) of adenomatous polyps. It is one of the most clearly
understood and well studied of the inherited colorectal cancers with an incidence
varying from 1 in 7,000 live births in Western countries to 1 in 22,000 in developing
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countries 340. FAP is associated with a number of other cancers, it is therefore
important to follow people with FAP, even after a prophylactic colectomy 341.
A similar condition called Attenuated Familial Adenomatous Polyposis (AFAP)
occurs later in life and in a slightly different area of the bowel (proximal colon as
oppose to distal colon or rectum) 342. There is also a condition called attenuated
Polyposis which does not involve germline mutations in the APC gene, but in genes
that interact with APC or mismatch repair genes which increase the risk of somatic
APC mutation.
The second major condition is called Hereditary Non-Polyposis Colorectal Cancer
(HNPCC), also known as Lynch syndrome, which is thought to account for 5-8% of
colorectal tumours 336. Lynch syndrome I is specifically familial colorectal cancer,
Lynch syndrome II is other cancers of the GI tract or reproductive system. The
average age of diagnosis of HNPCC is 11 years earlier than the average age of
diagnosis for other colorectal cancers 343.
FAP and AFAP are the result of a CIN, germline, truncating mutation in the tumour
suppressor gene APC, with the mutation on chromosome 5q, distal and proximal to 5’
respectively. 90% of the people carrying this mutation will develop CRC by the time
they are 45. A large number, around 40-60%, of the families diagnosed with HNPCC
have pathogenic, MSI mutations in mismatch repair genes.
There is a rare autosomal recessive condition called Turcot’s syndrome which is
having both FAP and HNPCC which can lead to CRC and tumours in the brain and
skin. Other than these two there are a number of other, less common syndromes which
are associated with an increase in colorectal cancer risk, though these may be more
strongly associated with other cancers: Peutz-Jeghers syndrome, Juvenile Polyposis,
Cowden, Li-Fraumeni and Bloom syndrome. A summary of the genes involved is
shown in table 3.2.
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FAP - Adenomatous Polyposis Coli (APC)
The APC gene is on chromosome 5q21-22 and encodes a protein important for cell
adhesion and signal transduction. The loss of APC is one of the first events in the
chromosomal instability (CIN) pathway.
There have been more than 1000 mutations of the APC gene discovered 344 more than
300 of which are associated with disease. More than 98% of APC mutations are
nonsense or frameshift, leading to the synthesis of a truncated protein which cannot
suppress the cellular overgrowth. The most common occurs in 10% of FAP and is a
deletion of 5 bases. A hypermutable tract in APC has been identified in the
Ashkenazim population, but not in non Jewish populations, which both increases
incidence and reduces age of onset for carriers 345. In some cases, less obviously
familial CRC can be caused by incompletely penetrant, comparatively rare missense
mutations in the APC gene.
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Biallelic inactivation of APC can also occur through other routes, Spirio et al found
some families affected by attenuated polyposis had the loss of mutant germline APC
accompanied by  new somatic mutations in the remaining allele 346.
HNPCC
A large number of polymorphisms in the human mismatch repair (MMR) proteins
MLH1, MSH2, MSH6, PMS1, and PMS2 have been found to co-segregate with
HNPCC 347. Over 90% of the polymorphisms discovered so far occur in hMLH1
(human mutL homolog 1) and hMSH2 (human mutS homolog 2) 348 as shown in the
table below.
Table 3.3 MMR Gene Polymorphisms, adapted from Mitchell et al, 2002









16, 1852, AA-GC Lys618Ala
4, 350, C-T Thr117Met
19, 2146, G-A Val716Met
4, 320, T-G Ile107Arg
Missense
2, 199, G-A Gly67Arg
Insertion 13, 1490, C Frameshift from codon 497
16 3.5kb deletionDeletion
16, 1846, AAG Deletion lysine codon 616
IVS*5, 4541 (d) Out of frame deletion
hMLH1
IVS deletions (d)/
insertions (i) IVS*14, 1667 (d or i) Allele silenced
Nonsense 7, 1216, C-T
Missense 6, 965, G-A Gly322Asp
12, 1786, AAT Deletion asparagines codon 596
hMSH2
Deletion
IVS*5, 942+3 In frame deletion, exon 5
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Attenuated Polyposis
One of the main tumour promoting effects of the somatic mutations associated with
attenuated polyposis is that they can lead to an over-activation of the Wnt (wingless)
signalling pathway, up regulating expression of genes that promote cell growth. This
pathway is shown in figure 3.4, and shows the functional role of APC and other
molecules involved in signalling 349:
Figure 3.4 The Wnt Signalling Pathway
When the Wnt signal binds to the Frizzled compound, it also binds to AXIN, which
leaves the β-catenin in its stable state. In the absence of Wnt signalling, the AXIN
forms a compound with APC and GSK-3β, which phosphorylates β-catenin into a
compound that is degraded in the proteasome. β-catenin, in its stable state, initiates
cell proliferation, therefore its degradation halts cell proliferation. The mutated APC
leads to an accumulation of β-catenin in the cell nucleus, leading to cell proliferation
and colorectal cancer. β-catenin is also a key component of the cadherin complex,
which controls cell-cell adhesion and influences cell migration 349. Once the excess β-
catenin translocates to the nucleus, it interacts with other transcription factors
including the T-cell factor enhancing factor (TCF). TCF-4 is the predominant TCF
expressed in colorectal epithelium 339. Target genes up-regulated by TCF-4 include
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CYCLIN D1, C-MYC, MATRILYSIN, C-JUN, FRA-1, urokinase-type plasminogen
activator receptor and the peroxisome proliferators activator receptor.
The genes on the Wnt signalling pathway include: CTNNB1 ( -catenin gene, 3p22.1),
BTRC ( -transducin repeat-containing protein gene, 10q24.3), ICAT (inhibitor of -
catenin and Tcf-4, 1p36.2), AXIN1, AXIN2 (17q23-q24), TCF4 and CDX-2. Other
genes up-regulated by the Wnt pathway include two members of the CNN family of
growth factors WISP1 and WISP3, and PPP2R1B a subunit of the PPA-2 tumour
suppressor gene involved in β-catenin phosphorylation 350.
Mutations of β-catenin, much like mutations in APC, make β-catenin insensitive to
the compound leading to its degradation. The majority of CTNNB1 mutations are
missense mutations in a portion of exon 3 encoding for the GSK-3β phosphorylation
consensus region of β-catenin, hindering the ability of GSK-3β to phosphorylate β-
catenin 351. The majority of CTNN1B mutations are very rare with the missense
mutation N287S only found heterozygous in 0.6% of a control group 352.
Mutations in the AXIN1 gene include T1942C and G2063A, at 21% and 3%
respectively in the general population 353. There are other rare variants (P312T,
R398H, L445M, D545E, G700S and R891Q) which have also been identified and
may contribute to CRC risk 352.
The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of
heterozygosity in breast cancer, neuroblastoma and colorectal adenomas 354. The
AXIN2 gene codes for the Axin-related protein Axin2, which interacts with APC,
GSK3 β and β-catenin to promotes β-catenin phosphorylation and subsequent
proteasomal degradation 355. However, the mutated Axin2 stabilises β-catenin and
activates β-catenin/T-call factor signalling 354. The deregulation of beta-catenin is an
important event in the genesis of a number of malignancies.
Although the majority of human colorectal cancers have high levels of β-catenin or
TCF transcription up regulated, due either to inactivation of the APC (tumour
suppressor gene) or activating mutations of β-catenin, one group identified a CRC cell
line with neither of these more common mutations. Instead they found a truncating
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mutation, a 4bp deletion, in the CDX-2 gene 356, which combined with animal models,
suggested that the CDX-2 gene may contribute to the tumour suppressor effects of
APC. There is a G to A substitution in the Cdx-2 binding site, called 1e-G−1739A
(rs11568820), which has been associated, the G allele at 81% and the A at 19%,
following Hardy-Weinberg equilibrium.
Other genes related to β-catenin function include presenilin 1 (PS1), a gene normally
associated with Alzheimer’s disease, which regulates β-catenin stability by assisting
its phosphorylation and subsequent degradation 357. MYH is a mismatch repair gene,
which has been implicated in multiple adenomas, including attenuated polyposis, and
is a base excision repair gene that corrects oxidative DNA damage. Although not
specific to the Wnt pathway, MYH/MUTYH increases the likelihood of G:C>T:A
transversions in the gastrointestinal tract. Initially two Missense mutations were
identified, Y165C and G382D, 358. The genes involved in the Wnt signalling pathway
leading to attenuated polyposis are shown in table 3.4:
Table 3.4 Genes Involved in the Wnt Signalling Pathway
Action Genes
Up-regulation by TCF-4 CYCLIN D1, C-MYC,
MATRILYSIN, C-JUN, FRA-1
β-catenin CTNNB1
On Wnt pathway BTRC, ICAT, AXIN1, AXIN2,
TCF4, CDX-2




The remaining familial CRCs are composed of a large numbers of different
syndromes involving polymorphisms in the tumour suppressor genes, mismatch repair




Tumour suppressor genes are often identified by the allelic imbalance within polyps.
Other than APC, the most widely researched tumour suppressor gene in CRC is p53,
mutations in the germ line of which lead to the rare, autosomal dominant Li-Fraumeni
syndrome (LFS) 359. This is susceptibility to a wide range of cancers, including breast,
bone, brain and leukaemia.
Juvenile Polyposis syndrome (JPS) is an autosomal dominant syndrome characterized
by a specific type of polyp in the entire gastrointestinal (GI) tract, particularly the
stomach, small intestine, colon, and rectum 360. The term "juvenile" refers to the
nature of the polyp, not the age of the patient. There are two genes associated with
JPS: BMPR1A and SMAD4 (also known as MADH4 and DPC4), which together
account for approximately 20% of cases of JPS 361. Mutations in BMPR1A have also
been identified in association with Hereditary Mixed Polyposis Syndrome (HMPS),
which is another autosomal dominant syndrome that can led to CRC but with a
histological variety of polyps 362.
Peutz-Jeghers Syndrome (PJS), also known as Hereditary Intestinal Polyposis
Syndrome (HIPS), affects the entire GI tract and is often diagnosed by areas of
hyperpigmentation on the hands, feet and mouth 363. Peutz-Jeghers can be caused by a
variety of mutations in the STK11 gene (also known as LKB1), located on
chromosome 19p13 which encode the serine/threonine kinase 11 protein 364, with
most mutations leading to a truncated protein. However, there maybe other mutations
which also lead to PJS 365 which could be due to a pathway relationship between PJS
to another inherited tumour syndrome, Tuberous sclerosis complex (TSC) 366 which
does not affect the colon or rectum.
There is a tumour suppressor gene PTEN, which removes phosphate groups from
tyrosine, serine and threonine. Mutations in PTEN lead to a spectrum of disorders
called PTEN hanartoma tumour syndromes (PHTS) which include Bannayan-Riley-
Ruvalcaban syndrome (BRRS) and Cowden syndrome.
107
Mismatch Repair (MMR) Genes
Cancers with MMR gene defects carry tens of thousands of small insertions and
deletions in short tandem repeats 367. Other than Lynch syndrome and attenuated
polyposis, variations a mismatch repair gene, BLM, can lead to a syndrome called
Bloom, also known as Bloom-Torre-Machacek syndrome. This is an increased
susceptibility to a broad spectrum of cancers including CRC.
Oncogenes
There are two main genes associated with familial GI stromal tumour: KIT and
PDGFRA. One of the most prominent proto-oncogenes in CRC is a member of the
RAS family of genes, K-RAS, with a small number of mutations in N-RAS 339.
Another gene often thought to be an oncogene, but is in fact a transcription factor with
tumour suppressor characteristics, is TP53, coding for the p53 protein, germline
mutation of which lead to Li-Fraumeni syndrome. There are a large number of
mutations and modes of action of the p53 gene, which in its wildtype state recognises
DNA damage and induce cell cycle arrest.
Polymorphisms in the Glutathione S-Transferase (GST) superfamily
The GSTs are a superfamily of dimeric phase II metabolic enzymes, which protect
cellular macromolecules from damage by catalysing the conjugation of electrophilic
molecules and products of oxidative stress with reduced glutathione 368. They are
involved in the metabolism of a number of environmental carcinogens,
chemotherapeutic agents and endogenously derived reactive oxygen species.
In humans, there are five subfamilies: Alpha, Mu, Pi, Theta and Zeta 369, of which
there are two Alpha classes and four Mu classes. There has also been a mitochondrial
GST, GST Kappa, identified.
GSTM1 codes for the cytosolic enzyme GST- μ 370, with approximately 50% of
Caucasians homozygous for a deletion in GSTM1 371. The GSTM1 null allele leads to
an absence of GST- μ enzyme activity 372. There has been conflicting results in
studies into the risk associations with GSTM1 and colorectal cancer. Some studies
found an association with increased colorectal cancer risk 373, 374 or no association 375-
377, or differing association depending on the site of the tumour 378. There is also
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hypotheses that GSTM1 may interact with smoking or meat intake 379, where further
studies would be useful.
There are two alleles of the GSTM3 gene: GSTM3*A and GSTM3*B. The
GSTM3*B variant has a 6bp deletion in intron 6, which creates a recognition
sequence for a Yin Yang 1 (YY1) transcription factor 380. GSTM3 is linked to
GSTM1, and it has been proposed that GSTM1*A confers an increase in
susceptibility due to an association with GSTM3*B 381.
The Pi subclass, GSTP1, expressed in epithelial tissues has been found to be highly
over expressed in colon cancer 382. The GSTP1 gene is polymorphic, with nucleotide
313 of exon 5 changing from adenine to guanine resulting in an amino acid change at
position 104 of the GSTP1 protein 383. This change substantially diminishes CSTP1
enzyme activity 384. The polymorphisms of GSTP1 include wild-type (AA) in 42 –
69% of the population, heterozygous (AB) in 35% and homozygous for the variant
(BB) in approximately 105 370.
The GSTT1 null allele, which abolishes GST θ enzyme activity 372 and has been
associated with ulcerative colitis, has been found associated with increase in risk of
colorectal cancer 375. This supports the hypothesis that the GST T enzyme is involved
in the detoxification of unidentified xenobiotics in the large bowel. This frequency of
this allele in Europe is between 10-21% 379. A meta-analysis also found that GSTT1
conferred an increased risk of colorectal cancer in Caucasians 385, and that the
combination of the highest risk GSTM1and GSTT1 genes has an odds ration of more
than 2 compared to the null genotypes. A different, more recent meta-analysis found
both GSTM1 and GSTT1 null alleles to confer an increase in risk in Caucasian
populations, but not in Chinese 386. Another study found that the GSTT1 null
genotype association with colorectal cancer was stronger in current smokers,
suggesting a possible interaction 370, a later meta analysis found a similar, though still
insignificant interaction with smoking 387.
Polymorphisms in the Matrix Metalloprotineases (MMPs)
Matrix Metalloprotease (MMP) are a group of zinc-dependent endopeptidases, which
degrade products in the extracellular matrix (ECM). Such degradation in the tissue
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surrounding a tumour is a critical process in cancer development and metastasis 388. A
number of MMPs have been associated with colorectal cancer, although there is
speculation over whether higher levels of MMPs precede or follow the onset of
cancers. The majority of the work has focused on the biological role of MMPs and
their levels of gene expression in cancerous versus benign tissue.
The MMP family is comprised of a number of enzymes that share similar active
domains and are numbered according to their order of discovery. An increased
expression of MMPs 1, 2, 3, 7, 9, and 13 have been associated, in separate studies,
with an increase in malignancy, microsatellite instability and a decrease in prognosis
389.
Other Metabolising Genes
Cytochrome P-450 CYP1A1 is expressed in the large bowel 390 and is involved in the
metabolism of oestrogen and polycyclic aromatic hydrocarbons (PAHs), found in
tobacco smoke and consumption of high levels of certain meats 268, 391. There are three
common polymorphisms and a fourth that has been detected in an African American
cohort. The CYPAP1A1*2A (m1) and CYPAP1A1*2C (m2) are associated with
higher levels of biomarkers for PAH exposure 392 but are not conclusively linked to an
increase or decrease in risk. The CYPAP1A1*4 (m4) variant has only been studied
once 393, when it was found to be associated with decreased risk of CRC, but this has
not been verified in further work.
The alcohol dehydrogenase (ALDH2) gene has been associated with CRC in Japan,
especially in heavy drinkers 394. Microsomal Epoxide Hydrolase (mEH) is a protein
which mediates the transport of bile acids and plays a central role in the metabolism
of PAHs 395. In smokers and those who regularly eat well done meat, there was an
association between mEH polymorphism and CRC.
Methylenetetrahydrofolate reductase (MTHFR) is a vitamin B12 dependent enzyme
that catalyses the conversion of 5, 10 methylenetetrahydrofolate, involved in purine
and thymidine synthesis, to 5-methylenetetrahydrofolate, for methionine synthesis.
This process also creates SAM, the universal methyl donor in humans involved in
DNA methylation 396. People with an identified polymorphism, MTHFR C677T
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(rs1801133), which causes an amino acid change from an alanine to a valine, have
~30% of the enzyme activity of the CC wildtype, heterozygotes (CT) have ~65% 397.
A mutation in MTHFR could therefore influence both DNA synthesis and DNA
methylation. This polymorphism has been found to reduce enzyme activity and has
been investigated or an associated to CRC risk, with conflicting independent results
398-400. There have also been studies that have identified differences in risk for dietary
variables in a sample stratified for MTHFR genotype, suggesting a possible
interaction role 401, 402. There is another polymorphism A1298C, which also decreases
enzyme activity. Three other polymorphisms have been identified: T1059C, T1317C
and G1793A, though not studied in great detail 403-406.
Compounds phosphorylated by the phosphatidylinositol 3-kinases (PI3Ks) activate a
wide number of downstream targets. The mechanisms of the PI3Ks may go some way
to explaining the role of the tumour suppressor gene PTEN in tumour development.
Polymorphisms in these genes, particularly PIK3R1, have been associated with
colorectal cancer 407, 408.
N-Acetyltransferase Polymorphisms
N-Acetyltransferase (NAT) has two isozymes, NAT1 and NAT2, which are
responsible for activating and deactivating aromatic and heterocyclic amine
carcinogens. There are two polymorphic genes that code for NAT activity, NAT1 and
NAT2, and one pseudogene, NATP 409. An early observation, whilst using isoniazid
to treat TB, was that the human population is divided into slow, intermediate and
rapid acetylator phenotypes. There have been a number of conflicting studies
regarding a possible association between the rapid NAT2 polymorphism and
colorectal cancer 409, 410. It is biologically plausible that rapid isoforms of NAT1 and
NAT2 more readily activate certain carcinogens, thus putting the colon at more risk
411. However, studies investigating the relationship between the NAT phenotypes and
smoking or meat consumption have found indications of a possible interaction effect
412.
Anti- Inflammatory Pathway Genes
The idea that NSAIDs could prevent colorectal cancer is based on the relationship
between chronic inflammation of the bowel and the associated increase in risk 249, the
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assumption being that the reverse is true. Anti-inflammatories have also been shown
to reduce adenomas in people with FAP 413.
The most widely recognised mode of action for aspirin and other NSAIDs is targeting
the cyclooxygenase (COX) family which are important enzymes in the synthesis of
prostaglandins, which have a role in inflammation. NSAIDs are all competitive
inhibitors of COX, with aspirin covalently modifying the protein irreversibly 414.
There are two types of cyclooxygenase: COX1 and COX2. Aspirin inhibits COX1
and modifies COX2, which normally produces the pro-inflammatory metabolite
prostaglandin E2 (PGE2), to produce lipoxins, which are anti inflammatory.
The mechanism by which inflammatory molecules influence CRC risk is still not fully
understood. It has been suggested that the prostaglandins target the Wnt pathway, also
the target of the mutated APC gene. In the Wnt pathway, NSAIDs act in a similar way
to the action of wildtype APC, by reducing the cyclooxygenases, which in turn reduce
the prostaglandins. In the presence of inflammation, the prostaglandins bind with a
compound, activating a G-protein coupled receptor (Gαs) which binds to AXIN,
having the same effects on β-catenin as the Wnt pathway 249.
It has also been suggested that COX2 inhibitors work by preventing the COX2
stimulation of tumour cell growth and formation of new blood vessels
(neoangiogenesis) 415. Polymorphisms of the COX family have been investigated,
with an amino acid change Pro17Leu in COX1 and G(-765)C in COX2 both being
associated with colorectal cancer risk. Polymorphisms in hepatocyte growth factor
(HGF) and  the ERK signalling pathway have also been associated with cox-2
activation 416.
Other modes of action include the up-regulation of the prostate apoptosis response 4
(Par-4) gene following NSAID treatment 417. NSAIDs also antagonise NF-κB, a
transcription factor found to be elevated in many cancers and with a role in
inflammation 418. There are certain metabolic enzyme genotypes that can modulate the
chemopreventative effects of NSAIDs by impairing the metabolism, especially
UGT1A6, UGT1A7 and CYP2C9 419-421. Other pro-inflammatory genetic
polymorphisms associated with colorectal cancer risk include IL-10-592, an anti-
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inflammatory cytokine with a role in modulating gastrointestinal tract inflammation
422.
Digestive Pathway Genes
For dietary variables associated with colorectal cancer, the different genes and
resultant proteins involved in their metabolism may provide clues to different levels
of susceptibility.
Vitamin D
Different polymorphisms in the vitamin D receptor (VDR) gene have been associated
with a number of cancers and chronic diseases 423. The CDX2 gene that may play a
role in the action of APC, is normally related to the Vitamin D pathway.
Folate
Other than MTHFR, other genes involved in folate metabolism include methionine
synthase reductase (MTRR A66G), cystathionine β-synthase (CBS exon 8, 68 base
pair insertion) and thymidylate synthase (TS enhancer region and 3’ untranslated
region). Overexpression of TS is linked to resistance to TS-targeted chemotherapy
drugs. Tandem  repeats located in the TS enhancer region (TSER) gene have been
shown to influence TS expression 400.
Low Penetrance Susceptibility Genes
There are a few genes with low penetrance that have been associated with colorectal
cancer, these are: CASP8 424, PUO5F1P1 , GREM1, SCG5,
8q24 425-427.
Gene Environment Interactions
A number of different genes have been either found or hypothesised to interact with
NSAIDs. For example, there is evidence of a possible interaction between aspirin and
p53 mutations. A study comparing different compounds that work on the same
pathway found that aspirin based G1 arrest and apoptosis (a mechanism that restrains
cell proliferation) activated p53 and p21 in an ataxia-telangiectasia-mutated (ATM)
kinase dependent way 428. There is also evidence of an interaction between a variant
113
of the IL-10 gene and aspirin use 422 with carriers of the IL-10-592 allele being more
likely to derive benefit from the anti-inflammatory actions of aspirin due to a lower
production of their own anti-inflammatory interleukin-10.
An interaction between GST enzymes the toxicity of chemotherapeutic drugs has also
been found 376. GSTs are involved in the metabolism of polycyclic aromatic
hydrocarbons (PAHs) for which there is inconsistent evidence for an association with
CRC 370. One study found no independent effects of GSTP1, M1 or T1
polymorphisms but did find an increased risk when interacting with the NAT2 slow
genotype 429. Significant interaction effects have been found between all three variants
of the CYP1A1 gene and meat intake 392, between two of the variants and leafy
vegetable consumption, but not with smoking.
There is no direct correlation between mEH and colorectal cancer, but there is a
relationship within certain subgroups: smokers; meat consumption, especially those
who consume well done meat; and certain GST genotypes 395. Similarly, those with
slow NAT polymorphisms are more likely to have an increase in risk as a result of
smoke exposure and frequent consumption of red meat 412.
The association of the MTHFR gene and colorectal cancer has been proposed to be
dependent on a number of different environmental variables. The protective effect of
the 667T variant has been found to be enhanced by high levels of folate intake 399, 400,
430 an effect negated by high levels of alcohol 431. The A2756G mutation has also been
found to have a protective effect enhanced in people with a low alcohol intake 432. It
has been proposed that these effects could also be the result of other B vitamins on the
same metabolic pathway. One study found that vitamin B2 was inversely associated
with colorectal neoplasms, an effect more pronounced in those with the MTHFR TT
genotype 402. Low intake of folate, vitamin B12 and vitamin B6 have also been found
to increase risk in those of the TT genotype 401.
Interactions for other genes on the folate pathway, other than the obvious potential
interaction with folate, include methionine, alcohol consumption and vitamin B12 400.
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3.7 Conclusions
Colorectal cancer is a good example of a disease with both genetic and environmental
risk factors, which potentially interact in a lot of ways. Combining the development of
a novel method with the data from a colorectal cancer study could be an important
first step for the field of interaction statistics and public health genetics.
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Chapter 4
Introduction to the Data Used in




Methodological development and evaluation were carried out using simulated data,
before applying the new method to a real dataset consisting of colorectal cancer cases
and controls. Artificial data allows us to dictate the outcomes and explore different
complex underlying interaction models. In this instance the parameters are based on
those found in the real dataset, to minimise the complications that features such as
distribution may introduce in the later analysis. Therefore it is essential to describe
and characterise the data from the colorectal cancer dataset before beginning the
simulations.
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4.2  Description of SOCCS data
The study of colorectal cancer in Scotland (SOCCS) is a large, prospective,
epidemiological case control study in which large volumes of both dietary and genetic
data have been collected for analysis. The methodology is explained in more detail as
the Edinburgh arm of the COGENT study 433, including the supplementary tables.
4.2.1 Study Population
Cases were recruited by research staff based at clinical research centres across
Scotland. Ascertainment bias was minimised by ensuring that recruitment occurred
soon after diagnosis. Recruitment typically took place within 2-3 months of the initial
diagnosis of adenocarcinoma of the large bowel.
The controls were identified at random within calendar, age, sex and area of residence
restrictions from a population based register of people registered with a general
practitioner in Scotland (the Community Health Index) and invited to participate.
They were recruited in the same time period as the cases and matched, one control per
case, for age (± 1 year), gender and area of residence. The matching was carried out to
minimise the effects of gender, age and socioeconomic status and prioritise the
identification of genetic differences. This study was designed with different aims to
the ones in this thesis but the data is suitable for the analysis, however it makes it
impossible to study the effects of age, gender or area of residence in terms of gene-
environment interaction. The exclusion criteria included: death before ascertainment;
being too ill to participate; if the cancer was a recurrence of colorectal cancer as
opposed to the first presentation or if the patient was unable to give informed consent.
4.2.2 Preliminary Analysis of Data
The environmental exposures of interest include basic characteristics, such as BMI,
dietary factors and other lifestyle measures, such as exercise and NSAID intake. The
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case/control status of the simulated sample will be determined by a variety of
different risk algorithms, testing different levels of confounding and attributable risk.
Therefore an individual within the artificial dataset may be a case under a certain
simulation and a control under another. This is necessary to ensure that the algorithm
can detect gene-environment interactions in a range of plausible circumstances and
the simulated sample is not biased towards what would be expected following basic
analysis or reviewing the literature. Therefore it is more important to differentiate by
biological factors, such as gender, than to identify differences between the cases and
controls using basic, crude methods. Univariate analysis on the environmental
variables and case outcome is carried out in detail in Chapter 8.
4.2.2.1 Basic Characteristics
Table 4.1 shows the distribution of age and anthropometric measurements by sex of
the SOCCS population, with one outlier removed, which are then explained in more
length individually.
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Table 4.1 Description of Basic SOCCS characteristics

















Min 21 22 1.39 1.32 42.2 33.1 15.3 12.5
1st
Quart
56 53 1.70 1.57 73.0 60.2 24.1 23.0





















71 70 1.80 1.65 90.0 76.2 29.1 28.8
Max 83 101 2.13 2.06* 167.0 142.9 53.8 55.9
*after removal of outlier
Age
The age of the study population ranges from 21 to 101 years and is approximately
normally distributed with a mean of 62.3 years. Males and females did not differ
significantly in age distribution. This is not what would be expected from a random
sample or all recorded cases, where more cases would be found with increasing age.
However, the SOCCS study wanted to focus on the genetic risk factors with the
heritable factors being more associated with CRC at a younger age and therefore
selected the study population accordingly.
Height, Weight and BMI
Preliminary analysis of height found one woman to be 2.565m (more than 8ft 4 inches
tall), with a very low BMI (automatically calculated from the height and weight
measures). These are unlikely values and suggest an error, either in measurement or
recording of the data. Therefore the height variable for this participant has been
recoded as a missing variable, along with BMI.
Once this variable was recoded as missing, the distribution of height for the whole
population was as would be expected from a combined male and female population,
shown in Figure 4.1. Approximately normally distributed but with two peaks (*)
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representing the peaks of two normal distributions. When divided by gender, the
distributions were approximately normal, shown in Figure 4.2.
Separating the height by gender, results in two normally distributed populations with
an average height of 1.75 and 1.62 metres, for males and females, respectively.
Another area where there are differences dependent on gender is weight, with males
tending to weigh more than females. However BMI is approximately the same for
males as for females, with the females having a slightly larger range.
Females – Height (m)
(%)





Males – Height (m)
(%)
















Figure 4.2 Height Separated by Gender




The dietary variables are all continuous measures calculated from a food frequency
questionnaire in which the participants reported which foodstuffs they consumed and
the approximate level of consumption. These data were then analysed by nutritionists
to quantify the weights of nutrients, fibre and alcohol being consumed daily. The
cases and controls were asked to complete the questionnaire retrospectively for the
year prior to diagnosis or recruitment, respectively.
In describing the dietary variables, preliminary analysis showed the consumption of
all the variables to be severely skewed. Although this is in some way expected, the
degree of skew-ness required further investigation. There was a single participant, a
control, for whom the consumption of every single dietary variable was the maximum
amount registered, usually 4 or 5 times the next highest value. For example Retinol
consumption had a median of 511μg and the second highest consumption of 12,465μg
with this participant consuming 39,681μg. Other figures were similarly unrealistic,
especially given that the participant had a BMI of 32 kg/m2, which although high is
inconsistent with the recording of low levels of exercise and consumption of ten times
the average number of calories than the rest of the sample. Therefore this person’s
data have been removed from the dataset.
Sources of vitamins and minerals in food and the recommended daily allowed (RDA),
as considered in 2009, were found on the Food Standards Agency website:
http://www.eatwell.gov.uk/healthydiet/nutritionessentials/vitaminsandminerals
Recommendations for minimum recommended amount were found on the British
Nutrition Foundation webpage:
http://www.nutrition.org.uk/home.asp?siteId=43&sectionId=s
Table 4.2 presents the preliminary analysis of the dietary habits of the SOCCS
population as a whole. As case control status was allocated to people within a
simulated population based on controlled and varied risk factors, it was not important
at this point to divide the parameters by case-control status. In fact, it could have
biased the method towards finding specific results from this particular population that
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could be observed by basic analysis of separate risk factors without accounting for
multiple testing.  The solubility explains whether the nutrient is fat soluble and
therefore does not need to be eaten every day to meet recommended requirements, or
water soluble and not stored by the body for future use. The RDA is not applicable for
nutrients that have sources other than dietary ones or for nutrients that have such a
range of sources that it is unlikely someone could become deficient. RDA measures
may be different for children or pregnant women, neither of which was included in
the SOCCS study.
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Table 4.2 Dietary variables from SOCCS Questionnaire
Variable Min 1st Quart Median Mean 3rd Quart Max Solubility RDA (adults, unless
stated)
Vitamin D (μg) 0.08 2.55 3.90 4.82 5.82 71.13 Fat NA
Retinol (μg) 22.0 319.0 511.0 697.6 814.0 12465.0 Fat 700 (M)  600 (F)
Calcium (mg) 124 840 1089 1158 1391 5092 NA 700
Thiamine (mg) 0.20 1.60 2.02 2.21 2.55 19.50 Water 1.0 (M)  0.8 (F)
Riboflavin (mg) 0.30 1.64 2.08 2.22 2.64 10.79 Water 1.3 (M)  1.1 (F)
Niacin (mg) 3.9 18.6 23.6 25.4 30.1 142.3 Water 17 (M)  13 (F)
Pantothenic Acid
(mg)
1.11 5.26 6.67 8.23 8.75 68.99 Water NA
Fibre (g) 2.9 15.9 20.7 22.4 26.9 98.8 NA 12-14 (FSA)
20-35 (FDA)*
Alcohol (g) 0.00 1.70 8.10 13.16 19.20 161.50 NA NA
Vitamin B6 (mg) 0.39 2.20 2.79 2.98 3.50 15.28 Water 1.4 (M)  1.2 (F)
Biotin (μg) 8.0 38.9 48.7 51.7 60.2 275.6 Water 10 - 200
Vitamin B12 (μg) 0.30 4.90 6.90 8.19 9.90 80.00 Water 1.5
Folic Acid (μg) 45.0 256.0 322.0 343.2 400.0 1815.0 Water 200
*Different advisory bodies have different recommendations for fibre intake
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As can be seen from the table, there is an extremely large range in consumption for
most of the dietary variables, with at least a four-fold increase, rising to fifteen fold
for retinol, between the 75th percentile and the maximum value. These maximum
values did not all correspond to the same individual and are therefore less likely than
the earlier high value to be a mistake in classficiation.
The same basic analysis was carried out on all the dietary variables, all of which were
positively skewed but normal following transformation, except alcohol consumption
which was re-classified as a binary variable. A summary of the importance or
associated risks for each variable is given below, with Vitamin D illustrating the
distribution.
Vitamin D
Vitamin D has an important role in maintenance of organ systems, regulating calcium
and phosphorus in the blood and calcium absorption into the kidneys, which in turn
enables normal mineralization of the skeleton. It also has a role in the immune system,
promoting phagocytosis, anti-tumour activity and immuno-modulatory functions 434.
Vitamin D can be created by our skin on exposure to UVB sunlight. Vitamin D is
found in oily fish and eggs. Other food sources include fortified foods such as
margarine, breakfast cereals and powdered milk.
Vitamin D (ug)
(%)















Figure 4.3 Distribution of Vitamin D Figure 4.4 log Transformation of Vitamin D
Distribution
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In this population, the consumption of vitamin D, shown in figure 4.3, is very
positively skewed with the mean (4.8) larger than the median (3.9) and a maximum
consumption of 71.13μg. The transformation to the log(vitamin D consumption),
however, is normally distributed, as shown in figure 4.4. Therefore, when generating
artificial data that represents vitamin D consumption, the lognormal distribution was
used.
Retinol
Retinol is also known as vitamin A, a fat soluble vitamin important for bone growth
and vision, especially in low levels of light. It helps maintain healthy skin and
mucosal layers and strengthens the immune system. Vitamin A deficiency in
childhood can lead to xerophthalmia, a leading cause of childhood blindness in the
third world (Humphrey 1992). Those suffering from Vitamin A deficiency tend to
grow more slowly and suffer from more persistent or severe infections than those with
normal vitamin A levels. It is also dangerous to take large doses of vitamin A
supplement on top of a healthy balanced diet, as Vitamin A toxicity can lead to liver
damage, a risk that increases with age 435.
Good sources of Retinol include cheese, eggs, oily fish, dairy products, fortified
margarine and yoghurt. One of the richest sources of retinol is liver. In the study
population retinol consumption is more drastically skewed than vitamin D, with a
mean of 511.0 μg and a median of 697.6 μg. The consumed volumes are slightly
below the RDA but not worryingly so.
Calcium
Calcium is essential for the normal growth and maintenance of bones and teeth, with
long term deficiency leading to rickets 436 poor blood clotting,  osteoporosis 437 and
periodontal disease 438. Calcium needs to be eaten regularly as it is water soluble and
not well stored by the body.
Food sources for calcium include milk, cheese and other dairy foods, green leafy
vegetables (except spinach), soya beans, tofu, and fish in which the bones are eaten,
such as sardines and pilchards. There are also many fortified foods with added
calcium including soya milk and soya produce, breakfast cereals and bread and other
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baked goods made from fortified flour. Calcium in the SOCCS study population is not
as skewed as many of the other variables, probably in part due to the large variety of
possible sources, but still benefitted from transformation. Only 13.1% of the
population eats less than the recommended 700mg a day.
Thiamine
Thiamine is also known as vitamin B1 and works with other B vitamins in
metabolism and maintenance of nerves and muscle tissue. A deficiency of thiamine
can result in a pandemic human deficiency disease called beriberi 439. It is also a
deficiency commonly seen in alcoholics, as alcohol and acetaldehyde have direct
toxic effects on thiamine-related enzymes in the liver 440 .
Thiamine is found in most food types. Good sources of thiamine include pork, dairy
products, vegetables, fruit and wholegrains. Some breakfast cereals are fortified with
thiamine. The SOCCS population has a mean Thiamine consumption of 2.214 and a
median of 2.02. Both the mean and median, and in fact the first quartile measure, are
considerably more than the minimum RDA, which is 1mg for men and 0.8mg for
women.
Riboflavin
Riboflavin is also known as vitamin B2, it is a micronutrient and is involved in
cellular and metabolic processes including the metabolism of carbohydrates, fats,
proteins and ketone bodies. There is evidence that riboflavin has a role in iron
handling and a deficiency contributes to the aetiology of anaemia when iron intakes
are low 441. Biochemical signs of deficiency occur after only a few days of dietary
deprivation.
Riboflavin is found in milk, eggs, fortified breakfast cereals, rice and mushrooms.
Exposure to daylight can degrade riboflavin, so these items should be stored away
from direct sunlight. However, the mean (2.217) and the median (2.08) are both
higher than the RDA for riboflavin: 1.3mg for men and 1.1mg for women.
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Niacin
Niacin is also known as vitamin B3 and is an essential human nutrient. It plays a
precursor role in metabolism, DNA repair and production of steroid hormones by the
adrenal gland. A prolonged deficiency of Niacin (or its precursor tryptophan) causes
pellagra, a disease that is still endemic in parts of the world, including Africa and
Mexico and within more vulnerable people in affluent societies (homeless people,
alcoholics, those with eating disorders) 442.
Good dietary sources of niacin include beef, pork, chicken, wheat flour, maize flour,
eggs and milk. The majority of the SOCCS population are consuming the minimum
recommended daily amount of niacin (13mg for women, 17mg for men), with some
taking considerably more.
Pantothenic Acid
Pantothenic Acid is also known as vitamin B5 and is necessary in the formation of
coenzyme-A (Co-A). It is also an important metabolic vitamin critical in the
metabolism and synthesis of carbohydrates, fats and proteins. A deficiency of
pantothenic acid leads to general clinical malaise 443.
There is a large variety of sources of Pantothenic acid. Good sources include chicken,
beef, potatoes, porridge, tomatoes, kidney, eggs, broccoli and whole grains such as
brown rice and wholemeal bread. It is also found in many fortified breakfast cereals.
More than 60% of the study population consumed between 5 and 10 mg of
pantothenic acid per day. There are so many sources of pantothenic acid that there is
no RDA.
Vitamin B6
Vitamin B6 is also known as pyridoxine and is a water soluble vitamin. It is a co-
factor in amino acid metabolism and in the release of glucose from glycogen. It is
important for maintaining blood sugar levels and for the formation of haemoglobin. A
deficiency of vitamin B6 (along with low intake of folate) can lead to
hyperhomocysteinemia and an increased risk of heart disease 444.
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It is found in most food groups, especially meat, cereals and fortified breakfast
cereals. With an RDA of 1.4mg for men and 1.2mg for women, the majority of people
reported consuming at least this amount of vitamin B6.
Biotin
Biotin, also known as vitamin B7 or vitamin H, plays an important role in the citric
acid cycle, the generation of biochemical energy during aerobic respiration. It is also
important for cell growth, production of fatty acids and the metabolism of both fats
and amino acids. Biotin helps maintain blood sugar levels and strengthens hair and
nails 445.
Good dietary sources of biotin include meat, eggs and dried mixed fruits. However,
deficiency is extremely rare, as intestinal bacteria generally produce an excess of the
body's daily requirement. Therefore, some health boards do not even recommend a
minimum daily amount. This was one of the least skewed of the dietary variables,
with a mean of 51.7μg and median of 48.7μg, but still was more normally distributed
after being transformed.
Vitamin B12
Vitamin B12 is important for the function of the brain and the central nervous system.
It plays an important role in cell metabolism, especially in regards to DNA synthesis
and regulation, but also in the metabolism of fatty acids and energy production. It is
necessary to process folic acid. A deficiency of vitamin B12 can lead to anaemia and
has been implicated in a spectrum of neuropsychiatric disorders 446.
Vitamin B12 is mainly found in meat products and certain algae such as seaweed.
Good sources include meat, salmon, cod, milk, cheese, eggs, yeast extract, and some
fortified breakfast cereals. The reported consumption of vitamin B12 varied from
0.3μg to 80.0μg, with a mean consumption of 8.2μg and a median of 6.9μg, in a
positively skewed distribution. Despite being water soluble, vitamin B12 is stored by
the body, in the liver and it takes years for a deficiency to develop. The RDA is only
1.5 μg a day, with almost the entire population reporting eating this much.
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Folic Acid
Folic acid is also known as vitamin M and folacin. Folic acid and folate are the two
forms of vitamin B9, a water soluble vitamin. Folate is necessary for producing and
maintaining new cells as it is needed for synthesising the DNA bases thymine and
purine. This is especially important when the body is undergoing a period of rapid cell
division and growth, such as pregnancy 447. A deficiency in folic acid during foetal
development can cause neural tube defects and spina bifida in newborn babies 448.
Folate is found in small amounts in a large number of foods. Good sources include
broccoli, Brussels sprouts, asparagus, peas, chickpeas, brown rice and fortified
breakfast cereals. The distribution of the consumption of folic acid in the SOCCS
population is only slightly positively skewed. The mean was 343.2μg and the median
was 322.0μg. Both mean and median are above the RDA of 200μg a day.
Fibre
Fibre is not a vitamin or mineral, rather a class of materials that are continuous
filaments or discrete extended segments. Dietary fibres, also commonly known as
“roughage,” are important for digestion, as the indigestible part of plant foods that
move through the digestive system, absorbing water and making defecation easier.
There are two types of dietary fibre, water soluble and insoluble. The soluble fibre
undergoes a metabolic reaction, fermentation, producing gas and short chain fatty
acids which themselves have considerable health benefits. Insoluble fibre attracts
water and increases bulk and softness of the stool, making it easier to pass.
Sources of soluble fibre include oats, rye, beans, fruits and fruit juices, certain
vegetables (broccoli, carrots), root vegetables and a seed husk called psyllium.
Sources of insoluble fibre include wholegrains, bran, nuts and seeds, vegetables and
the skins of some fruits, including tomatoes.
The British Nutrition Foundation recommends a minimum of 12-14g of fibre a day for
a healthy adult, whereas the American Dietetic Association recommends a minimum
of 20-35g a day for a healthy adult, depending on calorie intake. The median and
mean reported fibre intakes of the SOCCS population were, at 20.7 and 22.4
respectively, both above the minimum requirement from both advisory bodies.
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Total Energy Consumption
Energy requirements and consumption vary by gender, the following figures (4.5-4.8)
show the female and the male energy consumption and the log transformation of the
consumption respectively:
The distribution for both males and females is initially skewed, changing to normally
distributed following log transformation.
Energy requirements vary from one individual to the next, depending on factors such
as age, sex, body composition and physical activity level. It is therefore difficult to
generalise about the study population. Using the mean BMI, median activity level and
Log adjusted energy consumption (kJ)
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Figure 4.5 Male Energy Consumption Figure 4.6 Male Energy Transformed
Figure 4.7 Female Energy Consumption Figure 4.8 Female Energy Transformed
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age for each gender independently, table 4.3 shows the recommended and the real
median levels of energy consumption, one calorie being equivalent to 4.1868kJ.





Real kcal Real kJ
(median/mean)
Males 1931 8085 2575 10780
Females 1747 7314 2241 9384
As the results show, the energy consumption is higher than would be recommended,
although to assess overeating would require the individual recommended intake to be
calculated and compared to the real intake.
Alcohol
Although technically, the chemical description of alcohol includes a number of
compounds, in dietary terms alcohol is meant to mean ethanol. Unlike the other
dietary variables it is the presence or increase of alcohol in the diet that is likely to be
a risk factor as oppose to its absence. Alcohol is found in alcoholic beverages, of
which there are three main categories – beers, wines and spirits. There are also trace
amounts of alcohol in some recipes and some chocolate liqueurs.
One limitation of using a food frequency questionnaire for the year preceding
diagnosis/recruitment is that it cannot differentiate between lifetime non drinkers and
those abstaining due to past problems with alcohol: this is a common problem in the
epidemiological studies of alcohol consumption. With the majority of the SOCCS
population being retired, it is unlikely that their alcohol consumption in the
questionnaire represents their lifetime habits. These limitations need to be taken into
account during any analysis of alcohol (or any other dietary factor) consumption.
The distribution of alcohol consumption is different from all the other dietary
variables. However, the data can be divided into groups based on frequency of alcohol
consumption based on the risk categories and divisions in the Health Survey for
Scotland 2003 (http://www.scotland.gov.uk/Resource/Doc/924/0019811.pdf). This
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divides the group by those that drink less than three drinks a week compared to those
who drink three or more drinks a week, as shown in table 4.4.
Table 4.4 Binary Alcohol Consumption by Gender
Males (%) Females (%)
Number of alcoholic drinks per
week
3 or more Less than 3 3 or more Less than 3
HSE 2003 42 58 26 74
SOCCS 46.5 53.5 31 69
4.2.2.3 Categorical Lifestyle Measures
There were a number of categorical environmental risk factors measured, a summary
of which is shown below in table 4.5. The data was gathered using a questionnaire and
therefore uses the patient’s own definition of their physical activity level or smoking
status. However, deprivation was assigned using postcode data.
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Table 4.5 Description of Categorical Lifestyle Measures
Variable Category Percentage of sample (n)
No Drugs 66.6 (3206)
Mini Aspirin 16.9 (814)
Other NSAID 12.1 (584)
Normal Aspirin 3.2 (153)
Mini Aspirin and other NSAID 0.7 (32)
NSAIDs




1 - 3.5 25.6 (1189)
3.5 - 7 11.7 (544)
Physical Activity (hours


















The genetic variables in SOCCS are single nucleotide polymorphisms (SNPs), on the
microarray Hap 550, which checks 550,000 human SNPs. The exact panel selected for
this study were identified by reviewing the literature for genes with an association
with colorectal cancer, found in Chapter 3.
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The SNPs used in the simulations were selected using “Tag SNP Picker,” this is an
algorithm developed to select the best SNPs for a specified area, taking into account
linkage disequilibrium with nearby variants to maximise efficiency and power 449.
This sample is just meant to represent a SNP panel of similar size to the one used for
the real analysis. As the real analysis will inevitably happen later than the simulated
analysis and benefit from any knowledge on limitations and strengths gained from it,
knowledge of specific SNPs identified previously may bias the methodology towards
these SNPs in particular. This is particularly problematic as the literature identifying
specific SNPs contains examples from the same dataset as this study uses. It is
therefore more appropriate to keep the panel more general and representative, not
structured towards specific, expected SNPs.
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4.3 Artificial Data
4.3.1 Generating the Data
A programme simulating all the data was constructed using R, the code is contained in
Appendix 4.1. It was necessary to set a seed for the random number generation to
ensure that the same data would be generated each time, if the entered parameters
were the same, so the data analysed for chance effects were identical to that being
analysed by the contrasting methods. Prior to variable simulation, the sample size, any
risk effects and the number of populations being generated was entered. The
populations were simulated sequentially, so the first was complete and saved before
the simulation began on the second. The environmental and SNP data was generated
separately before being combined into a data frame.
4.3.1.1 Environmental Variables
The first variables generated were those which differ between the sexes and gender,
for example in generating the height for a male the following code was used:
height<-round(rnorm(SampSize/2, mean= 1.752, sd= 0.069),digits=2)
The normal distribution is used in this case as the male height was normally
distributed; those variables that were normal following transformation were selected
from the log normal distribution. The mean and standard deviation were also taken
from the preliminary analysis of the SOCCS data. After initial analysis of the
generated data, it became clear that very occasionally some figures were outside those
realistically possible. Therefore a function, called “restrict” was developed for use in
such cases. In such a case, the value was recoded as the maximum or minimum
realistic value, for unrealistically small or large values respectively.
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 Any figures from the “Health Survey for Scotland” were given as a population mean
and a standard error of the mean (SEM), which was translated to a standard deviation
for the purpose of generating data.
4.3.1.2 Generating Genetic Variables
Following the systematic review of the literature to identify candidate genes, markers
were chosen based on the information on the gene structure and linkage
disequilibrium blocks available at the International HapMap Project
(www.hapmap.org). The population of Utah residents with Northern and Western
European ancestry from the CEPH collection was used as a reference collection as it
most closely resembles the ancestry of the SOCCS population. Although there will be
some differences in SNP frequencies between the reference population and the study
population, the figures were used purely for simulation with the expectation that the
method could be used on a number of different populations irrespective of SNP
frequencies.
Genes and SNPs excluded
As the hypermutable tract in the APC gene identified in the Ashkenazi population has
not been identified in non-Jewish populations, it was not included in simulations.
Similarly, rare dominant mutations and those that more commonly cause other
cancers were not simulated as people with other cancers were removed from the
SOCCS study and it was therefore unlikely that the level of mutation in the study
group will match the population frequency. These included K-RAS and TP53. Genes
that would be impossible to identify using SNP data, for example the tandem repeats
in the TSER gene, have not been included in the simulations. Known dominant
polyposis syndromes, HNPCC or bi-alleleic MYH mutation carriers were excluded
from the SOCCS analysis.
Included
As well as the candidate SNPs with not excluded, the simulations included genes in
which the mutation rate increases as the cancer develops, despite the lack of
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heritability. The mutations in juvenile polyposis - associated genes DCP4 and
SMAD4 are found at 0% in adenomas but 35% in invasive carcinomas - suggesting a
role in cancer progression, which would not be identified particularly well in a
standard case-control study. As the full function is not yet known, it is possible there
is an unidentified interaction effect. A full list of the polymorphisms used can be
found in Appendix 4.2.
4.3.1.3 Assigning Case or Control Status
A number of different methods were investigated to assign case control status with
differing success rates. Initially, the probability of being a case was estimated as the
fitted value from a logistic regression model with a linear predictor capturing the
relevant risk model, an example of which is shown below. In the example Beta1 refers
to the regression co-efficient of the effect from not taking NSAIDs (the higher risk
category) and Beta2 is the regression coefficient of the interaction between not taking
NSAIDs and a risk allele.
Risk of case <- α + (β1*NSAIDs) + (β2*NSAIDs*allele) + e
Therefore additional risk was added to individuals with particular traits. To ensure
there were equivalent numbers of cases as controls, the whole simulation was run as a
loop effectively filling the “case spaces” and “control spaces.” However, this was
both time consuming and was producing data with an odds ratio very different from
that assigned. Also, as the data will be case control, it was not good practice to be
using a relative risk based estimate to assign risk. Generating the controls on a loop
until there was enough was effectively drawing the controls from a 50:50 risk groups
and the cases from 70:30 (if there was a 20% increase in risk). In practice this meant
that there was too much statistical noise and that the desired effect was diluted.
Therefore a function was written that used the available information and basic algebra
to assign case control status. In each simulation there will be a number of values or
proportions that are pre-assigned and can be changed for different simulations, they
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are also necessary to know for this function, and, during this description, have been
assigned the following symbols:
OR = x Sample Size = S
Proportion exposed = y Proportion of cases = z
The a, b, c and d are as normally used in a traditional odds ratio, two by two table,
with the defined features in bold:
Outcome
Y N
Y a b SyExposure
N c d S-Sy
Sz S-Sz S
Using these equations to find b, c and d in terms of a found that:
b = Sy – a c = Sz – a d = S - Sz – Sy + a
Then, substituting these relationships into the sample size expression, a + b + c + d =
S, we obtain:
(x – 1) a2 + (Sy + Sz - Sxy - Sxz - S)a  + S2xyz = 0
=> Aa2 + Ba + c = 0
Where:
A = x – 1 B = (1 - x) * Sy + (1 - x) * Sz – S C = S2 xyz
As these are all known values, they will at this point in the function have a numerical
form and be entered into the quadratic root solver (Root = -B ± √ (B2 – 4AC) / 2A). This
will give two roots, the positive solution is then selected. This method allows the case
control ratio to be determined in advance and is more appropriate for a case control
study where an Odds Ratio would be used to assess any effects. The code for this
function is included in Appendix 4.1.
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4.3.2 Simulation Designs
There are three main stages to the simulation study: the first involves the different
parameters within the method and how to maximise the power; there are data
variations obvious prior to analysis, such as sample size or case-control ratio; and
finally there is the underlying data model, including inheritance and interaction
model. This simulation allows data to be simulated that represents each of these
situations. These areas are covered in more detail in Chapters 5 and 6.
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4.4 Discussion
The Scottish Diet Action Plan (SDAP) 450 states that the diet of Scotland is so poor
that if current trends continue, diet will remain a contributing factor in the poor health
of Scotland relative to the rest of the UK and Western Europe. Such a poor diet
increases the toll of unnecessary premature death, long-term illness and dental ill-
health within Scotland.
However, the nutrient intake of the majority of the SOCCS population falls within the
healthy range for the majority of variables. One reason for this difference is that the
dietary variables are based on self reported consumption from a food frequency
questionnaire, which may be subject to recall bias or be affected by what people are
aware they should be eating, thus underestimating the unhealthy foods and overstating
the healthy.
A shortcoming of using artificial data is the generation of each variable
independently. For example, there would be no correlation between the level of
calorie consumption and the likliehood of being assigned a high BMI. The patterns of
association between risk factors within a real data set are absent from the generated
set. Trying to assess and define every small relationship the variables may have with
one another would be extremely difficult and time consuming. For the main aim of
this project, although such associations may be desirable, they do not necessarily have
to mimic those in real life. It is likely that, by chance, there will be spurious
associations between variables and if such cases stand out for that reason, hopefully
further analysis will elucidate this, much as would happen in real life. For example,
even if the artificial data set had people with lower BMIs eating more than their
heavier counterparts, it is the effect of this association on the analysis that is important
not the specifics of the relationship. In fact, an unrealistic relationship between
variables would suggest that the data had not been generated with expected results in
mind.
However, the risk estimates for different dietary variables may have been influenced
by risk factors falling into such groupings. People who follow a healthy diet may have
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better outcomes for a number of different reasons and combination of reasons yet the
majority of risk factor studies approach these risk factors in a univariate fashion. In
fact only fibre and folate are being studied, in some places, as having an association.
Current statistical methods and standard sample sizes do not allow such complexity to
be taken into account for every study, yet it is worth bearing in mind when doing
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5.1 Introduction
As discussed in Chapter 2, the size of many data sets compiled for disease-risk factor
studies are too large for the convenient use of traditional statistical methods, making it
extremely difficult to identify interactions between genetic and environmental factors.
For this purpose it is important to either develop new methodologies or use well
recognised methods in different ways to search through and break down the data. The
term for such searching of so many possibilities is “data mining.” Although the term
is sometimes used pejoratively to refer to methods of manipulating or repeating
statistics to get a desired result from a standard data set, which is more accurately
described as data dredging, data mining can be a justified, investigative endeavour,
laying no claim to a significance threshold, for such large volumes of data.
5.1.1 Aims
The aim of this section is to optimise the power of the Mixed Tree Method for a
variety of different data scenarios. Success will be considered by the computational
intensity, successful identification of the interaction and the identification of false
positives. This will allow an efficient design, both informative and enabling further
simulation studies, whilst controlling the computational burden. Small scale
simulation studies are used to investigate features of the method and guide
methodological development.
5.1.2  Data mining
Data mining is the extraction of patterns and relationships from large data sets. Ten
years ago, the improvements in technology in many different scientific fields meant
the volumes of data available were rapidly increasing requiring a new generation of
tools for analysis. This field of development was called knowledge discovery in
databases (KDD) 451.
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There are three phases to data mining: exploration, model building and deployment.
The exploration phase involves preparing the data for analysis and selecting features
to bring the number of variables to a manageable level. The model building and
validation phase extracts the knowledge from the data and determines the best
possible way to describe the patterns within the data. The deployment phase uses this
knowledge to create estimates for outcomes outside the dataset and to make
predictions of future outcomes.
Data mining is used in a number of different areas including business: marketing 452,
tailoring advertisements to groups, analysis; government work: security and
identification of dangerous people, trends in voting and areas of influence, identifying
money laundering 453, 454; and scientific research: bioinformatics, physics, genetics 455.
It should be noted, however, that data mining in medical research comes with a host
of ethical and practical considerations including: privacy of data and patient
confidentiality; data ownership and potential lawsuits; and the explanation of potential
risks and benefits 456, 457.
There are a number of different methods that can be considered to be forms of data
mining, depending on how they are used. For example, regression is commonly used
without a prior hypothesis on which variables might be having an effect on the
outcome or how the effect comes about. One popular method of data mining is tree
based; the currently used forms of tree based searching are described in section 2.3.2
but in order to develop a new form of using these methods it is important to start from
their basic form and understand how they can be used.
5.1.3 Tree Methods and Applications
“Our philosophy in data analysis is to look at the data from a number of different
viewpoints. Tree structured regression offers an interesting alternative for looking at
regression type problems. It has sometimes given clues to data structure not apparent
from a linear regression analysis. Like any tool, its greatest benefit lies in its intelligent
and sensible application.”
- Breiman, Freidman, Olshen, Stone
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Background
The most widely used implementation of decision trees, for statisticians, is CART,
which stands for Classification And Regression Trees. This is a recursive partitioning
method developed by Breiman, Freidman, Olshen and Stone in the early 1980s 195.
When using CART, a hypothesis space is completely searched considering all the
possible values, for all the variables, before selecting the attribute that best divides
each set into distinct groups based on the selected outcome. CART only uses binary
splits. CART considers the optimal split to be the one with the largest decrease in
node impurity (Δi). In bioinformatic circles, a number of slightly different algorithms,
ID3, C4.5 or C5.0, are used. These algorithms use a measure of uncertainty called
information entropy and choose the split with the greatest information gain.
Classification Trees and Regression Trees
Classification trees are used for categorical outcomes, or discrete target variables (e.g.
case/control status in an epidemiological context). The aim is to retain “purity” of the
nodes, where an ideal model would produce nodes that solely contain either cases or
controls, not a mixture of both. The effectiveness of a split is based on the
homogeneity of the subsamples following the split. CART can employ a number of
different splitting rules based on different measures of classification accuracy. Three
commonly used splitting rules are the gini splitting criteria, twoing and entropy,
descriptions of which are found in Table 5.1. In some cases the resulting tree is fairly
insensitive to which measure of purity is used and gives a fairly consistent result
across the different measures. The goodness of fit for classification trees is measured
using misclassification rates.
In Table 5.1, pi is the relative frequency (Observed numbers in a class / total
observations) of class i at a node (t) where a split is performed, also called the relative
frequency of defectors. The left and right hand sides of a split are referred to as L and R
respectively.
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Table 5.1 Commonly used Splitting Criteria for Partitioning Methods
Purity Measure Description Uses
Gini (IG) Σpi(1-pi) Most efficient when p=0 or 1
Twoing (PLPR/4)[(Σ|p(i|tL) – p(i|tR)|]2 Useful when 50:50 split required
Entropy -Σpilogpi Most efficient when p = 0.5
The gini index is an impurity measure based on estimated class probabilities, which is
maximised when all the observations are equally distributed across the classes. Gini
impurity is calculated by adding together the range of probabilities of a series of
objects being selected multiplied by their risk of misclassification. The Gini impurity
measure is zero when everything is correctly classified. The gini splitting criteria
attempts to identify the largest homogeneous group from the data and separate it from
the remaining data in order to lower impurity 458.
Twoing attempts a more even separation than the gini index. Twoing denotes the
variables as classes. At each node, the classes are separated into two superclasses and
the decrease in node impurity (Δi) is calculated as a two class problem, finding the
split to maximise Δi. The advantages to twoing are the strategic splitting where
initially apparently dissimilar classes can be grouped together by having more
“important” characteristics in common before being separated further down the tree.
Twoing does not ignore any characteristic, but separates the populations that are too
small to affect the split differently (usually differentiating them from the more
significant by putting them in parenthesis). This makes both the position and relative
importance of a variable in a tree easy to understand.
The entropy based splitting criteria is based on normalised information gain, a non
symmetric measure of the differences between two probability distributions 459. An
advantage of the entropy based trees is that they are heuristic. Based on Occam’s
razor, entropy splitting methods have a preference for simple trees over larger trees,
though not necessarily the smallest.
There are other splitting criteria that vary only slightly from the main ones discussed.
Class probability is based on the same equation as the gini criteria but focuses on the
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probability structure of a tree, not the classification structure or prediction success.
Cross probability splitting attempts to divide the data based on probabilities of
response and assigns class based on probability trees. It is theoretically possible for
class probability to employ the twoing or entropy algorithm in place of the gini.
Selecting the optimal tree
It is important to bear in mind that the building of an accurate tree relies upon the data
set being representative; otherwise the results will only be directly applicable to the
sample. It is important to verify and validate the resulting trees, which can be done in
a number of ways. For searching methods, the most common method for identifying
the optimal model is cross validation. Cross validation requires the partitioning of a
data set into subsets at random and performing the searching method on one of the
subsets (the training set) and using the other set (the testing set) to validate the results.
Normally a numbers of rounds of cross validation are performed and the results
collated and averaged across the rounds. Ten fold cross validation, used in MDR and
described in section 2.3.2, would split the data into ten sets, using the subset of nine of
these to train the model and the remaining subset to test it for each subset in turn.
Other cross validation methods include “repeated random sub sampling validation”,
where the dataset is randomly split each time into a training and a testing set and
“leave one out cross validation” where repeatedly and methodically a single
observation is removed from the data set to be used as the testing set.
More specifically to tree methods, identifying the best tree depends on the balance
between accuracy, computational burden, bias, variance and manageable data. Trees
are usually pruned to show the most useful data. Pruning can be done after a large tree
is grown and then pruned back to a manageable size or can be determined before the
tree is grown, although this may be difficult to know in advance. Pruning is done by
sequentially collapsing the nodes that have the smallest difference in purity and
involves a trade off between bias and variance. Cost complexity pruning adds a
complexity cost per terminal node and the cost complexity measure is calculated by
adding the complexity cost of the tree to the misclassification cost penalties. Such
costs are pre-determined and are based on the requirements of each analysis. If
accuracy is so important that it is preferable for every variable to have a node
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containing itself, there will be no misclassification; this would be achieved by setting
the complexity cost very low and the misclassification cost high.
Weaknesses of Tree Methods
The weaknesses of tree based methodologies are that they are unable to capture a
linear relationship, the best they can do is a step function approximation of a linear
relationship. It would therefore not be the most efficient way to model a dataset, if the
main underlying structure in the dataset is linear. However, this is not the primary aim
of exploring large data sets to identify possible gene environment interactions.
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5.2 Mixed Tree Method (MTM)
5.2.1 Rationale behind the Mixed Tree Method
One of the important factors in developing this approach is the inherent difference
between the epidemiological history of environmental variables and that of genetic
variables. Environmental risk factors are well studied and fairly well understood, with
large volumes of evidence supporting association and complementary biological
mechanisms. It is also unlikely that anything completely unprecedented will be
discovered regarding the risk of an environmental variable, as an environmental factor
which has never, in any study, been shown to confer risk, will not normally have been
measured and recorded for analysis That is not to say that studies of interactions add
nothing to environmental risk factor studies, but that they more likely add to the
understanding of the risk factor than to its discovery. Therefore, it would be
inefficient to mine environmental variables in the same way as the genetic data,
looking for completely new risk factors.
A second important issue is that studies into the risk of environmental variables tend
to have considerably larger odds ratios for the independent effects. If all the
environmental and genetic variables were included in a single statistical model, the
more minor environmental risk factors would be considered more important than the
most important genetic risk factors. For example, in a decision tree, the environmental
variables would dominate the earlier branches and disrupt the later branches
containing the genetic factors, making it possible to miss an interaction effect between
the two.
Similarly, even main effects for polymorphisms are likely to be a magnitude higher
than for interaction effects, so it might be expected that independent genetic effects
would dominate the upper branches of the individual trees. There are currently no
methods available that remove such variables in order to treat them differently and
allow the study of second order effects in general.
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Therefore any novel method must accommodate the following:
 Different approach to environmental and genetic variables
 Larger effect sizes of environmental variables
 Genetic main effects vs. interaction effects
5.2.2  Outline of Method
The data are analysed sequentially, using separate data sets that each contain a single
environmental variable and all the genetic variables. Once the process is completed
for the first environmental variable, it moves on to the second, and then the third and
subsequent ones until all the environmental variables have been used in one complete
analysis. Missing values are removed from the single analysis for which there is no
environmental data, although any variable with a large proportion of missing data will
be looked at in more detail to try and elucidate if there is a non-random reason for the
missing values. If testing a more specific hypothesis, it is possible to run the method
just for one environmental variable, or a smaller set of SNPs, and study the results in
more depth.
Step 1
For continuous variables, the data set is forced to produce a single split tree using only
the environmental variable, the cut-off value for the grouping is then isolated and two
data sub groups are produced, those below or equal to the cut-off value and those
above it, similar to the first step of a CART approach. In the case of binary variables,
the data is just split into the two variables present. For categorical variables with more
than two levels, dummy variables are created for each level and the single split
divides up the data based on them. For example, NSAIDs can be a number of different
drugs and combinations of the two, so each drug is entered as a dummy variable with
both the individual and combined presence of a drug coded as true.
Within each analysis, any genetic effects dominating the subtrees will be treated as
having both potential main effects and interaction effects; the method will then be re-
run with them removed to minimise their effects on other variables. Once a genetic
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main effect has been found to have a significant main effect, at the end of one
analysis, it will be removed from the data for the further analysis. It can also be
planted as a root in its own analysis to look for gene-gene interactions.
Step 2
Each subgroup from step 1 is then used to produce a separate tree, effectively the
same as two branches of the same tree after one split, using the genetic variables. The
results from the two subtrees are then compared to one another and the most
important variables are selected for the next step. Variations developing the selection
algorithm to maximise the selection of important trees is explored in this chapter. The
variables are considered important if they are at the top of either sub tree or if there is
a large difference between the sub trees regarding the position of the variable.
Step 3
Once the best method of selecting important variables has been identified through
preliminary analysis, the important variables from the third step are entered into a
logistic regression model. Depending on their selection criteria they will be entered as
an independent effect, an interaction effect, or both. After the regression step, the final
results are compiled. A summary of all three steps is shown in Figure 5.1.
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This is the basic structure, the more specific elements of the method still to be
assessed and decided include: the particular method of tree growth and tree control;
splitting criteria; and identification and analysis of potential interactions. Using small
simulation analysis to develop the method and determine the specfics of each step is
summarised in this chapter.
5.2.3 Computational Intensity
Initial simulations showed that the MTM is reasonably computationally intensive,
particularly in the context of simulation studies with a large number of repeated
analyses. This was explored using a number of different data generation methods and
operating systems, none of which reduced the problem to a manageable level.
Sub 1 Sub 2
A single column of data is selected containing
values for one environmental variable, genetic
variables and case/ control status. The
environmental variables are analysed sequentially
Trees compared
Sub-trees grown separately
Key variables selected and analysed
Results
A tree with a single split is produced, using
regression for continuous variables and
classification for discrete environmental variables
Fig 5.1 Graphic Depiction of the Basic Mixed Tree Method
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Without a technical solution, it was necessary to look more closely at the different
elements of the study, especially the data input variables, to identify the time
consuming elements. The areas requiring such study included the number and format
of environmental variables being entered into the analysis. It was therefore a
reasonable judgement to carry out two analyses, one containing an interaction effect
and one with no determined effects for comparison.
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5.3 Method Development
The method was implemented using R (http://www.r-project.org/) incorporating the
rpart function 460 and the random forest function 461 and a help guide on recursive
partitioning in R 462. However, the majority of the method was written for this thesis,
including selection of the data for each analysis, the loops for implementing the
functions and the settings chosen. More importantly the selection algorithm and
analysis was developed and perfected drawing on the results from the practice
analysis.
5.3.1 Data Preparation
The initial steps of an MTM analysis involve preparing the data, identifying which
data set is to be used, removing missing values and specifying which environmental
variable will provide the initial split or “root.” As this was a simulation study, there
were no issues of missing data, however in a real analysis univariate anaylsis of the
variables would be carried out prior to analysis and the missing values treated
according to the results of such analysis.
In the following sections, in cases where each individual result has to be examined, a
smaller dataset extracted from the main simulation data was used that contained
information on NSAID intake and the simulated SNPs associated with genes from the
Wnt pathway only. This subset contained 63 SNPs from 14 different genes. In this
smaller test run, only 100 datasets were run each time. In the larger analyses, 175
SNPs and 1000 replications were used.
Occasional limitations during the data generation step led to a reduction in the
expected identification rate, purely as an artefact of the data. In these instances the
same analysis was also run using an optimum version of regression, where only the
variables involved in the risk model were entered into the analysis model. This was
purely as a comparison to show that the MTM was analysing imperfect data and to
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indicate the results that could be expected from a “perfect” performance and was
therefore more appropriate for gauging the success of the method.
5.3.2 Presentation of Results
As the method develops different measures of success are used to measure
performance, depending on which steps are finalised. Throughout, one of the main
measures of success will be the identification of the pre-determined effect, either main
effect or interaction effect. This will be referred to as the “target SNP,” in the case of
a main SNP effect, “target interaction” for the target SNP and its interacting
environmental variable and “interacting SNP” for the SNP involved in the interaction
but identified separately.
To determine the most effective way to identify interactions or main effects, different
features of the results were considered. The different modes of SNP selection are
recorded as they may give clues to the underlying model of the interaction.
The most obvious candidates are the SNPs at the top of each sub-tree. Theoretically,
being at the top, or very near the top, of both trees would suggest a potential
independent effect, although possibly an interaction effect as well, these variables are
refered to as “Ind” variables. Being at the top of one tree but not important in the
other would more likely suggest an interaction effect. SNPs identified in this way are
referred to as “Top” variables. Although an Ind variable occupies a top position, it is
the relative positions between the two subtrees that determines classification. The
number of positions under consideration to define these labels is explored in section
5.3.3.3.
Another feature that may identify a SNP as being important is its association with
movement between subtrees, which requires measurement of the difference in
position – with position referring to the ranking of variable by importance following
the random forest analysis. These are referred to as “Move” variables. SNPs
exhibiting such positional differences can be identified by a ranking score which
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measures the difference in position between the two subtrees whilst according more
weight to having a high position in one tree:
Score = (pos in tree 1 – pos in tree 2)2 / (smaller position)2
The following table gives a summary of the different features of the SNPs following
the random forest stage and how they will henceforth be described. In a number of
situations the SNP at the top of one subtree would also be the one exhibiting the most
movement, in which case it is classed as Top:
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Table 5.2 Key for Describing Variables Selected Following the Random Forest
Step of the MTM
Variable name Identification Method
Independent Type 1 (Ind1) Top of both subtrees after random forest step
Independent Type 2 (Ind2) Top of one sub tree and position 2-5 in the other
Top variable 1 (Top1) Variable top of one sub tree, below position 5 in the
other
Top variable 2 (Top2) Variable second in sub tree, below position 5 in the
other
Move variable 1-n (move1) Variable occupying a top 5 position with greatest
difference between  sub trees
Move variable 1-n (move2) Variable occupying a top 5-10 position with greatest
difference between  sub trees
The initial analysis measures the success of different splitting criteria, by studying in
detail how often the interacting SNP is identified using the different splitting criteria
and in which format.
When attempting to identify the potential interacting SNPs, success at identifying a
target SNP with a main effect will quantify the results defined as Ind1 and Ind2.
Identification of the interaction will measure the relative success of the different result
features to assess the most effective way for the method to select the variables to enter
into the regression step.
5.3.3 Implementation of the Mixed Tree Method
With the basic structure of the mixed tree method decided, it was necessary to
determine the specifics of each step. For the sub-tree stage both the growing and
comparison of the sub-trees need pre-specified limits, the recursive partitioning stage
needs a choice of splitting criteria and finally, a determination of how to best select
potential interactions from the data.
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5.3.3.1 Tree Growing
Tree size is not limited during the growing process, so the trees tend to be large and
overfitted. In order to recognize the important genes in a large tree, the trees can be
reduced in size or large numbers of trees generated and then averaged.
There are two methods that can be used to reduce tree size: pruning and shrinking 463.
Pruning determines importance using a cost-complexity measure and recursively snips
off the least important branches of a tree. The pruning is done by automatically
selecting the complexity parameter associated with the smallest cross-validated error.
Pruned trees have some advantages over un-pruned trees: they are smaller, avoid
over-fitting and are better at dealing with statistical noise.
Instead of pruning a tree towards the main root node, the nodes can be shrunk towards
their direct, nearest, parent node. Whereas pruning reduces the tree as a whole with
the relative importance of each branch compared to all others, shrinking is more
specific to the node involved. Shrinking uses a convex combination parameter; a fitted
probability at a node, a convex combination of the probability of the parent and the
frequency of the offspring nodes 464. This is effectively bagging, combining the output
from bootstrapped samples, each branch individually.
However, producing a single tree from all the data, even using pruning or shrinking to
make the results more accessible, is susceptible to a large amount of statistical noise
and influenced by random effects. It is not possible to differentiate between the
random differences between subtrees with no effects and those that differ because of a
real main or interaction effect.
Therefore the option of integrating other tree approaches at this stage was explored.
As discussed in chapter 2, the random forest method creates a number of trees from
the same dataset and then averages across the tree. Therefore using a random forest
approach to generate the subtrees reduces the statistical noise. The advantages to this
approach include balancing the error in unbalanced data sets and generating a measure
of importance for the variables in determining classification, the splitting criteria. To
decide on a method, both a measure of decrease in accuracy and a measure of
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decrease in node impurity, known as the Gini index, were tried. Twoing and entropy
were not compatible with the random forest R function or preferable in theory.
Twoing is more informative looking at individual trees, but such information gain
would be negated by the combinatorial approach of random forests. Also, attempts by
twoing to create similarly sized groups would lead to a similarity across the forest
trees, instead of creating the forest average tree from the most information available.
Similarly, entropy has a preference for simple trees and the resultant forest would not
be created from trees with the variation and information of node impurity or Gini.
5.3.3.2 Splitting Criteria
Which splitting criteria would be more successful in the mixed tree method was not
clear theoretically or from the literature. Therefore examining a number of small,
practice simulations using only the steps described thus far, was the best way to
decide between them. In this case it was important to be able to study the details of
every result to get a clear picture of the results, information that would be impractical
to study from 1000, or even 100 simulations. Therefore ten datasets of ten populations
were analysed using first the accuracy measure, then the Gini criterion. It would have
been possible to develop a large number of trees and select ten at random, however,
the use of different set seeds allows random variation whilst allowing repeated and
more in depth analysis on specific data.
Ten datasets of ten were produced with an OR of 2 for a SNP-environment
interaction. The results of different selection criteria using a basic, single interaction
with no main effects model are shown in table 5.3. Detection is described as the
proportion of identification under the different selection options described in Table
5.2. The measure of which splitting criteria is more successful is based on a
combination of identification and the method of selection. For example, if the results
indicated that it was necessary to consider all top three (Top3) positions, in both
subtrees, to achieve a 90% identification rate, that is taking six variables into account,
five of which will be false positives. However if it is possible to achieve an 80%
identification rate using just the SNPs at the top of the tree, that involves only 2
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variables – up to one false positive. In this scenario the latter would be considered
more successful.









Gini 100% (Top) or  90% (Move3 + Ind1)29
Accuracy 90% (Top), 1 null result
Gini
Gini 90% (Top) or 100% (Top + Move1)17
Accuracy 90% (Top), 1 null result
Gini
Gini 100% (Top) or 100%(Move1 + Ind3)88
Accuracy 90% (Top) or 100% (Top3)
Gini
Gini 100% (Top) or  100% (Move1 + Ind1)52
Accuracy 90% (Top) or 100% (Top2)
Gini
Gini 90% (Top and Move1)34
Accuracy 80% (Top2)
Gini
Gini 90% (Top) or 100% (Top2) or 100% (Top + Move2)111
Accuracy 80% (Top + Move 3)
Gini
Gini 90% (Top) or 100% (Top3)9
Accuracy 100% (Top3) or 90% (Top + Move3)
Gini






Gini 100% (Top) or 100%(Move2)40
Accuracy 100% (Top)
Gini
From these results, the Gini index performs better in the majority of cases than
accuracy in identifying a basic interaction. Simply selecting the variables from the top
of each sub tree would identify the interaction 92% of the time, rising to 95% if the
variable with the greatest movement was also identified (assuming it was a different
variable, which was usually not the case). Using accuracy, the interaction was
identified 84% of the time, with no improvement if movement was included in the
selection criteria.
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Although different data models may slightly change the selection criteria, these are
the two most basic measures and provide a good representation by which to compare
the two indices. In all the following analyses, the Gini criterion was used.
5.3.3.3 Identification of Potential Risk Factors
With the tree growing and splitting criterion determined, the next stage was how best
to decide which SNPs to select from the trees to maximise the chance of identifying
any underlying effects. Considering that the selection of a single SNP could involve
entering both the SNP and its potential interaction into a regression formula, it is
necessary to minimise the number of variables being entered into the regression
formula as far as possible. It is also important that the method is capable of
identifying independent SNP effects as well as interaction effects, or a combination of
both depending on the underlying interaction model. For a hypothesis generating
method, all additional information gain is beneficial.
Data containing independent effects
The first step in developing the method to identify independent effects was to
establish the best way to select them and then evaluate them. To establish the
selection criteria, a dataset was generated with the parameters shown in Table 5.4:
















Target SNP 2.0 0.6634
Interaction 1 0.4421
63 1000 0.5 Dominant
Focusing on the selection stages, prior to the regression step, table 5.5 shows how
often an independent effect is detected using three different criteria: the first column
shows the rate of identification if a variable is considered to have a main effect only
when it is at the top of both sub-trees, described earlier as Ind1; the second when
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selecting variables at the top of one sub-tree and positions 1-3 in the other; with the
third column considering position 1-5 alongside a top position, which was earlier
described as Ind2; the fourth column considers top 3 positions in both trees
simultaneously; and similarly, both top 5 in the final column.
Table 5.5 Effect of the Sub-tree Position on Identification Rate
Positions 1 & 1 1 & (1-3) 1 & (1-5) (1-3) & (1-3) (1-5) & (1-5)
Identification (%) 43 64 76 96 97
False detection
(%)
2 6 6 31 105
From these results, there is a large improvement in performance without too large an
increase in false detection when considering positions 1-5 alongside one variable in
the top position. However, considering positions 1-3 or 1-5 in both sub trees
simultaneously leads to a substantial increase in the false detection.
Therefore, a reasonable balance between specificity and sensitivity in identifying an
independent effect includes variables at the top of one sub tree and in position 1-5 in
the other tree. The increase in successful identification is greater without an
equivalent increase in false detection. There is still one last methodological step after
this one to eliminate false positives. The following table shows the results when
incorporating this final stage, at different significance thresholds, thus adding a
quantitative element to the results.













0.01 100 20 16 4
0.001 100 7 4 0
0.0005 99 6 1 0
0.0001 96 2 0 0
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Data containing only an interaction effect
 For the second simulation, the data contained no independent effect; only people with
both the risk SNP and the environmental factor were at increased risk. In this case the
SNPs at the top of each sub-tree were selected (Top1) as the earlier work on splitting
criteria found this to be the strongest selection method.
However, the best parameters and positions involved in selecting the Move variables
were explored further. Initially, the SNP that showed the most movement and
occupying position 2-5 in one sub-tree were selected, the sub-tree position was then
extended to 2-9 to gauge any improvement. Table 5.7 shows the parameters of the
simulation, Table 5.8 the results at significance levels 0.01 and 0.001.
















Target SNP 1 0.6634
Interaction 2.0 0.4421
63 1000 0.5 Dominant















0.01 54 100 3 102-5
0.001 29 93 0 2
0.01 54 96 15 32-9
0.001 30 91 0 2
Therefore, increasing the Move positions considered did not dramatically increase the
identification of the interactions, for this model. Increasing to an ever greater number
of positions is unlikely to have much more of an effect as the denominator of the
Move calculation is based on the position.
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Data containing both main and interaction effects
Using the results from the independent and interaction analyses, it was then necessary
to check that neither dominated the results when used in combination at the expense
of the other. Therefore data were generated based on a model in which the gene had
an independent effect, which was amplified by the environmental factor, the
parameters shown below in table 5.9, the results in table 5.10.
















Target SNP 2.0 0.6634
Interaction 2.5 0.4421
63 1000 0.5 Dominant















0.01 100 94 19 1 13
0.001 100 81 8 1 0
0.0005 100 77 5 1 0
0.0001 100 65 1 0 0
Even at low significance thresholds, the mixed tree method was extremely successful
at identifying the gene effect and moderately effective at identifying the interaction.
Considering the interaction was only increasing the OR by 0.5 and there would have
been some statistical noise from the data generation, this was a good result. Further, in
depth analysis of the underlying interaction model can be found in Chapter 6.
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5.4 Analysis of Parameters under Investigator Control
There are a small number of parameters under investigator control (or nearly so), the
selection of which can affect the results. The environmental variables being entered
for analysis, given that the Mixed Tree Method (MTM) is effectively analysing them
sequentially, could be entered either as a group or individually. The format of the
environmental variable can also be changed, especially in cases where there are well
recognised thresholds or very small numbers in a categorical grouping.
In order to optimise the results in subsequent simulations and future practical
application, analyses were run to measure the effect of these parameters. The aim was
to construct the method with maximum power, with respect to the parameters under
investigator control. However, in some instances, the computational intensity in trying
to run so many datasets, each so large in nature, on a standard, personal computer was
problematic and time consuming.
Initial simulations were run using different numbers of environmental variables, to
measure computational intensity and the feasibility of the other simulations. The
second parameter was the format of the environmental variables, especially when
there was an option to re-classify from continuous to binary.
5.4.1 Number of Environmental Variables
The number of environmental variables analysed at one time was primarily an issue
affecting the simulation studies, where the required number of replications increased
the computational burden to an unmanageable level. The most obvious candidate for
reducing the time of the analysis without losing too much information was the number
of environmental or “root” variables being analysed at one time. The MTM
effectively analyses them separately, so measuring successful identification for a
variable with an effect does not necessarily need all the variables to be entered into
the analysis simultaneously. It would depend on what the computational benefits are
for different assortments of variables.
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A number of simulations were run comparing the time taken to run different numbers
of datasets containing different numbers of environmental variables. More detail can
be found in Appendix 5.1 but prior to any adaptations it took more than 300 hours to
run analysis on 1000 datasets each containing 21 environmental variables.
There were three factors that influenced run time: number of “root” variables; number
of replications; and the number of datasets generated and being saved in the system
memory. Once the false error rate had been established there was no analytical
advantage to running large number of variables alongside the target variable for each
run. As long as there was one variable with an effect and one that had no set effect
with which to compare, it was possible to gain a full picture of what the results would
be in such a situation without adding too much time to the simulation.
5.4.2 Format of Environmental Variables
There are situations where prior knowledge may dictate an obvious way to divide a
categorical or continuous variable into binary or discrete groupings, for example the
dietary variables have a recommended level of consumption. Simulations were run to
test the effect of variable type on identification rate.
Categorical Environmental Variables
To analyse the effect of recoding categorical environmental variables, duplicate
analyses were run using NSAIDs as the split variable in both the categorical and re-
classified format. The recoding is shown in table 5.11 and the parameters for the test
simulation in table 5.12. In this instance, an optimised regression, as described in
section 5.3.1, was run for comparison to identify to where in the method the
difference could be attributed.
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Table 5.11 Recoded Class of NSAIDs from Categorical to Binary
Variable Discrete classes (%) New classes (%)
None  (66.6) 0 (66.6)
mini aspirin  (16.9)
standard aspirin  (12.)
other NSAID  (3.2)
mini + other  (0.7)
NSAIDs
standard + other  (0.5)
1 (33.4)


















Target SNP 1 0.6634
Interaction 2.5 0.4421
175 1000 0.5 Dominant
The results from this simulation, showing true and false positive identification across
a spectrum of significance thresholds, are shown in Table 5.13. Table 5.14 shows the
logistic regression results for an analysis of only the target variables.
Table 5.13 Percentage of Datasets Identifying Interaction, NSAIDs as Discrete
Compared to Binary Variable
Significance Threshold
0.01 0.001 0.0005 0.0001
NSAIDs in Discrete Classes









Neither Int or SNP 8.4 25.6 31.5 50.0
Other Int 9.8 1.7 0.5 0.1
Other SNP 2.3 0.6 0.3 0.1
When Recoded as Binary Variables









Neither Int or SNP 3.0 8.9 12.6 22.8
Other Int 22.1 4.9 2.4 0.3
Other SNP 3.1 0.8 0.6 0.2
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Table 5.14 Percentage of Datasets Identifying Interaction, Difference in Discrete
and Binary Classification Using an Optimised Version of Logistic
Regression
Significance Threshold
0.01 0.001 0.0005 0.0001
NSAIDs in Discrete Classes
Target Int 28.4 9.9 7.3 3.6
Target SNP 83.1 58.8 50.8 33.6
Neither Int or SNP 16.3 40.9 48.8 66.2
When Recoded as Binary Variable
Target Int 54.8 25.8 20.7 10.8
Target SNP 98.3 92.0 88.0 77.4
Neither Int or SNP 1.7 7.9 11.9 22.5
These results show that MTM identifies interactions with binary variables more
successfully than discrete classes, which could be in part explained by the risk model
being based on an effect which is essentially binary, that of an elevated risk from not
taking any NSAID. There is a greater chance that the categorical format would
misclassify the variables in some cases and therefore have poorer results. In the
majority of successful datasets for the discrete variable, it was splitting in effectively
the same way as when it was recoded as binary.
Using the categorical variables to split was least successful at identifying the target
gene when the subgroups were most different in size. For example, if the data had
split based on the consumption of any non-aspirin NSAID or not, only 3.3% of the
population would be in one tree and 96.7% in the other. This suggests that binary
recoding may be more valuable in circumstances where there is a logical grouping of
small variables into a cohesive group; as such small groups may be wrongly selected
more often as different, just through chance. It is worth noting though that some of
this effect could be due to the binary nature of the risk model and if this is a concern,
the analysis can be repeated using the categorical groupings.
Therefore in further analysis, when there is an obvious divide – both logically, based
on the nature and prior knowledge of the variable, and numerically, giving close to
50:50 split – recoding will be used. In some circumstances these criteria are better met
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by recoding the variable into new ranked categories, for example: smoking in table
5.15 which shows, for the four categorical variables, the recoding which should
maximise their results and will be used in Chapters 6 and 8:
Table 5.15 Recoding of Categorical Variables into Binary Classes
Variable Discrete classes Proportion (%) Binary classes Proportion (%)





non 41 0 41
none 55.9 0 55.9
0-3.5 hrs/day 25.6








mini + other 0.7
NSAIDs













Compared to binary and ranked variables, continuously distributed variables had the
lowest identification rate and highest computational intensity during the preliminary
runs. On further investigation it was found that was largely down to the settings for
the partitioning step of the method. For the other variable types, the difference in
complexity required between resultant subsets to justify a split was set very low in
order to force the method to split when there were no real effects. However this meant
that for continuous variables, the split favoured extreme outliers and very small
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resultant subsets on one side of the tree. This was fixed by setting the cost complexity
parameter higher and the minimum resultant sub-tree size to 20% of the initial
sample.
There are a number of different approaches for turning quantitative traits into binary
covariates. The most commonly used, especially in the context of nutritional
variables, are recommended thresholds. These however may not always give the most
information possible, especially if they divide the data into very uneven subgroups.
Given that the nature of tree based methods requires a split, the ideal divide would be
both data driven in nature and result in sub groups of similar size.
To examine the effect of recoding a continuous variable as binary the following
parameters were used, with an OR of 1.5 for being overweight, defined as having a
BMI of greater than or equal to 25, (and having the SNP) and 2.5 for being obese,
BMI greater than or equal to 30, (and having the SNP). The overweight category in
the table includes those who are obese as the risk is additive, to have a BMI above 30
is also to have one above 25. The frequencies are approximate as the weight and
height are generated on a spectrum before the cut-off limits are applied. Table 5.16
shows the simulation parameters, 5.17 the results. The analysis is only run twice using
the terms overweight or underweight, the obesity grouping is mentioned in the
parameter table as it confers additional risk during the data generation stage.
This was also examined more thoroughly using the optimised regression, as dicussed
in section 5.3.1. Table 5.18 shows the optimised logistic regression results with those
from the MTM in brackets for comparison.
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Table 5.17 Percentage of Datasets Identifying Interaction for BMI as a Continuous
Variable and Recoded as Binary
Significance Threshold
0.01 0.001 0.0005 0.0001
BMI as a continuous variable
Target Int 56.1 27.9 22.1 13.4
Target SNP 24.7 10.0 7.4 3.2
Neither Int or SNP 43.9 72.1 77.9 86.6
Other Int 10.4 2.3 1.8 0.6
Other SNP 28.3 9.0 6.2 2.4
When Recoded as Binary (overweight) Variable
Target Int 81.6 56.3 48.0 31.5
Target SNP 1.3 0.1 0 0
Neither Int or SNP 17.9 43.6 52.0 68.5
Other Int 15.8 4.0 2.4 0.7
Other SNP 60.2 21.4 14.7 6.6
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Table 5.18 Percentage of Datasets Identifying Interaction with BMI from Optimised
Regression versus MTM
Significance Threshold
0.01 0.001 0.0005 0.0001
BMI as a continuous variable
Interaction (Int)
found
57.3 (56.1) 28.1 (27.9) 12.2 (22.1) 13.3 (13.4)
Gene found 25.2 (24.7) 10.5 (10.0) 7.8 (7.4) 3.3 (3.2)
Neither Int or gene
found
42.7 (43.9) 71.9 (72.1) 77.9 (77.8) 86.6 (86.7)
When Recoded as Binary (overweight) Variable
Interaction (Int)
found
81.9 (81.6) 57.3 (56.3) 49.1 (48.0) 32.2 (31.5)
Gene found 31.7 (1.3) 11.7 (0.1) 9.1 (0) 3.6 (0)
Neither Int or gene
found
17.9 (18.1) 43.6 (42.7) 52.0 (50.9) 68.5 (67.8)
In some instances the MTM performed better than the optimised regression. This can
be explained by the presence of other variables, reducing the residual variation
attributed to the environmental main effect and random statistical noise. From these
results it can be seen that almost the entire improvement in identification using the
binary classification can be attributed to the regression step of the method.
This variable also appears to be more successful when recoded as binary but again the
risk model has been optimised towards the binary variable as risk was assigned at a
higher level above a cut-off of 25 during the generation step. Recoding would be less
accurate when increase in risk does not line up identically to established parameters
(e.g. BMI thresholds of 25 and 30 conferring an associated risk). Therefore, a number
of small simulations were run with an associated increase in risk for a BMI above 23-
33, but keeping the 25 cut-off for analysis. This will help distinguish between the
preference for binary variables and the problem of matching the risk model to the
analysis. The results are shown in Figure 5.2:
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Figure 5.2 Association between BMI Associated Risk and Predefined Cut-off at 25
It does therefore not seem beneficial to split the data into pre-specified binary or
ranked groups prior to the whole MTM analysis. However, prior to the regression
stage regrouping the variables based on the cut-off point from the earlier recursive
split might improve the performance of this stage of the analysis. To assess if this was
the case, the same analysis was run again using the continuous variable, but before the
final regression step the variables were re-grouped based on their earlier partitioning
threshold. The results from this are shown in Table 5.19.
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Table 5.19 Identification when the Binary Classification for the Regression Step is
Dictated by the Earlier Recursive Split
Significance Threshold
0.01 0.001 0.0005 0.0001
Interaction (Int)
found (%)
65.2 38.8 31.1 18.8
Gene found (%) 96.7 90.1 88.1 80.4
Neither Int or
gene found (%)
3.3 9.8 11.8 19.5
Comparing these results to the earlier table, this technique was more successful than
either the regression or MTM on a continuous variable. The proportion of datasets
that did not detect either the interaction or the SNP was even lower than when the
variable was recoded as binary. As the initial advantage from binary recoding was
primarily explained away by the more effective regression step, recoding only at the
final stage using a data driven boundary keeps the mixed tree method more flexible in
dealing with different cut off points, especially when the data has not been generated
using identical limits, as it was here.
5.4.3 Summary of Mixed Tree Method
In order to maintain effectiveness but reduce computational time the simulations in
the next chapter were run with only the two environmental variables, NSAIDs and
smoking, to assess the levels of successful identification and the false positive
identification respectively. Variables originally in discrete classes were regrouped to
form binary variables with a ratio as close to 50:50 as possible. Continuous variables
were analysed in their original format, with some limitation defined to ensure
reasonable group sizes, until the final regression step where they are entered as binary.
Using a data driven split for the variables prior to regression improves the
applicability of regression to the analysis. As hypothesis generating, a more
quantitative way to compare the interactions across the different environmental
variables is useful and a logistic regression step is well suited to this purpose
following the variable selection.
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Therefore after some basic analysis the final specifications of the method include the
following list:
• Random forests instead of pruning for the initial sub-tree summary
• Using the Gini index as splitting criteria
• Identifying independent effects through their high position in both sub-trees
• Selecting potential interactions from their tree position (top of one sub tree)
and movement using a score criteria that assesses variables in a top 5 position
• A final logistic regression step
• A single environmental variable involved in an interaction and a single
variable not involved is adequate for future simulations
• The MTM has greater power analysing binary variables than categorical, and
the regression step is more effective when continuous variables are recoded
using the initial data-driven dichotomosation.
Taking these decisions into account, a depiction of the final method is shown in
Figure 5.3. In chapter 6 the MTM is used on replicated datasets to ensure consistency.
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Sub 1 Sub 2
A data frame is created from the larger
dataset containing values for one
environmental variable, genetic
variables and case/ control status
A tree with a single split on the selected
variables is produced, using regression for
continuous variables and classification for
discreet environmental variable
Sub-trees grown separately, using the
Gini splitting criteria and random forest
generation
Key variables selected and analysed,
using both position in subtree and score
criteria for variable movement
RESULTS
Trees compared
Variable position high in both trees
select as main and interaction effect
Large difference in tree position










Figure 5.3 Mixed Tree Method incorporating Improvements
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5.5 Discussion
The preliminary runs of the method showed some unexpected results. The sensitivity
of the method and degree of positive results yielded when trying to define the splitting
criteria was reassuring. However, the high level of false positive results found during
the sub tree comparison is something that will have to be considered very carefully. In
effectively forcing the method to choose the best variables, even from a pool of
variables with marginal or no effects, a large false positive rate is inevitable. Although
steps were taken to minimise this through implementation of the random forest and
the logistic regression steps, the underlying theory of selecting the most important
variables in relative, not threshold based, terms may result in low specificity and mean
the method is better suited to particular study designs or situations. The following
simulations focus on a case-control design, as that is the format of the real data
analysed in Chapter 8.
5.5.1 Similarities and Differences with other methods
The classification procedure CART is forced to find the split point for a single
variable but not used for the entire tree generation. The theory behind CART stays the
same but the use changes slightly. The trees are grown using Random Forests,
however it is how the resultant trees compare to trees grown from data on the other
side of the initial split that is important, not so much the trees themselves. Logistic
regression is used as an estimation stage following the hypothesis generated by the
data mining.
What makes MTM different is that it treats the environmental variables and the
genetic variables differently and exploits their inherent differences to best identify
interactions between them. Other methods which combine genetic and environmental
data, as if they are of one type, will find it hard to remove the larger and more
dominant effects of the environmental variables. Also, the way potential effects are
detected using this method gives more information about their mode of action.
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5.5.2 Conclusions
The mixed tree method was highly successful at identifying interactions and main
effects, maintaining a high level of success as the significance threshold became
smaller and the level of false positive identification decreased. The small simulation
has shown that the identification for main effects was improved, without a large
increase in false positive results, when taking sub tree positions 1-5 into account
instead of just 1-1, or 1-3 (assuming position 1 in the other tree). However, identifying
the variables involved in an interaction with no main effects was not improved by
increasing the catchments.
Preliminary results indicated that the success of the mixed tree method will vary
depending on the underlying model of interaction and may be more limited in the
absence of genetic main effects. There was a high level of false positive identification,
however, which is why it was necessary to add a regression step at the end. Although
logistic regression alone would not reduce the false positives without any correction
for multiple testing, following the MTM a much smaller selection of variables is
entered into the regression and minimises this problem. High false positive rates are
more acceptable, at a practical level, in hypothesis generation than they would be if
the method was intended to be definitive. It was however a shortcoming of the
method, which will need to be considered during each future simulation.
Overall, the results reported in this chapter were promising and indicated a successful
role for this method in hypothesis generation. The parameters and limitations of the




Testing the Parameters of the Mixed




The central aim of this chapter is to assess the effectiveness of the mixed tree method
in identifying gene-environment interactions in data with a variety of known
parameters. Following on from the results in Chapter 5, where methodological and
technical aspects of the method were assessed, this section uses the finalised method
to analyse data containing different dimensions or containing different features of
interest.
6.1.2 Simulations and Parameters
The data under analysis contains the simulated list of environmental and genetic
variables, identified from the literature and described in more detail in Chapter 4.  The
analysis is run sequentially using a list of environmental variables as the initial split or
“root” variable. Construction of the artificial data allows variation in the nature of the
data and the interaction present. As in Chapter 5, the parameters of each analysis are
presented in a table, an example of such a table, for data with no main effect but an
interaction effect is shown below:
















Target SNP 1 0.6634
Interaction 2.5 0.4421
175 1000 0.5 Dominant
The majority of the simulations use these basic parameters with variation in one area
approached at a time, the table will show in bold the variable under study and the
different values assigned to that variable in different simulations. The risk factor
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frequency refers to the prevalence within the simulated population. The effect size is
dictated by reversing the calculation of an Odds Ratio from a contingency table,
knowing the OR in advance and filling in the probability of entering each of the cells
in the table accordingly, as described in Section 4.3.1.3. All the other variables are
generated straightforwardly using the probability of falling into each category;
therefore there is some statistical noise between the datasets and the desired estimates.
More detail on the data generation algorithm can be found in Chapter 4.
Throughout the chapter is concerned with interaction identification; however the
parameters under investigation fall into three main categories:
• Changes in known data characteristics
• Changes in underlying effects
• Combinations of known and underlying effects.
These analyses are approached in order of increasing complexity to ensure the
information gain can be correctly attributed to the correct variable and any problems
are understood and adapted for in later analyses. Similarly to chapter 5, in cases where
imperfect data may be affecting the results, an optimised version of regression,
containing only the target variables, is used for comparison.
Due to the nature of the SOCCS dataset the interaction considered are all passive
interactions, based on the presence or absence of a SNP variant. Future work includes
data on gene expression and active interaction models, but this has not been examined
in this study.
Data Characteristics
These are the features of the data that can be seen prior to analysis. These include the
sample size, number of SNPs being analysed and the allele frequency of these SNPs.
It is important to assess how effective the MTM is for these characteristics before
undertaking more compex analyses.
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Underlying Effects
Underlying effects are the risk associations and interactions that are found from the
analysis of a normal dataset, but can be generated deliberately for simulated data. This
includes the effect size of any risk estimates, both main and interaction, and the more
complex features of interaction model and inheritance model. The interaction model is
the combination of main and interaction effects present and the inheritance model
refers to the recessive, dominant and co-dominant nature of inheritance.
Combinations
The last section looks at how the effects of some of the parameters influence the
results of others. The combinations include the variability of the following: effect size
and sample size together; and the possible combinations of allele frequency,
inheritance model and interaction model.
6.1.3 Presentation of Results
The measures of success used throughout will be the proportion of the datasets where
the interaction is correctly identified and the proportion of false positive results. Given
the increase in computational intensity with increasing number of environmental
variables, only two are used for these analyses: NSAID intake and smoking. NSAID
intake attempts to identify the interaction (SNP*NSAIDs) and measures the other
identified SNPs or interactions alongside the real interaction.
Smoking has no real effects and provides a comparative measure of false positive
identification, for both interactions involving the target SNP and the false
identification of interactions between smoking and a different SNP. Only the latter is
a true measure of false positive identification as the identification of an interaction
involving the target SNP with variables other than that intended may add information
to the type of interaction or suggest a main effect.
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6.1.4 Simulation Limitations and Decisions
The simulated dataset will not include any missing data. When real data is being
analysed, the nature and potential reasons behind any missing data will dictate how it
is handled. In the context of a simulation study, especially when comparing different
methodologies on identical data, simulated missing-ness would be an entire sub-topic
comparing the different imputation methods for each different method. Analysis on
real data will examine the specifics of any missing data before a decision is made on
the most appropriate way to handle it.
Throughout the simulation, the exposure to the environmental variable is
approximately 50%. The difference in unknown exposure is investigated through
different allele frequencies. To examine the effect of a range of environmental
exposures, especially those at the extreme ends of the spectrum, would require
adjustment of the preferred splitting criteria. Given that the real data is more easily
grouped into similarly sized samples, it is more important to maximise the
identification power for this scenario. However, the environmental variable and how it
is grouped is somewhat under investigator control and can be dictated prior to analysis
to ensure groups of similar sizes. For continuous variables, it is possible to dictate the
minimum proportion desired in each group to negate the effect of outliers.
The focus in these simulations will be on a two way interaction, which is most
appropriate for the comparison methods and the sample sizes involved in the real data
set. Future work would include more complex interaction models. Similarly, the focus
will be on a case-control design, similar to the SOCCS study design from which the
real data is drawn. Different case-control ratios are explored, giving some insight into
the ability of the MTM to handle this feature of other study designs.
6.1.5 Analysis
Once the optimum method and data input approach was established, the analysis most
similar to that of real data was undertaken. The first stage is the analysis of the most
basic characteristics, in the sense that they are known prior to commencement of
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analysis. This is followed by the underlying effects and the potential interactions
between them. The results include a measure of false positive identification and the
successful identification rate.
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6.2 Analysis of Simulated Data
This section details the different parameters of the data that can be seen prior to
analysis but cannot be manipulated or changed. These parameters include the sample
or population size, the number of SNPs from the candidate panel, the allele frequency
of these SNPs and the case-control ratio.
6.2.1 Sample Size
In order to determine the effect that the sample size has on the levels of successful
identification and false positives, simulations were run with the parameters shown in
Table 6.2:























There were memory constraints in analysing 1000 datasets containing 2000 or 3000
people, on a standard computer. It is important for comparison with other methods
and the adaptation of the method for other analysis to solve this instead of using
specialist equipment. Therefore, this analysis was done by running 500 datasets twice
or 250 datasets four times, using different set seeds (29, 17, 88, 63). As using different
set seeds can sometimes result in correlations between streams of pseudo-random
numbers generated 465, these four numbers were used to generate 1000 random
numbers and these numbers plotted on a scatter plot to look for any structure. No such
correlations were observed. This is shown in more detail in Appendix 6.1. The results
from the simulation are shown below in table 6.3.
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Table 6.3 Percentage of Datasets Identifying Interaction at Different Sample Sizes
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Sample Size 200 500 1000 2000 3000 200 500 1000 2000 3000 200 500 1000 2000 3000 200 500 1000 2000 3000
Target Int 1.9 8.4 54.3 90.1 98.9 0.6 2.2 26.0 72.9 93.0 0.2 1.3 19.6 65.2 90.0 0.2 0.5 10.7 49.4 81.8
Target SNP 7.2 28.1 97.2 100 100 3.4 21.2 91.0 100 100 2.2 18.2 87.6 99.9 100 0.8 11.6 77.0 99.8 100
Neither Int
or SNP 92.7 71.9 2.8 0 0 96.3 78.8 8.7 0 0 97.6 81.7 12.3 0.1 0 99.0 88.3 23.0 0.1 0
Other Int 24.9 26.9 21.0 20.7 20.9 3.2 4.7 4.4 5.2 5.2 1.9 3.1 1.9 3.4 2.8 0.2 1.1 0.2 1.1 1.1
Other SNP 17.6 8.2 3.1 1.9 1.3 3.7 1.3 0.7 0.2 0 1.6 0.9 0.3 0 0 0 0 0 0 0
Splitting on environmental variable with no effect (smoking)
Target SNP 1.6 10.0 66.4 97.4 99.9 0.5 4.4 44.7 91.7 99.3 0.5 3.4 37.5 88.2 98.7 0 2.2 24.0 80.1 97.6
Target SNP
and smoking
0 0.5 1.0 1.7 1.5 0 0 0 0.1 0.1 0 0 0 0 0 0 0 0 0 0
Other Int 25.4 28.5 25.3 25.4 26.2 2.2 3.0 7.2 4.8 5.4 0.9 2.2 3.9 3.2 3.4 0 0.5 1.2 0.9 0.9
Other SNP 19.1 13.9 16.5 17.7 19.9 4.2 2.1 5.4 3.7 4.5 2.4 1.7 3.0 2.0 3.1 0.7 0.3 1.1 0.8 0.9
Int refers to the interaction, with Target Int being an interaction between NSAIDs and the expected (Target) SNP. These descriptions are used throughout.
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There are very few surprises regarding the effect of sample size on identification. The
low level of successful identification in small sample sizes (200 – 500 people) is to be
expected with such a high significance threshold. It would not be recommended to use
a complex, multistage analysis on such a small sample size. The power of the MTM,
like many other statistical methods, increases with sample size.
6.2.2 Number of SNPs
For the majority of statistical methods reviewed, the number of SNPs included in the
analysis was a limiting factor for successful identification, even at numbers much
smaller than the number of SNPs in a GWAS. To measure if this is also the case for
MTM the following data was generated.






















As with the sample size simulations, there were computational limitations in
generating 1000 datasets, each with 300 SNPs, therefore two runs of 500 were
generated using different set seeds (29 and 17) before being combined in the table.
There were no large discrepancies between the two sets of 500 prior to combination.
During initial test simulations it was found that at a very low number of candidate
SNPs (10 or less), there were a number of simulations that were producing unusual
results due to the probability of being in the “top 5,” being artificially high Once these
methodological restrictions had been recognised and characterised, the results from
the main analysis are shown in Table 6.5 below.
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Table 6.5 Percentage of Datasets Identifying Interaction as SNP Numbers Increase
                                                                              Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Sample Size 50 100 175 300 50 100 175 300 50 100 175 300 50 100 175 300
Target Int 59.3 54.8 54.3 56.4 31.1 30.9 26.0 28.2 24.4 24.1 19.6 21.6 12.7 12.7 10.7 11.7
Target SNP 97.6 97.6 97.2 98.3 91.2 91.3 91.0 92.9 88.4 88.4 87.6 89.7 80.4 78.4 77.0 78.3
Neither Int
or SNP
2.4 2.8 2.8 1.7 8.7 8.7 8.7 7.1 11.4 11.6 12.3 10.3 19.5 21.4 23.0 21.7
Other Int 13.2 17.3 21.0 19.7 1.6 3.4 4.4 4.5 0.8 2.1 1.9 2.3 0.4 0.6 0.2 0.1
Other SNP 2.1 2.2 3.1 2.0 0.4 0.3 0.7 0.4 0.2 0.2 0.3 0.1 0 0 0 0
Splitting on environmental variable with no effect (smoking)
Target SNP 75.3 73.6 66.4 68.9 48.3 49.9 44.7 48.6 41.0 41.8 37.5 41.1 25.5 26.6 24.0 26.4
Target SNP
and smoking
1.2 1.3 1.0 1.1 0.1 0.1 0 0.1 0 0.1 0 0 0 0.1 0 0
Other Int 17.1 19.4 25.3 24.2 2.4 3.4 7.2 6.1 1.5 1.5 3.9 3.5 0.1 0.7 1.2 0.9
Other SNP 8.0 13.9 16.5 14.8 1.7 3.1 5.4 4.0 0.8 2.3 3.0 2.0 0.2 0.7 1.1 0.5
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The results from differing SNP numbers do show some interesting results, in
particular it was interesting that the number of SNPs under analysis at one time does
not adversely affect the successful identification of the interaction nor increase the
volume of false positives, unless very small numbers are involved. When there is an
interaction present between a SNP and environmental variables, neither with a main
effect, the SNP is often selected as a main effect – both for the variable it interacts
with and other variables that have no main or interacting effects. This may in part be
due to the absence of any other main effects, so the slight increase in associated risk
for the proportion of carriers that are experiencing the interaction effect confers the
effect to the group as a whole. The SNP has a higher sensitivity and specificity than
its interaction term. In terms of false positive identification, the rate is lower in the
presence of real effects and does not increase as the number of SNPs (and therefore
the potential number of interactions) increases.
Although current genetic screening can contain much larger numbers of genes than
300, it is reassuring that for the numbers analysed the successful identification is
consistent as the number of SNPs increases yet the number of false positives does not
increase. Although it is not possible to extrapolate from such low numbers to millions
of SNPs, this is a good result compared to other approaches.
It may also suggest that for large numbers, a method that effectively ranks the results
against one another may be better suited than one with absolute significance
thresholds, although this is unlikely to be the MTM specifically, without adaptation.
This method has been designed to work on a selected panel of SNPs, which the
literature review suggests is around 200 SNPs for colorectal cancer. Therefore, these
results are reassuring that the MTM may be suitable for such analysis.
6.2.3 Allele Frequency
To assess how effective the MTM is at identifying risk alleles and their interactions, it
is necessary to compare the identification rate when the target allele is at a variety of
frequencies within the study population: therefore a number of simulations were run
when the target allele is at frequencies 0.1, 0.25, 0.5, 0.75 and 0.9 under a dominant
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inheritance model. The genotype frequencies are assumed to be in Hardy Weinberg
equilibrium based on the allele frequency. The parameters for this simulation are in
table 6.6, the results in Tables 6.7.
It is worth noting that at very low frequencies, the odds ratio associated with the
interaction effect will be closer to 1 than in the higher frequencies. It is difficult to
accurately simulate an OR of 2.5 with only 0.1% in the exposed group.
















Target SNP 1 0.1 0.25 0.5 0.75 0.9
Interaction 2.5 0.07 0.17 0.34 0.51 0.60
175 1000 0.5 Dominant
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Table 6.7 Percentage of Datasets Identifying Interaction at Different Allele Frequencies under a Dominant Inheritance Model
                                                                   Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
35.9 66.9 38.5 2.5 0.1 16.6 38.4 15.7 0.5 0.1 12.9 31.0 11.8 0.3 0.1 5.4 19.0 5.9 0 0
Target SNP 57.7 97.7 89.9 10.4 0 57.4 96.4 76.6 4.5 0 56.9 94.9 70.0 3.7 0 53.1 91.1 54.6 1.4 0
Neither Int
or SNP 42.3 2.3 10.1 89.0 99.9 42.6 3.6 23.0 95.4 99.9 43.0 5.1 29.6 96.2 99.9 46.9 8.8 44.8 98.6 100
Other Int 25.2 22.6 21.8 27.4 4.6 4.6 4.6 5.6 6.1 6.1 2.9 2.8 3.1 3.4 3.3 1.1 0.6 0.9 1.0 0.4
Other SNP 17.7 1.7 3.9 32.3 35.4 5.2 0.4 0.9 9.9 10.3 2.5 0.3 0.8 6.6 5.8 0.3 0 0.2 1.7 1.2
Splitting on environmental variable with no effect (smoking)
Target SNP 15.3 70.7 53.1 2.1 0 13.7 58.6 31.3 1.1 0 13.2 53.4 24.5 0.7 0 10.7 39.6 13.6 0.3 0
Target SNP
and smoking
0.5 1.4 0.9 0.4 0 0.1 0.2 0.1 0 0 0.1 0.1 0.1 0 0 0 0 0 0 0
Other Int 29.4 24.7 22.9 27.7 26.2 5.7 5.3 5.3 6.3 5.7 3.2 2.6 2.4 4.3 1.3 1.3 0.5 0.4 0.7 0.5
Other SNP 28.5 17.8 17.1 36.9 37.6 7.2 5.1 4.9 11.2 10.1 4.7 3.0 2.8 5.9 1.0 1.0 0.6 0.7 1.5 1.0
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In order to fully interpret these results it is important to take the risk factor in context
of “exposure.” This would be the proportion of the population that are exposed to the
risk allele: in the case of a dominant inheritance model this would be people carrying
either one or two copies of the allele, in a recessive inheritance model the exposed
group are only those carrying two copies as a single copy would not confer an
increase in risk, or exposure. As the model is dominant and the genotype frequencies
following Hardy Weinberg equilibrium, the exposure rates are higher than they
appear, table 6.8 shows how the allele frequency relates to exposure rate in this case:
Table 6.8 Relationship between Allele Frequency and Exposure
Allele
Frequency
0.1 0.25 0.5 0.75 0.9
Proportion
Exposed
0.19 0.4375 0.75 0.9375 0.99
Taking the exposure rate into account, the level of identification being most
successful at an allele frequency of 0.25 is unsurprising – it is the point at which the
level of exposure is closest to 0.5. As the allele frequency and exposure increase past
this point identification rate decreases and the level of false positives increases. The
trend of identification is very similar to the rate at which the target SNP is identified
following different environmental splits, where there is no main or interaction effect
present (in this case smoking).
6.2.4 Case-control Ratio
In order to use the MTM in situations where the case-control ratio is not perfectly
matched, a simulation was done using the parameters shown in Table 6.9. This will be
important if the method is to be applied to data gathered from a cohort study, where
the proportion of controls is normally higher than cases. The results are shown in the
Table below, 6.10.
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Target SNP 1 0.6634
Interaction 2.5 0.4421
175 1000 0.25, 0.5,
0.75
Dominant




0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Cases (%) 25 50 75 25 50 75 25 50 75 25 50 75
Target Int
13.5 54.3 23.2 4.3 26.0 9.6 2.9 19.6 7.0 1.6 10.7 2.3
Target SNP 54.8 97.6 56.8 40.0 91.0 40.1 34.0 87.6 33.4 18.9 77.0 22.7
Neither Int or
SNP 44.9 2.8 42.9 59.7 8.7 58.5 65.8 12.3 65.5 80.9 23.0 77.1
Other Int 21.6 21.0 20.2 4.3 4.4 4.1 2.4 1.9 2.2 0.7 0.2 0.7
Other SNP 15.6 3.1 14.6 4.6 0.7 4.1 2.9 0.3 2.4 0.7 0 0.3
Splitting on environmental variable with no effect (smoking)
Target SNP 21.9 66.4 18.4 12.3 44.7 7.8 10.5 37.5 6.2 4.6 24.0 2.6
Target SNP
and smoking
0.3 1.0 1.3 0 0 0.1 0 0 0 0 0 0
Other Int
26.8 25.3 25.8 5.1 7.2 5.9 3.0 3.9 3.6 0.8 1.2 1.1
Other SNP 26.8 16.5 25.9 7.3 5.4 7.0 4.6 3.0 4.4 1.1 1.1 1.4
These results suggest that a 50:50 split, or close to it, gives the best possible level of
identification, this is not a surprising result. It is reassuring that identification of the
SNP is still fairly high in the lower ratios as this suggests some flexibility towards
cohort data.
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6.3 Underlying Data Structure
There are some features of the data that are not obvious and are only understood after
analysis; they are in fact the reason to do analysis in the first place. These variables
include the presence of a main SNP effect, the size of the interaction effect or
association, the inheritance model of the SNP and the underlying interaction model.
There is also the interplay between these factors to consider.
6.3.1 Effect Size
The size of the underlying effect is in the form of an Odds Ratio (OR), the odds of
being a case in the exposed group to the odds of it occurring in the unexposed.
Therefore, the variability of identification for different effect sizes may be influenced
by the sample size. Following the basic simulation of differing effect size,
combinations of effect size and sample size will also be analysed. To study effect size,
an OR of between 1.5 and 3.5 is assigned to the interactions term using the parameters
shown in table 6.11 The results are shown in table 6.12.

















Target SNP 1 0.6634
Interaction 1.5, 2.0, 2.5,
3.0, 3.5
0.4421
175 1000 0.5 Dominant
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Table 6.12 Percentage of Datasets Identifying Interaction across Different Effect Sizes
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Effect Size
(OR)
1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5
Target Int
4.3 26.9 54.3 76.2 87.6 1.4 9.3 26.0 48.4 68.1 0.9 7.3 19.6 40.3 59.3 0.3 3.6 10.7 24.8 43.6
Target SNP 18.8 75.1 97.2 99.8 100 7.5 57.6 91.0 99.3 99.8 5.5 50.4 87.6 98.7 99.8 3.0 33.5 77.0 95.6 99.6
Neither Int
or SNP
80.6 24.6 2.8 0.2 0 92.1 42.0 8.7 0.7 0.2 94.3 49.1 12.3 1.3 0.2 97.0 66.2 23.0 4.4 0.4
Other Int 26.1 23.7 21.0 19.7 19.3 4.9 4.9 4.4 5.4 4.1 2.7 2.7 1.9 2.6 2.0 0.4 0.2 0.2 0.5 0.4
Other SNP 27.7 8.8 3.1 1.7 1.3 8.6 3.2 0.7 0.4 0.2 5.1 2.5 0.3 0.2 0.2 1.2 0.8 0 0.1 0
Splitting on environmental variable with no effect (smoking)
Target SNP 6.0 32.4 66.4 89.8 96.5 3.0 17.0 44.7 72.3 88.4 2.1 13.7 37.5 64.5 83.1 0.6 7.9 24.0 49.4 71.4
Target SNP
and smoking
0.8 1.0 1.0 1.5 1.6 0 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Int 24.3 27.8 25.3 26.4 25.8 6.3 6.6 7.2 5.6 6.9 3.5 3.9 3.9 3.4 3.9 0.7 0.8 0.9 1.1 1.2
Other SNP 33.6 23.3 16.5 14.3 17.1 10.8 7.5 5.4 3.8 4.9 6.4 4.4 3.0 2.7 3.1 1.4 0.8 0.5 0.8 0.7
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These results show a number of interesting, if not unexpected, points. They repeat the
pattern seen earlier of less false positives in the presence of real effects. As the effect
size increased, the level of identification increased and the level of false positives
decreased. This was true for the false positives suggesting an interaction or main SNP
effect with the NSAIDs and for false positive SNPs identified under the smoking
variable. However, the false positive rate of interactions between smoking and other
SNPs was nearly constant across the different effect groupings for the target
interaction.
As would be expected, as the effect size increased, so did the likelihood of identifying
the target interaction, especially if both interactions and SNPs were considered. The
identification held consistently across the significance thresholds, whereas most of the
false positives did not.
Unexpectedly, the target SNP was identified at a very high level in the smoking
analysis. This suggests that in the absence of main or interaction effects, the SNP
which has an association when involved in an interaction is still more strongly
associated than other variables when splitting on other environmental variables.
6.3.2 Effect Size for Independent Effects
In order to measure how effective the MTM was at identifying an independent SNP
effect, a simulation was run with the parameters in table 6.13. Table 6.14 compares
this result to the results when an equivalent interaction term is generated, but no main
effect.




















175 1000 0.5 Dominant
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Table 6.14 Percentage of Datasets Identifying Interaction across Different Effect Sizes for a Main Effect versus an Interacting Effect
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Main SNP Effect
Effect Size 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5
Target SNP 20.7 80.3 99.0 99.7 100 9.0 59.6 92.6 99.3 99.8 7.1 52.7 89.4 98.9 99.8 3.8 35.3 77.8 96.0 99.6
Target Int
(False +ive) 1.7 2.0 2.1 1.9 1.9 0.2 0.2 0.2 0.3 0.2 0 0.2 0.1 0.1 0.2 0 0.1 0 0 0.1
Neither Int or
SNP 78.4 19.0 0.7 0.1 0 90.9 40.3 7.4 0.6 0.2 92.9 47.2 10.6 1.1 0.2 96.2 64.7 22.2 4.0 0.4
Other Int 25.3 23.9 26.0 26.6 25.4 6.4 5.8 5.4 6.5 6.0 4.2 3.5 3.4 3.8 3.8 1.6 1.5 1.2 1.1 0.4
Other SNP 27.9 20.7 27.0 29.5 32.0 7.7 5.5 7.6 8.8 9.8 4.3 3.5 4.8 5.4 5.5 1.1 0.9 1.0 1.2 1.3
Interaction Effect
Target Int
4.3 26.9 54.3 76.2 87.6 1.4 9.3 26.0 48.4 68.1 0.9 7.3 19.6 40.3 59.3 0.3 3.6 10.7 24.8 43.6
Target SNP 18.8 75.1 97.2 99.8 100 7.5 57.6 91.0 99.3 99.8 5.5 50.4 87.6 98.7 99.8 3.0 33.5 77.0 95.6 99.6
Neither Int or
SNP
80.6 24.6 2.8 0.2 0 92.1 42.0 8.7 0.7 0.2 94.3 49.1 12.3 1.3 0.2 97.0 66.2 23.0 4.4 0.4
Other Int 26.1 23.7 21.0 19.7 19.3 4.9 4.9 4.4 5.4 4.1 2.7 2.7 1.9 2.6 2.0 0.4 0.2 0.2 0.5 0.4
Other SNP 27.7 8.8 3.1 1.7 1.3 8.6 3.2 0.7 0.4 0.2 5.1 2.5 0.3 0.2 0.2 1.2 0.8 0 0.1 0
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These results show that the MTM can successfully identify a SNP main effect at a
level of 99% at an effect size 2.5, continuing to find the effect across an increasingly
strict significance threshold. The presence of a main SNP effect is only identified as
an interaction with the splitting variable at a very low level, which is not affected by
the identification of the main SNP effect. The false positive rate of SNP identification
is also unaffected by the presence and identification of an independent SNP effect.
Conversely, the presence of an interaction effect identifies the interacting SNP as a
main effect at a high level, increasing as identification of the interaction increases.
This analysis shows that the presence of main SNP affects do not adversely affect the
level of false positive identification and removing them from the data and repeating
the analysis could expect a similar level of false positives to that of a data set with no
main effects at all.
6.3.3 Effect Size by Sample Size
To assess the difference in identification rate across different combinations of sample
size and effect size, simulations were run on sample containing 500 and 2000 people
to compare against the results for 1000, for effects sizes 1.5, 2.0, 2.5, 3.0 and 3.5. The
results, at significance level 0.01 are shown in Figure 6.1, the results are recorded in
more detail in Appendix 6.2.
These results show that the identification increases as the sample size increases and as
the effect size increases. For all effect size and sample size combinations, the
interacting SNP is identified more often on its own than as an interaction.
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Figure 6.1 Level of Identification at Different Effect and Sample Sizes
6.3.4 Inheritance Model and Allele Frequency
Having looked at the effect of allele frequency under a dominant inheritance model
(table 6.7), the same allele frequencies were used to assess the successful
identification of the recessive and co-dominant models. The co-dominant model is
slightly different to analyse than the dominant and recessive, in having two different
risk levels: an increase in risk if heterozygous for the risk allele and a further increase
if homozygous. The simulations to test the effect of allele frequency in a co-dominant
model have an odds ratio of 1.5 for the heterozygotes, relative to the homozygous
wildtype, rising to 2.5 for those homozygous for the risk allele.
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The parameters of these simulations are shown in table 6.15, the results for recessive
and co-dominant inheritance models can be found in tables6.16 and 6.17,
respectively:
















Target SNP 1 0.1 0.25 0.5 0.75 0.9
Interaction 2.5 0.07 0.17 0.34 0.51 0.60
175 1000 0.5 Recessive
Smoking 1 0.510
NSAIDs 1 0.6664
Target SNP 1 0.1 0.25 0.5 0.75 0.9
Interaction 2.5 0.07 0.17 0.34 0.51 0.60
175 1000 0.5 Co-
Dominant
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Table 6.16 Percentage of Datasets Identifying Interaction at Different Allele Frequencies, under a Recessive Inheritance Model
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
0 1.3 37.2 68.7 42.3 0 0.1 14.7 38.7 20.5 0 0.1 11.0 30.9 17.1 0 0 5.3 20.1 9.0
Target SNP 0 6.3 88.8 98.5 72.2 0 3.1 73.7 97.4 72.0 0 2.4 66.0 96.4 70.9 0 1.1 51.2 91.5 65.0
Neither Int
or SNP
100 93.5 10.9 1.5 27.4 100 96.9 26.1 2.6 28.1 100 97.6 33.5 3.5 29.2 100 98.9 48.3 8.3 35.1
Other Int 31.0 27.2 19.8 21.1 22.9 6.2 6.5 4.6 4.0 4.8 3.4 3.3 2.4 2.0 2.6 0.6 0.8 0.8 0.5 0.5
Other SNP 36.5 33.3 3.6 2.1 11.0 9.5 9.4 1.2 0.5 2.9 5.5 5.9 0.8 0.2 1.8 1.3 1.3 0.3 0 0.3
Splitting on environmental variable with no effect (smoking)
Target SNP 0 1.9 52.3 70.8 19.3 0 0.8 30.3 59.4 17.8 0 0.5 23.9 52.9 17.2 0 0 13.2 38.2 15.2
Target SNP
and smoking
0.1 0.1 0.3 1.1 0.7 0 0 0 0 0.1 0 0 0 0 0.1 0 0 0 0 0
Other Int 29.6 25.4 26.6 23.9 27.7 6.5 5.6 4.8 5.0 6.7 3.8 3.1 2.8 2.5 4.4 1.2 1.2 0.5 0.7 1.2
Other SNP 34.1 32.5 16.5 17.4 28.1 8.1 9.5 4.7 5.4 9.9 4.6 4.8 2.4 3.2 4.7 1.2 1.2 0.7 1.1 1.0
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Table 6.17 Percentage of Datasets Identifying Interaction at Different Allele Frequencies, under a Co-Dominant Inheritance Model
                       Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
16.3 41.0 31.4 0.2 0 7.5 20.4 13.4 0 0 5.7 16.1 10.6 0 0 2.2 7.9 4.8 0 0
Target SNP 27.1 74.6 70.9 1.7 0.1 27.1 72.4 62.1 0.7 0 26.8 70.1 56.0 0.4 0 25.3 60.0 40.0 0.2 0
Neither Int
or SNP
72.9 25.4 29.0 98.3 99.9 72.9 27.5 37.5 99.3 100 73.2 29.8 43.6 99.6 100 74.5 39.7 59.8 99.8 100
Other Int 24.9 22.0 22.7 27.6 25.9 4.4 4.5 4.3 5.9 5.5 2.5 2.7 1.7 4.1 2.9 0.5 0.5 0.5 0.6 0.8
Other SNP 25.5 10.6 12.1 34.9 33.3 6.3 3.2 3.9 10.7 10.0 3.6 1.8 2.1 5.8 5.5 0.7 0.6 0.3 1.0 1.3
Splitting on environmental variable with no effect (smoking)
Target SNP 6.3 32.3 33.3 1.2 0 6.1 27.4 19.9 0.6 0 5.7 24.4 15.6 0.6 0 5.2 16.7 8.1 0 0
Target SNP
and smoking
0.8 1.1 0.9 0.5 0 0.1 0.2 0.2 0.1 0 0 0.1 0.1 0.1 0 0 0 0 0 0
Other Int 29.2 30.5 26.6 29.5 29.4 6.4 6.1 5.7 6.5 6.2 4.1 3.2 3.3 3.3 3.5 0.6 0.8 1.0 1.0 0.7
Other SNP 30.5 25.7 26.6 35.2 35.8 9.0 7.9 5.8 9.8 11.3 5.1 5.0 3.4 5.1 6.4 1.2 1.8 0.8 0.8 1.3
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Dominant and Recessive Inheritance Models
Although different in practice, the risk of a dominant or recessive allele is effectively
contributing to the same variable in the mixed tree model – exposure to the “at risk”
genotype. The exposed group will either be those with at least one copy of the gene or
only those with both but theoretically the analysis is the same, comparing exposure
status to outcome.
The identification of the interaction is lowest when the ratio of exposed and non-
exposed is largest. In the dominance model, an allele frequency of 90% translates to
99% of the sample being in the exposed group. Similarly, a person in the recessive
model an allele frequency of 10% has only a 1% chance of being exposed. So few
exposed makes it very difficult to identify effects, even when actively looking for
them using traditional methods. For example, even in an optimised regression model
containing only the target SNP, the NSAIDs and their interaction, the level of
identification was low. Table 6.18 show how this regression model compares to the
mixed tree method results using all 175 SNPs when the target SNP has a frequency of
0.9 and dominant behaviour (therefore 99% of the population is exposed).
Table 6.18 Percentage of Datasets Identifying Interaction in an Optimum
Regression and MTM for Low Exposure Frequencies
Significance Threshold
0.01 0.001 0.0005 0.0001
Reg. MTM Reg. MTM Reg. MTM Reg. MTM
Target Int 1.6 0.1 0.2 0 0 0.1 0 0
Target SNP 1.7 0 0.1 0 0 0 0 0
Neither Int or
SNP
96.9 99.9 99.7 99.9 100 99.9 100 100
The analysis is most successful when the exposed group contain approximately half of
the sample. For a dominant model this is most similar to an allele frequency of 25%,
translating to 43.75% of the population carrying the risk allele as either a heterozygote
or homozygote. In the recessive model, an allele frequency of 75% translates to
56.25% of the population being exposed. This goes some way to explaining the
difference in results from the two models.
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The Co-Dominant Model
The trends of identification for the co-dominant inheritance model are similar to the
dominant model, this makes sense as the exposure group is the same just with varying
levels of risk associated. The MTM does not estimate the size of risk, so cannot
differentiate well between the co-dominant and dominant models.
The results are probably poorer for the co-dominant model because of the difficulty of
assigning risk to small proportions of the sample.  In effect the sample is being split in
three before risk is being assigned, so the chance that one of the fractions will be too
small to effectively represent the desired OR is higher.
Conclusions on Inheritance Model
For all three models, the most easily identified SNP has an exposure frequency as
close to 0.5 as possible. Therefore, where possible, a literature search for information
on inheritance model prior to analysis would help identify the best SNPs for each
particular analysis (between 50-75% for recessive and 25-50% for dominant).
Similarly to the results from different SNP numbers, the target SNP is identified in the
analysis containing other environmental variables and at a higher rate than the
interaction effect. Again, the false error rate decreases when a real effect is present
and is not affected in any other way by the inheritance model of the target SNP.
6.3.5 Interaction Model
To recap the definitions of interaction type from section 2.1.2.2:
Type A: Having certain genotypes increases the likelihood of being exposed to the
environmental factor, which in turn increases the risk of disease.
Type B: The environmental factor has a main effect, increased in the presence of
certain genotypes which themselves have no main effects
Type C: The genotype has a main effect, enhanced by the environmental factor which
has no independent effect
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Type D: Neither have a main effect, but together the gene and environmental factor
confer an increase in risk
Type E: Both have main effect, the combination of which is higher than their additive
combined risk
Data were generated for each of the interaction models above, with OR of 1.5 for the
first line/main effects and 2.5 for the second, cumulative risk estimates. The
simulation parameters are shown in Table 6.19, the results in table 6.20.

















A * B C D E
Smoking 1 1 1 1 1 0.510
NSAIDs 2.5 1.5 1 1 1.5 0.6664
Target SNP 1.5 1 1.5 1 1.5 0.6634
Interaction 1 2.5 2.5 2.5 2.5 0.4421
175 1000 0.5 Dominant
* The associated risk for the target SNP in interaction model A describes the increase
on risk of taking NSAIDs, not an increased risk directly of case status.
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Table 6.20 Percentage of Datasets Identifying Interaction for Different Interaction Models
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Interaction
Model
A B C D E A B C D E A B C D E A B C D E
Target Int
0.2 80.4 78.1 54.3 61.1 0 55.4 52.4 26.0 33.9 0 48.1 45.3 19.6 28.0 0 33.2 28.6 10.7 16.5
Target SNP 0.3 99.3 99.4 97.2 96.7 0 97.5 97.5 91.0 92.1 0 96.2 96.3 87.6 88.0 0 92.0 91.8 77.0 80.1
Neither Int
or SNP
99.6 0.6 0.6 2.8 3.2 100 2.4 2.4 8.7 7.8 100 3.6 3.6 12.3 11.8 100 7.8 7.9 23.0 19.8
Other Int 26.4 17.2 16.4 21.0 18.7 5.7 4.0 4.1 4.4 4.0 3.3 2.0 1.8 1.9 1.4 0.8 0.2 0.1 0.2 0.3
Other SNP 35.6 2.5 2.0 3.1 2.3 8.8 0.5 0.4 0.7 0.7 4.7 0.2 0.2 0.3 0.4 0.5 0.1 0 0 0.2
Splitting on environmental variable with no effect (smoking)
Target SNP 18.5 74.4 77.4 66.4 65.2 9.1 56.9 59.6 44.7 47.0 7.0 49.8 54.0 37.5 40.3 2.6 33.2 38.0 24.0 27.0
Target SNP
and smoking
1.0 1.6 1.4 1.0 1.2 0.1 0 0.1 0 0 0.1 0 0 0 0 0 0 0 0 0
Other Int 26.5 26.4 26.0 25.3 25.4 5.8 5.7 5.6 7.2 6.5 3.4 3.1 3.3 3.9 1.1 1.1 1.0 0.7 1.2 1.0
Other SNP 27.2 15.4 13.8 16.5 15.4 8.2 4.1 3.7 5.4 4.5 4.9 2.8 2.0 3.0 0.9 0.9 0.5 0.6 1.1 0.7
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Conclusions on Interaction Type
As shown in the table, the interaction least detected – by quite some margin – was
Type A, and the best Types B and C. Taking SNP identification into account as an
identification, all four types other than A had very high levels of identification. As
seen in all previous runs, in the presence of a real, identified effect, the level of false
positive identification of both interactions and SNPs was lower.
It is debateable whether type A is an interaction at all, and not just a two step causal
pathway, which might explain why interactions are not so easy to identify using the
Mixed Tree Method (MTM).  The important step that is not working well under this
model is the initial splitting of sub-groups. When the initial sample is split based on
the environmental variable the SNP types are also divided into non-equal groups, with
more of the risk SNP genotypes in the groups positive for the risk factor. After this
splitting step however, there is no actual difference between the risk SNP and other
SNPs within the subgroup – the risk SNP only affects the likelihood of being in the
subgroup in the first place. Therefore the poor results are not entirely unexpected.
For the other four interaction types the results are reassuring. The relatively high
identification in Types B and C, especially B, is down to the effectiveness of the
environmental split and the variation in SNP allele frequencies within the groups. In
interaction Type D, the lower power may, in part be explained by the MTM less
consistently splitting the groups into similarly sizes sub-groups, as there is no main
environmental effect to make such a clear division. With larger sample sizes, the
identification rates were higher. Chapter 7 will compare these results to those obtained
using different analyitical methods to establish whether 70-80% identification can be
considered high in such a context.
6.3.6 Interaction Model, Allele Frequency and Inheritance Model
As the allele frequency and inheritance model have a combined effect that can be
explained by the level of exposure, analysis combining interaction model and allele
frequency will suffice in suggesting the trend by exposure. Table 6.21 shows the
parameters for these simulations:
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A * B C D E
Smoking 1 1 1 1 1 0.510
NSAIDs 2.5 1.5 1 1 1.5 0.6664
Target SNP 1.5 1 1.5 1 1.5 0.1, 0.25,
0.5, 0.75,
0.9
Interaction 1 2.5 2.5 2.5 2.5 0.4421
175 1000 0.5 Dominant
The results are displayed in Figure 6.2 and shown in table 6.22, for a significance
level of 0.01. Multiple tables covering the results in more detail can be found in
Appendix 6.3. Interaction Model A was almost wholly unsuccessful, with the results
similar to what would be expected by chance, it has therefore not been included in the
graph.
As an interaction can be identified either as an interaction effect or as a main SNP
effect for a single environmental variable, figure 6.2 displays the results as both
looking for interaction effects only and looking for the proportion of time the vairable
is identified as either an interaction or a main SNP effect for that enironmental
variable.
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Figure 6.2 Interaction Model and Allele Frequency
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Table 6.22 Percentage of Datasets Identifying Interaction for Different Interaction Models and Allele Frequencies
                                                                       Interaction Model
B C D E
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
11.2 80.8 61.8 8.6 0.2 11.6 83.3 65.7 11.2 0.1 16.3 41.0 31.4 0.2 0 12.1 59.2 42.9 5.7 0
Target SNP 13.2 94.8 96.6 29.0 0.7 13.9 98.6 98.2 35.7 1.0 27.1 74.6 70.9 1.7 0.1 15.8 89.9 90.6 23.5 0
Neither Int
or SNP
86.8 5.2 3.4 70.1 99.1 86.1 1.4 1.6 62.6 98.9 72.9 25.4 29.0 98.3 99.9 84.2 10.1 9.3 75.8 100
Other Int 26.1 17.0 18.9 24.8 27.1 17.7 11.9 12.7 10.6 17.0 24.9 22.0 22.7 27.6 25.9 28.5 20.1 19.6 23.6 28.5
Other SNP 31.7 3.5 3.4 21.2 37.9 18.0 1.4 2.7 10.4 20.5 25.5 10.6 12.1 34.9 33.3 29.8 4.3 4.8 21.8 38.0
Splitting on environmental variable with no effect (smoking)
Target SNP 0.8 48.9 63.0 8.4 0.2 1.2 64.8 73.2 11.6 0.1 6.3 32.3 33.3 1.2 0 2.0 47.2 55.1 7.1 0.2
Target SNP
and smoking
0.1 0.9 1.6 1.0 0.3 0.1 0.5 1.1 0.9 0.4 0.8 1.1 0.9 0.5 0 0.2 1.6 1.3 0.6 0.2
Other Int 30.4 25.7 28.3 28.0 30.1 19.3 18.0 20.0 18.3 19.8 29.2 30.5 26.6 29.5 29.4 30.0 25.2 25.3 29.0 28.6
Other SNP 34.1 21.9 18.3 32.2 35.1 21.2 12.1 10.9 15.3 18.6 30.5 25.7 26.6 35.2 35.8 31.9 22.1 17.2 31.5 37.4
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There were no great differences between interaction models when measuring the
differences over different allele frequencies. The same general pattern applied for all
the different interaction types, with the exception of type A. For all the interaction
types, the power of identification was higher as the exposure neared 50% (in the
dominant inheritance model used this is best represented by an allele frequency of
0.25).
At the lower frequencies, so an 0.1 allele frequency corresponding to 19% exposure,
interaction type D, where neither the gene nor environmental variable have a main
effect but combined have an interaction effect, performed slightly better than the other
interaction types. This could be an artefact from the data generation as effectively
only one risk estimate is being calculated and added to a single at risk group. Splitting
the data effectively into two different at risk groups prior to adding the risk effect is
less efficient at the lower frequencies as the at risk in each group will be very small.
Surprisingly, the type D interactions had the lowest rate of the target SNP being
identified when the root split was smoking. Unsurprisingly, type C, where there was a
genetic main effect compounded by the environmental variable, had the highest rate.
Like all the other simulations, the level of false positive identification for interaction
models B-D decreased when real effects were detected for both interaction and main
SNP effects.
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6.4 Ranking of Results
One of the main issues is how to move from these results to a method of identifying
potential interaction in real data. As the analysis is carried out on a pre-selected SNP
panel, then undergoes a number of parameter decreasing stages before being entered
into a regression model, it would be statistical bad practice to take the p-value
estimate as true and conclusive, without any correction or context.
Therefore, in order to identify the most plausible hypothesis from these results it is
necessary to develop a hierarchy of evidence and rank them accordingly. The
following criteria are a summation of the results from this chapter and the theoretical
basis of how this method will be applied to real data in a biological context.
Strong Evidence of a Main Effect
• Identified as an important variable in both subtrees of a single analysis and
across the majority of environmental variables
• In most cases a p-value for the independent effect below 0.01
Strong Evidence of an Interaction Effect
• Identified as an interaction term following the logistic regression step
• Highly significant p-value, below 0.01 or 0.05 depending on sample size and
other p-values obtained
• Biological Plausibility
• Replicated in Other Work
Intermediate Evidence of an Interaction
• Identified as an interaction with a borderline effect
OR
• Identified as a main SNP, which was significant and only found at the top of
one sub-tree for a single environmental variable
• Biologically Plausible
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Counter Evidence of an Interaction
• If further analysis reveals the genotype selected to be the heterozygote, whilst
grouping the homozygotes together – this is not biologically plausible
• Identified more than once throughout the full analysis, at low significance
levels
• No prior evidence base
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6.5 Discussion
From the analyses presented in this chapter there were a number of common
observations: the proportion of false positive results decreased in the presence of real
interaction effects, decreasing as the level of successful identification increased; the
real effects were more likely to be identified consistently across the different
significance thresholds, especially if the odds ratio is high or the sample size large;
the SNP involved in an interaction with one environmental variable was still
identified frequently as an independent effect for other variables. This last point may
be an artefact from the lack of any other marginal effects but may suggest a good way
to identify potential interactions: look for important SNPs across all variables then
look at the interaction identification rates for that SNP. However, further work would
be required to analyse combinations of effects before such an approach could be
validated.
The number of SNPs did not affect either the identification of real interactions or of
false positives, but did require slightly different settings for very low SNP numbers,
which can be easily adjusted. As regression is the significance determining step, it
was not surprising that the significance level, effect size and sample size had interplay
with similar parameters to regression – improving at higher sample and effect sizes. In
fact at the lower effect sizes (OR =1.5) the identification was ten times higher with a
population of 2000 than 500. The larger sample sizes showed increased identification
but not a higher false positive rate.
The model of inheritance was only relevant in dictating the exposure vs. non exposure
groups. In real analysis, where the inheritance model is known, the SNP selected
should split the sample as close to 50% exposed as possible. Therefore, if the gene
itself is known to have a dominant inheritance pattern, a SNP of a lower frequency,
approximately 25-50% would be preferable to that of a higher frequency. Where
unknown, the 50:50 SNP frequencies would be recommended.
Four out of five interaction types were consistently identified; with Type A
interactions not being picked up. It is debatable whether this kind of interdependence
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can even be classed as an interaction, it does not fit the criteria for interaction with
regards to statistical theory. Other interaction types were identified well (power
between 0.75 and 0.95) with the interaction more often being identified as a SNP for
all interaction types, especially at higher sample sizes – this suggests that it is the
numbers in the sub groups limiting identification when applicable.
The data from these simulations are based on a case-control study: an interesting area
of future research would compare results across different study designs, particularly
founder populations, where the people under study have common ancestry. In cases
where the population contains a high level of relatedness, there would be stretches of
DNA inherited together and therefore SNPs associated with one another. This would
have to be considered during the SNP selection process but would not in fact inhibit
the identification of a key SNP, especially if the method was being used to generate
hypotheses – in which circumstances position of SNPs would be seen and the
explanation become clear. The random forest procedure (as currently implemented in
R) allows settings for relatedness between the variables. With careful planning, there
is no methodological reason the mixed tree method would not work on founder
populations – however, it is an area for further research.
It is important, before starting analysis by MTM, to look carefully at the dataset and
establish the best way of entering the data for each of the environmental variables. In
a number of cases, particularly those with unusual or extreme measures, this will
involve some preliminary data preparation. However, the method has flexibility and
can be adapted to overcome a number of problems.
An important question is: how generalisable are the results gained from the MTM?
They are hypothesis generating, so not directly applicable to a population and
particularly not to individuals within that population. However, used within a larger
framework and investigation they could prove to be a crucial ingredient to a new arm
of gene-environment research.
At high sample sizes the results were very good, with close to 100% identification
(depending on which measure is used) with no corresponding increase in false
positives. These results are particularly reassuring given that the sample analysed in
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Chapter 8 contains a similar number of participants (1216). However, MTM, like
most statistical methods, would not perform well on a small sample size with a large
number of potential explanatory variables. The results on a sample of only 200, were
poor and it would not be a recommended sample size for MTM analysis. Between 500
and 1000 participants in total would be the recommended sample size, with the
number of cases and controls roughly equivalent.
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Chapter 7
Alternative Analytical Methods: How




To give a wider context to the results from the mixed tree method analysis the same
data were analysed using other statistical methods that have shown some success in
identifying interactions. These methods were discussed in more detail in Chapter 2,
where the methods considered most successful were logistic regression, regression
using stepwise selection, Multifactor Dimensionality Reduction (MDR) and the
extension to MDR to give a quantitative measure of association, Odds Ratio MDR
(ORMDR). Neural Networks (NN) provide a useful diagnostic tool for complex
diseases where interactions are present but are not directly comparable as they do not
select individual interacting effects and have a tendency to overfit the data.
7.1.1 Preparing and recoding the data
The datasets from the previous chapter required no adaptations for analysis using
logistic regression or regression using stepwise selection. There is no missing data in
the simulated datasets and in situations where transformation would aid the analysis,
this will be accommodated. The environmental variables were analysed sequentially –
analysing NSAIDs then smoking to represent a “real” effect and a false identification
rate, respectively. Analysing the interactions between environmental variables is not a
main objective for this study and would complicate the regression analysis, giving it
an unfair disadvantage.
A number of the covariates were dichotomised prior to modelling analysis, which
allows a more direct comparison with the MTM and MDR, which either performed
better or was restricted to binary covariates, respectively. Furthermore, it has been
claimed that, from the clinical point of view, binary covariates might be preferred
because they offer a simple risk classification into high versus low, assist in making
treatment recommendations, and in setting diagnostic criteria 466. On the other hand,
dichotomisation results in loss of information and power, if a linear rather than
threshold association pertains, and non-linear relationships such as U shape
associations will not be detected 467, 468. This must be considered, especially for any
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analysis identifying an interaction between a SNP and a continuous variable. However
in this dataset all the variables were normally distributed, either naturally or following
logarithmic transformation, so such problems were minimised to some degree.
In order to use the MDR/ORMDR function, all the variables (both genotypic and
phenotypic) under analysis had to be parameterised as “0”, “1” or “2”. Therefore, in
simulating binary data, the levels were replaced with “0” and “1” but the same set
seed used as before, so the actual data content remained unchanged. Continuous
variables were generated as such and categorised based on commonly recognised
limits, such as overweight having a BMI greater then 25 or above/below
recommended retinol intake. It was necessary to generate and re-classify to ensure the
data was the same as the MTM simulations, generating into two groups would have
used the random number generator differently and there may have been differences
introduced between the datasets by chance.
The genetic variables were recoded so that “0” referred to the homozygous
combinations considered to be the wild type, or reference allele. “1” was the
heterozygote and “2” was the homozygous mutant. The allele selected as the
reference allele was dictated by its status as such in the HapMap database.
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7.2 Methods
In order to assess how well the MTM compares to other statistical methods in the
search for gene-environment interactions, the data simulations were repeated and
analysed using the other methods. The results, both successful identification and false
positive identification, are compared quantitatively and other factors, such as
computational intensity and practicality, discussed. In each case the success is
measured by the identification of the interaction and the false positive results, unless
otherwise stated.
7.2.1 Logistic regression
The generalised linear model function from R 469 was used with the setting for
binomial regression and forward selection. The case status was the binomial outcome
variable with the explanatory variables including all the SNPs, an environmental
variable and the possible gene-environment interactions. The model was such that
gene-gene interactions were not considered, to minimise the number of variables
where possible, although this in itself would be unusual for such analysis.
7.2.2 Logistic Regression using Stepwise Selection
Stepwise regression was carried out using the step function from the MASS library in
R, with the stepAIC command using the parameter: direction = “both”. AIC (Akaike
Information Criterion) is a goodness of fit measure that favours smaller residual error
in the model, but penalises larger models with equally good fit and helps avoiding
overfitting. Similarly, the outcome was case control status and each environmental
variable analysed separately, alongside all the SNPs and potential interactions.
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7.2.3 MDR
Once the data had been generated and recoded accordingly, the data was analysed
using the ORMDR function in R 470, the first step of which is the MDR analysis. As
MDR chooses the best combination of risk factors, normally genotypes, and then
classifies these combinations into low or high risk sub groups, the measure of success
used is different. It looks for the combination with the lowest misclassification rate
from all the possible combinations, using cross validation and training set to identify
the combination and a test set to calculate the prediction error.  Therefore success is
measured by identification rate and misclassification rate.
The specific parameters used include: ten fold cross validation; the cross validated
sets being randomised; the maximum number of genes in combination set to two. In
some cases, when the numbers of cases and controls is not equivalent, it is necessary
to balance the proportion of cases and controls expected. This makes MDR robust to
class imbalance 471. The simulated data has balanced data, it is not necessary to adjust
the threshold used for assigning high and low risk labels.
7.2.4 ORMDR
ORMDR is effectively an extension of MDR that calculates risk estimates and
confidence intervals for these estimates. Although the ORMDR odds ratio estimator is
different, technically, from the standard estimator – it can be applied in the same way
with significant results having a confidence interval that does not include the value 1.
As well as classifying groups as high or low risk, the confidence intervals supplied by
ORMDR indicate the significance and size of this classification 193.
Similarly to the Mixed Tree Method, the quantitative measure of significance allows
the results to be evaluated at different significance thresholds. This is a better direct
comparison than just selecting the best interaction, as basic MDR does.
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7.3 Results
The literature suggested that large numbers of SNPs within a given dataset would
represent the most obvious challenge for the above methods. Whereas effect size,
sample size and allele frequency will affect accuracy, a large number of variables is
outwith the recommendations for use. For this reason, success over varying SNP
numbers was the first parameter examined; the other parameters are shown alongside
in table 7.1.























The results are presented in the same way, with the same measures of success as
Chapter 6: the target interaction involves the environmental variable and SNP that
have been assigned an interacting effect. A false positive interaction for an
environmental variable involves a different SNP, a false positive SNP main effect
includes any SNP except the target SNP.
7.3.1 Logistic Regression
The standard number of SNPs for comparing the other parameters, 175, was not well
tolerated using logistic regression with the number of parameters preventing
convergence. The results from analysis on 50 and 100 SNPs are shown below, with a
comparison to the results from Chapter 6 using the MTM at a significance level of
0.01. It is worth noting that the recommended Event Per Variable (EPV) ratio is
usually considered to be 10:1, with some estimates as high as 20:1, so these analysis
are often outside the recommendations for using logistic regression.
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Table 7.2 Percentage of Datasets Identifying Interaction at low SNP numbers for
Logistic Regression versus MTM
Number of SNPs 50 50 100 100
Method Regression MTM Regression MTM
Splitting on Target Environmental Variable (NSAIDs)
Interaction (Int) found 53.5 59.3 40.3 54.8
SNP found 98.2 97.6 97.7 97.6
Neither Int or SNP found 1.8 2.4 2.2 2.8
NSAIDS/ other SNP 81.9 13.2 304.8 17.3
False SNP 65.3 2.1 172.8 2.2
Splitting on environmental variable with no effect (smoking)
SNP still identified 77.2 75.3 77.9 73.6
SNP/smoking interaction 1.4 1.2 9.0 1.3
Both SNP and Env wrong 94.4 17.1 578.1 19.4
False SNP found 63.2 8.0 162.5 13.9
As can be seen, the sensitivity of both methods to detect the interaction is similar for
across both samples. However, the level of false positive identification for both the
false interaction and the false main SNP effects is considerably higher for logistic
regression and increases with the number of SNPs under analysis. With regard to
computational intensity, logistic regression was the faster method for 50 SNPs, but
considerably slower and prone to computational problems regarding convergence
when the data contained 100 SNPs. To counter the increase in computational
problems, slight adaptations were made to the regression parameters, specifically an
increase in the number of iterations.
When the sample contained 175 SNPs, logistic regression was time consuming and
generated a large number of errors. The glm algorithm did not converge for any of the
datasets, and in some cases the probabilities 0 and 1 occurred (for one dataset every
single SNP had an interaction with a significance level of 0). The glm settings were
adapted, considering up to 10,000 iterations and increasing the positive convergence
tolerance to 0.01, which despite the increased computation, left one dataset unable to
produce any results.
The results do suggest, however, that 175 SNPs and their interaction with the
environmental variable has a very high false positive rate. For example, after
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removing the most obvious problematic results gave, for 1000 simulations, a false
detection rate per simulation for interaction involving NSAIDs of 2780.8%. It was
also impossible, computationally, to run 1000 populations in one analysis – it was
necessary to run the simulation in four sets of 250 replications.
Although not shown, at 175 SNPs the detection rate for the interaction dropped to
17.9% for regression. Therefore, for the standard analysis of 175 SNPs, logistic
regression alone does not work as effectively nor as easily, both computationally and
in terms of power, as the Mixed Tree Method. It is also not possible to compare
logistic regression to the range of other parameters compared in Chapter 6, as the
standard number of SNPs for the other simulations is 175.
In conclusion, logistic regression is not an appropriate comparison method for this
study, nor an appropriate analytical method for this type of problem as:
• The false positive rate is too high
• Non convergence
7.3.2 Logistic Regression Using Stepwise Selection
7.3.2.1 Number of SNPs
The same parameters were used in this simulation as for logistic regression, as shown
in Table 7.3. Similarly to logistic regression, the computational time was extensive
with a single run (NSAIDs and SNPs) containing 175 SNPs taking 110 hours, as
opposed to approximately 8 hours for MTM. The results are shown below in table 7.3
for a significance level of 0.01.
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Table 7.3 Percentage of Datasets Identifying Interaction for Different SNP Numbers,




50 100 175 300 50 100 175 300
Splitting on Target Environmental Variable (NSAIDs)
Target Int
58.0 57.8 55.8 58.7 59.3 54.8 54.3 56.4
Target SNP
97.9 98.0 97.7 98.5 97.6 97.6 97.2 98.3
Neither Int or
SNP 2.1 2.0 2.3 1.5 2.4 2.8 2.8 1.7
Other Int
10.9 27.4 75.4 71.9 13.2 17.3 21.0 19.7
Other SNP 82.9 206.4 475.7 471.9 2.1 2.2 3.1 2.0
Splitting on environmental variable with no effect (smoking)
Target SNP
89.4 90.2 88.4 89.7 75.3 73.6 66.4 68.9
Target SNP
and smoking 0 0.2 0.2 0.4 1.2 1.3 1.0 1.1
Other Int
1.9 3.9 13.0 11.3 17.1 19.4 25.3 24.2
Other SNP 61.8 150.9 359.0 345.7 8.0 13.9 16.5 14.8
As the results show, the level of identification is very similar for stepwise regression
as MTM, with a similar preference in detecting SNP main effects over interaction
effects. However, the false positive identification rate is considerably higher for
stepwise regression compared to the MTM, increasing as the number of SNPs
increases. However, the false positive SNP identification is similar for 175 SNPs and
300, which is an improvement on logistic regression which increased in a more linear
fashion. Given the computational time and false positive rate, there is no advantage to
using stepwise regression in place of the MTM as the SNP numbers increase.
7.3.2.2 Sample Size
Considering the computational burden of the previous simulations, each set of
parameters for simulations examining sample size and subsequent variables were run
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100 times instead of 1000. The features of the simulations used to evaluate the
identification at different sample sizes are shown in table 7.4:























The populations containing only 200 and 500 members were too small to run stepwise
selection effectively. Outside the recommended case to explanatory variable ratio
(10:1), the probabilities 0 and 1 occurred for a large number of the simulations. The
results for 1000, 2000 and 3000, at a significance level of 0.01, are shown in the table
below, with the MTM results rounded up to facilitate comparison across the different
number of replications. For ease of comparison, all of the remaining analyses are
presented in this way, showing the results at the significance threshold of 0.01.
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Table 7.5 Percentage of Datasets Identifying Interaction for Different Sample
Sizes, Comparing Stepwise Regression and MTM
Stepwise Regression MTM
Sample size 1000 2000 3000 1000 2000 3000
Splitting on Target Environmental Variable (NSAIDs)
Target Int
56 90 98 54 90 99
Target SNP
98 100 100 97 100 100
Neither Int or
SNP 2 0 0 3 0 0
Other Int
75 61 39 21 21 21
Other SNP 476 352 297 3 2 1
Splitting on environmental variable with no effect (smoking)
Target SNP
88 100 100 66 97 100
Target SNP
and smoking 0 1 0 1 2 2
Other Int
13 13 4 25 25 26
Other SNP 359 248 220 17 18 20
For both stepwise regression and the mixed tree method, identification increased as
the sample size increased, with both methods performing equally well. The false
positive rate was considerably higher using stepwise regression compared to MTM,
with the exception of the identification of interacting effects with both variables
incorrect. This suggests the MTM has a preference for interaction effects, as was
intended. The SNP was more often identified than the interaction for both methods,
across all sample sizes.
7.3.2.3 Allele Frequency
In order to compare the level of identification across different allele frequencies, a
similar simulation to that in chapter 6 was run, except for 100 runs in place of 1000.
The parameters are shown below and the results in table 7.7.
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Target SNP 1 0.1 0.25 0.5 0.75 0.9
Interaction 2.5 0.07 0.17 0.34 0.51 0.60
175 1000 0.5 Dominant
Table 7.7 Percentage of Datasets Identifying Interactions for Different Allele
Frequencies, Comparing Stepwise Regression and MTM
Stepwise Regression MTM
Allele
Frequency 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Splitting on Target Environmental Variable (NSAIDs)
Target Int
25 65 42 3 1 36 67 39 3 0
Target SNP
88 100 89 22 2 58 98 90 10 0
Neither Int or
SNP 12 0 11 78 97 42 2 10 89 100
Other Int
56 67 66 81 74 25 23 22 27 5
Other SNP 463 423 467 484 478 18 2 4 32 35
Splitting on environmental variable with no effect (smoking)
Target SNP
77 94 80 13 4 15 71 53 2 0
Target SNP
and smoking 0 0 0 0 0 1 1 1 0 0
Other Int
13 14 13 16 14 29 25 23 28 26
Other SNP 385 347 334 378 356 29 18 17 37 38
As the results show, both methods were most effective in detecting the target
interaction, for a dominant inheritance model, when the allele frequency was
approximately 25%. The results for successful identification were similar in the two
approaches, but the stepwise regression had a much higher rate of false positive
identification, for both interaction and SNP main effects. The degree of false positive
identification for stepwise regression did not appear to be influenced by the presence
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or identification of real effects, unlike MTM where the level of false positive
identification decreased when a real effect was identified. As with the sample size
comparison, stepwise regression had a much higher level of identification, both real
and false, for SNPs compared to interaction effects. MTM had a higher false positive
rate of interaction identification than main effects.
7.3.2.4 Case Control Ratio
To assess the difference in results between stepwise regression and MTM for different
case-control ratios, a simulation of the following parameters was run.

















Target SNP 1 0.6634
Interaction 2.5 0.4421




Table 7.9 Percentage of Datasets Identifying Interaction for Different Case-control




0.25 0.5 0.75 0.25 0.5 0.75
Splitting on Target Environmental Variable (NSAIDs)
Target Int 23 56 27 14 54 23
Target SNP
76 98 73 55 98 57
Neither Int or
SNP 24 2 27 45 3 43
Other Int
100 75 69 22 21 20
Other SNP 562 476 493 16 3 15
Splitting on environmental variable with no effect (smoking)
Target SNP
56 88 53 21.9 66.4 18.4
Target SNP
and smoking 1 0 2 0.3 1.0 1.3
Other Int
18 13 9 26.8 25.3 25.8
Other SNP 415 359 354 26.8 16.5 25.9
Both the stepwise regression and the MTM performed best when the proportion of
cases and controls was similar. The false positive rate was higher for both methods
when the sample was unbalanced towards either cases or controls.
7.3.2.5 Effect Size
Using the same parameters as chapter 6, shown again in table 7.10, a number of
different populations were simulated with the effect size of the interactions varying
from 1.5-3.5 (OR). The results are shown in table 7.11.

















Target SNP 1 0.6634
Interaction 1.5, 2.0, 2.5,
3.0, 3.5
0.4421
175 1000 0.5 Dominant
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Table 7.11 Percentage of Datasets Identifying Interaction for Different Effect Sizes,
Comparing Stepwise Regression and MTM
Stepwise Regression MTM
Effect Size 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5
Splitting on Target Environmental Variable (NSAIDs)
Target Int
2 27 56 76 84 4 27 54 76 88
Target SNP
35 83 98 100 100 19 75 97 100 100
Neither Int or
SNP 65 17 2 0 0 81 25 3 0 0
Other Int
46 62 75 62 68 26 24 21 20 19
Other SNP 442 440 476 453 457 28 9 3 2 1
Splitting on environmental variable with no effect (smoking)
Target SNP
23 71 88 97 99 6 32 66 90 97
Target SNP
and smoking 0 0 0 1 1 1 1 1 2 2
Other Int
7 3 13 8 11 24 28 25 26 26
Other SNP 334 333 359 343 323 34 23 17 14 17
Unsurprisingly, the level of successful identification increased as the effect size
increased, the false positive rate was unaffected. Successful identification for the
interaction effect was very similar to that of the MTM, but again the false positive rate
was considerably higher. The interacting SNP was identified more often in the
smoking analysis for stepwise regression.
7.3.2.6 Inheritance Model and Allele Frequency
In another repeat of the simulation in Chapter 6, the parameters shown below, data
was simulated to represent populations with a different allele frequency for the risk
(target) allele under different inheritance models. The results from a dominant model
can be found in Table 7.7. The results for the recessive and co-dominant model are in
Tables 7.13 and 7.14 respectively.
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Target SNP 1 0.1 0.25 0.5 0.75 0.9
Interaction 2.5 0.07 0.17 0.33 0.5 0.59
175 1000 0.5 Recessive
Smoking 1 0.510
NSAIDs 1 0.6664
Target SNP 1 0.1 0.25 0.5 0.75 0.9
Interaction 2.5 0.07 0.17 0.33 0.5 0.59
175 1000 0.5 Co-
Dominant
Table 7.13 Percentage of Datasets Identifying Interaction for Different Allele




0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Splitting on Target Environmental Variable (NSAIDs)
Target Int
0 22 27 5 51 0 1 37 69 42
Target SNP
13 87 79 100 96 0 6 89 99 72
Neither Int or
SNP 87 13 21 0 4 100 94 11 2 27
Other Int
18 56 42 67 81 31 27 20 21 23
Other SNP 380 499 385 444 487 37 33 4 2 11
Splitting on environmental variable with no effect (smoking)
Target SNP
1 78 68 96 89 0 2 52 71 19
Target SNP
and smoking 0 0 0 1 0 0 0 0 1 1
Other Int
9 24 18 10 12 30 25 27 24 28
Other SNP 380 427 342 334 363 34 33 17 17 28
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Table 7.14 Percentage of Datasets Identifying Interaction for Different Allele




0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Splitting on Target Environmental Variable (NSAIDs)
Target Int
15 39 30 1 0 16 41 31 0 0
Target SNP
71 91 88 12 7 27 75 71 2 0
Neither Int or
SNP 29 9 12 88 93 73 25 29 98 100
Other Int
18 52 54 56 13 25 22 23 28 26
Other SNP 391 447 458 489 380 26 11 12 35 3
Splitting on environmental variable with no effect (smoking)
Target SNP
63 87 76 7 5 6 32 33 1 0
Target SNP
and smoking 0 0 0 0 0 1 1 1 1 0
Other Int
8 21 9 10 20 29 31 27 30 29
Other SNP 367 353 320 400 363 31 26 27 35 36
As with the other simulations, the identification results were very similar in character
to those found using the MTM. The closer the proportion exposed to the interaction
became to 0.5, the better the results. The false positive rate was much higher for
stepwise regression than MTM, as was the computational time.
7.3.2.7 Interaction Model
The five models of interaction described and simulated in Chapter 6 were repeated
using the parameters in the table below. Although the labelling of type A as an
interaction is debateable, the simulation was carried out in case the stepwise
regression recognised it as such. The results are shown in Table 7.16.
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A * B C D E
Smoking 1 1 1 1 1 0.510
NSAIDs 2.5 1.5 1 1 1.5 0.6664
Target SNP 1.5 1 1.5 1 1.5 0.6634
Interaction 1 2.5 2.5 2.5 2.5 0.4421
175 1000 0.5 Dominant
* The associated risk for the target SNP in interaction model A describes the increase on risk
of taking NSAIDs, not an increased risk directly of case status
Table 7.16 Percentage of Datasets Identifying Interaction for Interaction Models




A B C D E A B C D E
Splitting on Target Environmental Variable (NSAIDs)
Target Int
0 78 78 56 60 0 80 78 54 61
Target SNP
29 99 100 98 99 0 99 99 97 97
Neither Int or
SNP 71 1 0 2 1 100 1 1 3 3
Other Int
0 89 11 75 71 26 17 16 21 19
Other SNP 76 516 99 476 514 36 3 2 3 2
Splitting on environmental variable with no effect (smoking)
Target SNP
31 90 94 88 91 19 74 77 66 65
Target SNP
and smoking 1 1 0 0 0 1 2 1 1 1
Other Int
0 16 2 13 17 27 26 26 25 25
Other SNP 85 397 77 359 396 27 15 14 17 15
The results for interaction type A were better for stepwise regression than MTM,
although still worse than any of the other interaction models. Interestingly, the false
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positive rate and the computational time were both much lower for the type A model,
this contrasts with MTM, for which type A had by far the highest false positive rate.
In terms of successful identification, the other four models were fairly similar
between stepwise and MTM, but the false positive rate was higher for stepwise
regression. The SNP was identified at a higher rate in the smoking stepwise analysis
compared to the MTM.
The within stepwise comparisons show that the identification was highest, the false
positive identification rate lowest and computational time much reduced
(approximately 20% of the time taken compared to other models) for interaction
model C. This is the model containing an independent genetic effect, which is
enhanced by the environmental effect.
7.3.3 MDR and ORMDR
In order to use the MDR and ORMDR in a comparable way to the MTM and stepwise
regression, a dataset was created containing case status, NSAID intake, smoking and
the first 50 SNPs, all categorised and recoded in the appropriate way. This follows the
instructions in R for using the ORMDR function 472. The literature suggests that from
this data, MDR should be able to identify the strongest interaction effect and
quantitatively measure the strength of the interaction using the ORMDR extension.
However, the initial analysis using MDR and ORMDR produced consistently wrong
but similar results across the datasets, identifying interactions with an OR which,
when calculated by hand, showed a smaller OR than that of the target interaction in
the same dataset. Such a calculation was necessary as the ORMDR is not an
equivalent measure to OR. The identified interactions are shown below in Table 7.17,
the specific names of the SNPs are not relevant as they do not relate to the real SNP in
any way other than distribution.
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Table 7.17 ORMDR results
Interaction Identified Number of identifications
smoking and SNPx 26 / 1000
smoking and SNPy 54 / 1000
smoking and SNPz 10 / 1000
Looking closely at the results of the first dataset, both the identified and target
interactions showed a very significant interaction with the outcome using a χ2 test (p
values of 1.06 x 10-142 and 4.49 x 10-70 respectively). ORMDR selects the former
based on significance and not the size of the effect. Correspondence with the author of
the ORMDR function in R confirmed this to be the case.
One other complication in this case occurred for the dominant inheritance model of
the simulated data, with both those heterozygous and homozygous for the risk allele at
similar risk. When divided into separate groups, the groups were inevitably smaller
and the corresponding CIs wider. As this was the selection criterion, such an
inheritance model was at a disadvantage. Considering that one limitation of the MDR
method is the requirement for prior knowledge regarding continuous variables and
cut-off points, such grouping could reduce the power to detect effects due to the
smaller group size.
Another interesting feature is that it was possible to re-order the columns within the
dataset to get different results, an indication that the method or the computing
function being used were not performing accurately. Correspondence with the author
of the ORMDR function concluded that as these simulations use a risk model that
confers an increase in risk, not an absolute relationship, such results were an artefact
of there being no “real” effects present. Therefore, the model used throughout this
thesis was not an appropriate test bed for MDR or any related functions. Any potential
bugs in the programme are now being investigated by the author as such differing
results suggest there is a computational problem.
Given that ORMDR is based on a biological causal pathway model of inheritance and
the data in this case were generated to confer an increase in risk, it was not an entirely
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suitable method for analysis. To prioritise variables based on their precision over their




The problem of dimensionality was not solved by using logistic regression, where the
problem of high levels of false positive identification could be seen most clearly.
Even restricting the potential interactions to those between an environmental variable
and all possible SNPs (i.e. not considering SNP-SNP interactions), so that each
additional SNP only increased the potential for interactions linearly, not
exponentially, still generated models containing too many variables per observation.
However, logistic regression is a very good way to quantify the risk and significance
of any findings following a data selection method.
Using stepwise selection for variable selection in logistic regression improved the
performance and provided a good comparison method. The computational burden was
high and the results showed a higher false positive rate and a preference for
identifying independent effects. However, if known in advance that the interaction
model contained a genetic main effect, it would be useful to use both stepwise
regression and MTM and to compare the results. Stepwise regression was the most
effective comparison method and had very good levels of identification.
MDR and ORMDR are designed to use a slightly different selection criterion, the
significance of the results rather than the size. It is based on a biological causative
model and more suited to use in pathway genetics where such effects are more likely
to be absolute. Had there been no computational problems, such a comparison may
have been useful, but using currently available software there is no appropriate way to
test the effectiveness.
Each method analysed has been developed for a slightly different purpose and with
different data requirements or criteria. Logistic regression has been developed
primarily for environmental variables but has been implemented in many genetic
studies without adaptation. Using the stepwise variable selection function can be used
to reduce the dimensionality problem but has a very high level of false positive
identification, and is more suited to analyses where more information is known in
advance or a lower event to variable ratio. MDR was developed to find SNP-SNP
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interactions, although claims are made regarding its adaptability for gene-environment
interaction detection as well. None of these methods were designed for the data
characteristics or for the interaction type being looked at in this study and cannot
easily be compared to MTM in this respect.
However, stepwise logistic regression is directly comparable and provides strong
evidence that MTM maintains the power, found in other methods, to identify
interactions whilst decreasing the false positive identification rate. This is a reassuring
result, particularly for increasing SNP numbers which the previous chapter showed








The initial literature review identified a selection of SNPs from their associated genes
that could be simulated to realistically represent a sample of candidate SNPs.
However, during the development and testing stages of the method, the field of SNP
analysis gained considerable momentum. It was not practical to keep going back and
adding to the original panel during method development, as the simulations would
then be slightly different from one another and as an artificially simulated panel, it
would not have made much difference to the outcome. However prior to analysis of
real data it is essential to review more current, SNP based work, to identify a
representative panel of SNPs for real Mixed Tree Analysis. It was also necessary to
adjust the original list, ensuring all candidate SNPs were present on the SNP chip
used in the SOCCS dataset. The same search strategy was used as in Chapter 2, with
more focus on SNPs in place of genes and a particular search on the results found
from GWAS.
8.1.1 SNPs Associated with High Risk Genes or Disorders
A number of common, low penetrance genetic variants acting in either an additive or
multiplicative manner have been associated with familial and sporadic colorectal
cancer. Some of the SNPs have been identified by their association with genes
considered to influence colorectal cancer risk, some more recently through GWAS.
Although previously mismatch repair genes were not included in the list of SNPs used
in the simulation studies as the SOCCS dataset excludes those with other forms of
cancer, the most consistent association was found to be with rs6983267, which is in
the mismatch repair gene MYC. This SNP has also been found associated with
prostate cancer risk 425, 427, 473. Alongside rs6983267, another SNP on MYC is present
on the genotyping panel used in the SOCCS study: rs7014346. A similar gene to that
identied in the initial review, SMAD4, that is involved with TGFβ signalling,
SMAD7, contains three SNPs more recently found to have an association with CRC.
SMAD7 is also involved in Wnt signalling. One gene considered in Chapter 2 due to
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an association with Peutz-Jeghers Syndrome (PJS), STK11 (also known as LKB1) has
more recently been associated with the Wnt pathway 474, combining two areas of
interest identified in the earlier literature review (genes associated with syndromes
and genes on the Wnt pathway).
Two well characterised cancer genes were added to the initial list; CRAC1 is a high
penetrance susceptibility gene and CDH1 is an invasion suppressor. A number of
signalling genes have been identified, including: POU2AF1, a B cell specific
transcriptional co-activator; Eukaryotic translation initiation factor 3 (EIF3H);
Gremlin 1 (GREM1) which is an antagonist of the bone morphogenetic protein
family. Bone Morphogenetic Protein (BMP) 2 and 4 are both involved in signalling
and apoptosis. RHPN2 is a Rho binding protein. These genes and their associated
SNPs are shown in Table 8.1. SNPs highlighted in bold are present on the SOCCS
SNP panel and were available for analysis in this study.
Table 8.1 SNPs Associated with CRC Identified by their Genetic Association
Gene SNPs References
MYC rs6983267, rs10505477, rs7014346, rs10090154 425-427, 473, 475-479
SMAD7 rs4939827, rs12953717, rs4464148 480, 477, 479
POU2AF1 rs3802842 481, 482










8.1.2 SNPs Identified from GWAS
A number of genes have been identified or corroborated by GWAS in which a large
number of markers across the entire genome are studied. With the false positive
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identification rate a problem with such large numbers of variables, consistency of
findings across different studies and combining study populations can enhance the
validity of results. There are 10 SNPs, including rs6983267, which have been
consistently identified 489, eight of which are mentioned in table 8.1: rs16892766,
rs3802842, rs4779584, rs4939827, rs4444235, rs9929218, rs10411210 and rs961253.
The other, rs10795668, is not situated within a particular gene. Zanke et al combined
a number of different studies and identified the 8q24 locus (covering SNP
rs6983267).
A number of SNPs have been identified from GWAS that are not associated with a
known gene. These are shown in Table 8.2, with those available for analysis on the
SOCCS dataset in bold, as before.





rs355527, rs4951291, rs4951039 433
8.1.3 SNPs Interacting with Environmental Variables
A number of interactions have been identified between certain genes and
environmental variables and, less commonly, SNP-SNP interactions have been
identified.
Three genes that have been found to interact with smoking and/or alcohol are:
XRCC1, XRCC3 and XPD, which are all DNA repair genes that are known to
increase cell turnover and mutations rate. Whether there is a true XPD-smoking
interaction is still somewhat debatable 491, 492. The Growth Hormone 1 gene (GH1)
has a genotype associated with a decrease in risk of colorectal cancer, the same
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sample also found an association with drinking alcohol and a possible interaction
between the genetic and environmental factors.
Activating Transcription Factor 3 (ATF3) can be a tumour suppressor in colorectal
cancer. Tolfenamic Acid (TA) is a NSAID with anti-tumour and pro-apoptotic
associations. A study by Lee et al described TA stimulation of ATF3 expression,
which then induces apoptosis providing evidence of a biologically plausible
interaction 493. This is mediated through the phosphorylation of ATF2 – both of which
contribute SNPs to the new panel. Similarly, expression of XRCC3 has been found to
be susceptible to aspirin at a biological level 494. PPAR has also been found to have a
role connected to APC and NSAIDs 495.
There are a few other unusual findings that may suggest interactions. Haiman et al
found that the rs6983267 association with CRC, although replicated across most
populations, did not confer a significant increase in risk for those of African American
or Japanese decent 425. However a slightly different SNP at the same locus, rs7014346
at 8q24.21 has been found to have an association with CRC risk  in African
Americans 496. This could in some way be explained by the different frequencies of
the SNPs within these populations, the GG/TT genotypes being at a frequency of
0.679/0.057 in African Americans as opposed to 0.212/0.239 in Caucasians. The Odds
Ratio estimates are similar but the significance levels differ, so it is possible this is a
statistical artefact based on different allele frequencies. The CYP2E1 polymorphism
was only found to confer an increase in risk for Caucasians 497. They also found that
the tissue type affected the association between genetic variants and the cancer
development. Some studies found differences in risk for colon and rectal cancers
associated with different genotypes 479.
Genes that have been implicated in an interaction are shown in table 8.3, for which
candidate SNPs have been identified using HapMap, as before, and those available for
this analysis are shown in bold.
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Table 8.3 SNPs Involved in Interactions
Gene SNPs References
Interactions with smoking and alcohol
XRCC1 rs2682556, rs25487, rs213334, rs3213282,
rs2854501, rs1799778, rs2854496, rs3213255
XRCC3* rs861537, rs861531, rs861539
XPD (ERCC2) rs13181, rs17799787, rs3916874, rs238416,





ATF3 rs1195472, rs2137424, rs4543871, rs1877474,
rs11576473, rs10494952, rs1567710, rs3125295,
rs9430097, rs17019438, rs3125296, rs10746435,
rs10735510, rs3125289
ATF2 rs212349, rs1153685, rs7578569, rs11888507,
rs7566401, rs13388308
493
XRCC3* rs861537, rs861531, rs861539 494
PPAR rs1040436, rs2016520, rs1053049, rs2038086 500
8.1.4 SNP – SNP interactions
Abuli et al found an interaction between rs6983267 and rs9929218 489. By taking the
ten most commonly identified SNPs, all of which are included in the table above, and
running a pairwise interaction analysis, only the one interaction effect was found after
adjustment for multiple testing.
8.1.5 Conclusions from the Literature
There are ever increasing numbers of SNPs being identified as being associated with
CRC, and the presence of consistent findings in different datasets is a good indicator
of a true association. The majority of these loci are within genes that have a
biologically plausible association with CRC. The evidence of possible interactions is
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still sparse but has for the most part come from analysing a single environmental risk
factor against several genetic factors, not from analyses of multiple environmental and
genetic variables. This is reassuring as it corresponds to the approach, and the
reasoning behind the approach, taken in MTM analysis.
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8.2 SOCCS Data
The SOCCS data are from a case-control study in which control subjects were
matched by age, gender and area of residence in Scotland to CRC cases.  A full
description of the environmental variables recorded in the study can be found in
Chapter 4. The mixed tree analysis is run on a subset of the whole sample, 1216
people (461 cases and 755 controls), who had data available for the environmental
variables and the SNPs required, the univariate analysis is carried out on both samples
to identify any biases introduced through using the smaller sample.
The main bias to be considered is survivor bias; however the samples were drawn
from the participants at the same time as the environmental data was collected, which
should reduce survivor bias by some degree. In the case of degraded samples, it would
be impossible to resample from those who did not survive the interval between initial
and follow up sampling. Both the larger and smaller samples would be prone to recall
and sampling biases, inherent in the retrospective case control design. However,
analysing both the larger and smaller samples individually for environmental effects
explores to some extent, any bias introduced through selection of the smaller sample.
8.2.1 Data Preparation and Quality Control
Individuals with poor quality data can be identified by the proportion of missing data.
In the case of environmental variables this could suggest difficulties in the
questionnaire procedure or follow up. In the case of genotype data, this could result
from a low quality or degraded DNA sample, suggesting other SNPs from that sample
may be unreliable. It is also necessary to identify any SNPs with a higher than normal
proportion of missing values and remove these from the analysis where appropriate.
There was a single person in the study population who had missing data for 59 out of
222 variables; they were removed prior to the analysis. In the panel of SNPs used in
this analysis there was a single SNP (rs9430097) where 46/1216 (3.78%) of the
sample had a missing value. As this SNP was one of nine in the same gene, the loss in
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information incurred from eliminating it was minimal. There were only four other
SNPs containing any missing data at levels of 1.48%, 0.82%, 0.57% and 0.49%,
levels unlikely to suggest significant problems. As the proportion of missing data was
so low and evenly spread between cases and controls, it was considered safe to leave
them in the analysis with the missing values replaced by the most common genotype.
Missing environmental data can be handled slightly differently, given the nature of
the statistical method. Individuals were only removed from the analysis when they
had missing data on the environmental variable under study but were included for all
other analysis. Had there been significant volumes of missing data, such an approach
may have led to the analysis being carried out on effectively different study
populations, with the risk of introducing bias. For example, if there was an
environmental exposure only measured during follow up, those able to give that
information would naturally be those who had survived long enough to be measured.




In order to fully interpret any interaction results, it is necessary to carry out univariate
analysis on the environmental variables. This provides context to allow some
understanding of the underlying model of interaction. The population who filled in
environmental data and food frequency questionnaires is larger that the sample who
have both environmental data and have genotyping data. The univariate analysis are
run on both the sample with environmental data (approximately 4,800 people
depending on the variable) and the sample with both environmental and SNP data
(1,216 people). This allows interpretation of the variable effects for the specific
sample analysed and for interactions in a wider context.
8.3.1 Methods
As seen in Chapter 4, the environmental variables are of a number of different types.
There are binary, ordinal and categorical variables, and continuous variables
distributed normally, log-normally or non-normal even after transformation. Different
descriptive and comparative methods are appropriate for each type, as described
below.
Binary Variables
As described more fully in Chapter 4, the only binary variable is gender, although for
basic analytical purposes alcohol is treated as above and below a recommended
threshold value. The distribution of NSAID use, smoking status and exercise were re-
classified as binary variables for the mixed tree analysis. As alcohol was not normally
distributed, for either the larger or smaller samples, even following logarithmic
transformation, the binary counts of above and below a recommended intake were
used for analysis. In terms of NSAID intake, frequent use was defined as an intake of
at least 4 days per week for at least 1 month. This was a SOCCS definition, not one
specific to this study.
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As gender was matched when selecting the controls, it therefore can not be analysed
as an independent risk factor in this case. Gender remains in the dataset, however, as
there are other variables that differ by gender. For these binary variables, an Odds
Ratio estimate was used to assess association with outcome. For NSAID intake, the
binary variable is analysed using the Pearson chi-squared (χ2) statistic, with the null
hypothesis that there is no difference between the groups.
Categorical and Ordinal Variables
The categorical variables are NSAID intake and family history risk. Although NSAID
intake has an element of ranked increases these increases do not correspond to the
level in a linear way. The ordinal variables include smoking, level of physical activity
and deprivation level, some of which may be better analysed in a binary format. As
both exercise and deprivation increase in a natural order, the χ2 test for trend can be
used to assess a relationship.
For this gene-environment analysis the family history risk variable was removed as it
cannot be considered independent from genetic effects. In simulations, the mixed tree
method had low success in identifying the type of interaction that would follow the
sequence: genes influencing family history, which in turn influences risk of disease.
As it is debatable whether this model is even an interaction and given the low success
rate, analysis of the family history is not appropriate for this study.
Normally Distributed Variables
There were two variables that were normally distributed: Age and BMI. Table 8.4
shows the mean and standard deviation for both the case and control samples. BMI
for both cases and controls was normally distributed with a similar standard deviation;
therefore a t-test could be used to compare between the means of the two groups. The
cases and controls were age-matched, so there was no need for further analysis on the
age variable. However, it is worth noting that the sample in the analysis is younger
than the sample as a whole. The younger cases are more likely to have their case
status influenced by genetic effects, as the environmental effects are more cumulative
and the influence from the environment increases with age. If the age variable had not
been matched between cases and controls and was under study, such selection may
have introduced bias towards the genetic effects. It is possible that variables such as
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exercise or alcohol intake may be associated with age, so it is necessary to be aware
of potential sampling bias.
Table 8.4 Comparison of Cases and Controls for Normally Distributed Variables











Age (years) 62.0 (10.7) 62.4 (10.5) 50.3 (5.54) 51.16 (5.96)
BMI (kg/ m2) 26.6 (4.42) 26.8 (4.63) 26.9 (5.04) 27.2 (5.29)
Variables Normally Distributed Following Log Transformation
Almost all the dietary variables were positively skewed and responded well to log
transformation. Therefore the median and inter-quartile ranges, shown inside brackets,
were used to describe the distribution and the differences between cases and controls.
For the univariate analysis the dietary variables were transformed and then analysed
using a t-test
8.3.2 Univariate Results
Table 8.5 shows the case-control comparisons for the categorical and ranked
variables, using either Pearson’s χ2 or the χ2 test for trend. The p-values for binary
categorisation are shown in brackets. The sample containing environmental data and
the subset with both environmental and SNP data were analysed separately as such
analyses have slightly different aims (relevance to population versus relevance to the
interactions results).
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Table 8.5 Comparison of Cases and Controls in Both Samples, for Categorical, Ordinal and Binary Re-coded Variables
Sample Environmental Data (maximum n = 4837) Environmental and SNP data (maximum n =
1216)
Variable Grouping Cases (%) Controls p value
(binary)
Cases Controls p value
(binary)
None 1449 (70.5) 1757 (64.8) 378 (82.0) 567 (75.3)
Mini Aspirin 311 (15.1) 503 (18.2) 18 (3.9) 46 (6.1)
Other NSAID 220 (10.7) 364 (13.2) 56 (12.1) 118 (15.7)
Aspirin 47 (2.3) 106 (3.8) 3 (0.7) 14 (1.9)
Other NSAID + mini Aspirin 14 (0.7) 18 (0.7) 3 (0.7) 4 (0.5)
Frequent NSAID intake
Other NSAID + Aspirin 13 (0.6) 9 (0.3)
5.115 x 10-6
(7.05 x 10-7)
3 (0.7) 4 (0.5)
0.0786
(6.40 x 10-3)
Non 874 (42.4) 1200 (43.2) 228 (42.2) 361 (53.4)
Regular 818 (39.7) 1049 (37.8) 119 (22.0) 203 (37.6)
Ex-regular 343 (16.6) 509 (18.3) 190 (35.2) 111 (20.6)
Smoking
Ex-occasional 26 (1.3) 18 (0.6)
0.044
(0.179)
3 (0.6) 1 (0.2)
0.430
(0.578)
0 1139 (58.0) 1456 (54.3) 223 (49.7) 340 (45.9)
0 – 3.5 486 (24.8) 703 (26.2) 143 (31.8) 240 (32.4)
3.5 – 7 205 (10.4) 339 (12.6) 48 (10.7) 116 (15.7)
Level of Physical
Exercise (hours per day)
(n=2061-98)
7+ 133 (6.8) 185 (6.9)
0.029
(0.577)
35 (7.8) 44 (5.9)
0.062
(0.213)
1 194 (9.4) 258 (9.3) 40 (8.7) 61 (8.1)
2 434 (21.1) 568 (20.5) 99 (21.5) 139 (18.4)
3 532 (25.8) 758 (36.8) 118 (25.7) 212 (28.1)
4 488 (23.7) 645 (23.2) 105 (22.8) 167 (22.1)
5 218 (10.6) 293 (10.6) 51 (11.1) 86 (11.4)
6 140 (6.8) 178 (6.4) 29 (6.3) 67 (8.9)
CARSTAIRS Deprivation
Index
7 54 (2.6) 76 (2.7)
0.936
(0.799)




This shows that the binary version of NSAID intake is associated with a significant
difference in risk, with a decreased risk for those taking any form of NSAID
compared with none. The risk of smoking is only borderline significant, with a very
small increase in risk for smokers compared to non smokers in a binary format in the
larger sample. Also in the larger sample there is a significant decrease in risk as
exercise increases from 0 hours to 0-3.5 hours and then to 3.5-7 hours. The 7+ hours
do not fit the trend but this could be in part down to the smaller sample sizes, as could
the absence of such a significant effect in the smaller sample size. There is no
relationship between deprivation and case status in this data. The differences between
the larger and smaller samples are mainly evident in the lower p-values for the smaller
sample, as would be expected.
The cases and controls have a mean BMI of 26.6 and 26.8 respectively. The analysis
of association between case status and BMI gives a p-value of 0.3895, which showed
that there was no significant difference between cases and controls with respect to
BMI. Similarly, the OR for consuming above recommended levels of alcohol
compared to below was 0.9979, very close to 1, suggesting no effect.
Table 8.6 shows the results for the univariate analysis of the dietary variables, the
significance estimated by log transformation, followed by a t-test. It also shows how
the picture of independent effects changes by using the smaller sample for the
analysis compared to the larger sample.
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Table 8.6 Case and Control Comparison of Dietary Variables, Based on log-transformed Data
Whole group environmental Data
(maximum n = 4837)
Subset with environmental and SNP data














Vitamin D (ug) 3.94 (1.36) 3.88 (1.35) 0.527 4.70 (1.35) 4.62 (1.30) 1.73 x 10-3
Retinol (ug) 549 (6.33) 478 (6.20) 1.78 x 10-9 730 (6.21) 655 (6.16) 6.19  x 10-2
Calcium (mg) 1114 (7.00) 1074 (6.96) 1.60 x 10-4 1215 (7.03) 1173 (6.96) 0.449
Thiamine (mg) 2.04 (0.73) 2.01 (0.70) 1.38 x 10-2 2.33 (0.74) 2.31 (0.73) 0.220
Riboflavin (mg) 2.12 (7.46) 2.065 (7.11) 1.67 x 10-3 2.31 (0.77) 2.26 (0.74) 0.892
Niacin (mg) 23.6 (3.17) 23.6 (3.15) 0.142 27.2 (3.23) 27.0 (3.23) 0.954
Pantothenic Acid (mg) 6.78 (1.98) 6.575 (1.94) 1.82 x 10-2 8.61 (2.00) 8.92 (2.00) 0.778
Vitamin B6 (mg) 2.79  (1.03) 2.79 (1.01) 3.22 x 10-2 3.08 (1.06) 3.07 (1.05) 0.633
Biotin (ug) 49.1 (3.89) 48.3 (3.87) 0.1254 52.8 (3.90) 52.2 (3.89) 0.354
Vitamin B12 (ug) 7.0  (1.95) 6.8 (1.92) 0.1289 7.95 (1.93) 8.05 (1.90) 0.445
Folic Acid (ug) 324.0 (5.78) 321.0 (5.76) 5.06 x 10-2 353 (5.81) 351 (5.79) 0.900
Fibre (g) 20.7 (3.03) 20.6 (3.02) 0.4378 22.9 (3.05) 23.0 (3.05) 0.900
Energy (kJ) - Males 11240 (9.33) 10580 (9.26) 1.837 x 10-7 12743 (9.39) 11780 (9.31) 0.218
Energy (kJ) - Females 9556 (9.18) 9239 (9.15) 6.10 x 10-2 10891 (9.23) 10469 (9.20) 0.261
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The first point of interest is the different significance values between the two groups;
in most cases you would expect a lower level of significance for the smaller sample
size. Vitamin D is the only exception to this trend, with a higher significance in the
smaller sample, which may be in part attributable to the slightly more skewed sample,
simply down to chance or an artefact of the younger age of the sample and trends in
eating habits.
It was is intriguing to notice that the cases reported greater intake of almost every
measured variable, except Niacin and vitamin B6, which are equivalent. The controls
reported greater exercise levels, although not significantly, yet had a slightly higher
BMI overall, although again this was not significant. Although this could be due to
chance, it is counter intuitive and may suggest either weight loss due to illness in the
case group or recall bias, with the cases having more accurate recall when filling out
the food frequency questionnaire. It also suggested that it would be easier to identify a
dietary variable that conferred an increase in risk than one with a preventative effect.
Similarly, the sample selected for genotpypic data have higher rates of consumption
than the overall sample. These people were selected for the first phase of genotyping
by being in the youngest 10% of the overall sample. This was to enhance the risk
attributable to genetic effects, as cumulative environmental risk increases with age.
In the larger sample the most significant independent, nutritional effects were retinol,
calcium and riboflavin consumption, in each case with the cases reporting
significantly greater intake than the controls. The difference in total energy
consumption between cases and controls was also highly significant, but only in
males. There were some borderline effects: thiamine, pantothenic acid and vitamin
B6. In the smaller sample, the only significant effects were for vitamin D and fibre,
however even borderline effects inform the understanding of the results following the
mixed tree analysis.
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8.4 Mixed Tree Analysis
The environmental variables were analysed sequentially using the mixed tree method
and the partitioning method best suited to the variable type. Any independent results
found consistently across the different variables were removed and analysed
separately to identify any SNP-SNP interactions. The positively skewed variables
were log-transformed prior to partitioning.
Any individual with missing environmental data was only removed from the analyses
relevant to that specific variable. The missing SNP data was replaced with the mode
of the rest of the data for that variable, using the “na.roughfix” command within the
random forest function. This was suitable as the data were missing at fairly equal
proportions between cases and control and at very low frequencies.
8.4.1 Mixed Tree Results
The results for categorical and ordinal variables, entered as binary variables, found
with a significance threshold of below 0.05, are shown in Table 8.7. The significance
value given here is only relevant in the context of comparison within the method and
building an evidence base for further work, due to the multiple selection and testing
procdures the significance thresholds are not themselves applicable. The results from
initial MTM analysis on dietary variables are shown in table 8.8. Taken in context
with the results from the earlier univariate analysis on the environmental variables,
these results will inform the decision on which potential interactions require further
investigation. The significance threshold of 0.05 is not in itself definitive, given the
selection stages prior to this analysis, but is intended to add to a body of evidence of
potential interactions.
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rs2481952 0.33 (0.09) 6.44 x 10-4NSAIDs
rs1799977*NSAIDs 0.74 (0.22) 9.53 x 10-4
*
Smoking rs4918766*smoking -0.66 (0.18) 2.17 x 10-4
rs50871 0.40 (0.13) 1.32 x 10-3Exercise
rs50871*exercise -0.46 (0.17) 8.09 x 10-3
rs2481952 0.33 (0.10) 5.56 x 10-4Deprivation
rs6761246*deprivation 0.25 (0.10) 1.31 x 10-2
*
BMI rs2481952 0.25 (0.11) 3.45 x 10-2 *
BMI overweight rs10318 0.75 (0.34) 2.81 x 10-2 *











Vitamin D (μg) 1.21 none *
rs10733118 0.25 (0.12) 3.09 x 10-2 *Retinol (μg) 5.25
rs10733118*Retinol 0.24 (0.11) 3.95 x 10-2 *
Calcium (mg) 7.31 none *
Thiamine (mg) 1.14 rs2481952 0.58 (0.17) 1.75 x 10-3 *
Riboflavin (mg) 0.42 rs2481952 0.45 (0.19) 1.39 x 10-2 *
Niacin (mg) 3.13 none *
Pantothenic Acid
(mg)
1.64 rs12988520 0.71 (0.34) 1.81 x 10-2
Vitamin B6 (mg) 1.21 rs2481952 0.58 (0.23) 1.29 x 10-2 *
rs706716 3.31 (1.12) 5.12 x 10-3 *Biotin (μg) 3.41
rs706716 * Biotin -0.84 (0.29) 5.69 x 10-3 *
Vitamin B12 (μg) 1.64 none *
Folic Acid (μg) 5.46 none *




rs4148325 7.72 (3.36) 3.13 x 10-2 *Energy (kJ) -
Females
9.47
rs4148325*energy -0.82 (0.36) 3.49 x 10-2
*rs2481952 identified as one of the most important variables prior to the regression step of
the MTM, irrespective of later significance findings
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A large number of the analyses (18 /22) identified the SNP rs2481952 as a main effect
(marked with a * in Tables 8.7 and 8.8). None of the variables identified an
interaction effect with this SNP, which suggested that for this dataset this SNP does
have an independent effect of the other variables. This SNP was removed from the
dataset and entered as a root variable to look for any potential SNP-SNP interactions.
The results from the SNP-SNP analysis are shown in Table 8.9, for both splitting
rs2481952 by combining CC and CT and for combining TT and CT, thus representing
the presence of a C allele and a T allele respectively.
Table 8.9 SNPs with a Potential Interaction with rs2481952




rs4779584 0.35 (0.18) 2.77 x 10-3T allele
rs2481952 * rs50871 0.41 (0.19) 3.28 x 10-2
C allele rs4464148 -0.30 (0.10) 4.44 x 10-3
Once rs2481952 was removed from the analysis, the MTM returned the results listed
in Tables 8.10 and 8.11 and these were classified by strength of evidence, as
described in Section 6.4. At this stage the strongest evidence of an interaction is
represented by the identification of the interaction effect with a p-value below 0.01,
followed by the identification of the potential interacting effect below 0.01. Those
identified as interaction effects are considered to have stronger evidence of interaction
than when the SNP is identified independently but for only one environmental
variable. Following this brief classification, biological plausibility and similar
findings in other work are then assessed.
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rs4464148 -0.35 (0.10) 4.79 x 10-4
rs4464148 * NSAIDs 0.69 (0.24) 6.27 x 10-3
StrongNSAIDs
rs1799977*NSAIDs 0.72 (0.22) 1.35 x 10-3 Strong
Smoking rs4086116*smoking 0.72 (0.21) 7.34 x 10-4 Strong
rs50871 0.41 (0.13) 1.32 x 10-3Exercise
rs50871*exercise -0.46 (0.17) 7.69 x 10-3
Strong
BMI overweight rs10318 0.77 (0.34) 2.54 x 10-2 Weak




Table 8.11 MTM Results for Dietary Variables Once rs2481952 Removed







rs706716 5.02 (1.65) 2.31 x 10-3Folic Acid (ug)
rs706716 * Folic Acid -0.86 (0.28) 2.50 x 10-3
Strong
rs706716 2.92 (1.13) 9.49 x 10-3Biotin (ug)
rs706716 * Biotin -0.74 (0.29) 1.03 x 10-2
Strong
rs4148325 7.87 (3.36) 1.92 x 10-2Energy (kJ) -
Females rs4148325*energy -0.84 (0.36) 2.15 x 10-2
Strong/
Intermediate †
rs4148325 1.76 (0.78) 2.41 x 10-2Niacin (mg)
rs4148325*Niacin -0.49 (0.24) 3.92 x 10-2
Intermediate
rs10733118 -1.63 (0.76) 3.14 x 10-2Retinol (ug)
rs10733118*Retinol 0.25 (0.12) 3.70 x 10-2
Intermediate
Riboflavin (mg) rs6761246 0.54 (0.20) 6.24 x 10-3 Intermediate
Thiamine (mg) rs6761246 0.46 (0.18) 9.22 x 10-3 Intermediate
Vitamin B6 (mg) rs12988520 0.59 (0.25) 2.02 x 10-2 Weak










† Considering the smaller sample size, the less significant p-value does not necessarily
represent less evidence of an interaction
8.4.2 Summary of Results
A possible main effect was identified for one SNP, rs2481952 within the gene CDX2,
which may also have been involved with SNP-SNP interactions. NSAIDs had a
potential interaction effect with rs4464148 (within SMAD7) and rs199977 (within
MLH1), with SMAD7 also having a potential relationship with alcohol. There was a
cluster of effects, both independent and interactions, identified on the gene UGT1A6,
including possible interactions with vitamin B6, riboflavin, thiamine, niacin and
female energy intake. With respect to smoking, which itself was not significantly
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associated with CRC case status, there was a potential interaction with rs4086116,
without the equivalent SNP having an independent effect. rs4086116 is found in the
genetic region coding for CYP2C9. Both biotin and folic acid identified rs706716, on
PIK3R1, as having an independent effect and as an interacting variable, suggestive of
a marginal genotype effect modified by the dietary variable. The two SNPs within
GRAC1/GREM1, rs4779584 and rs10318, were identified by rs2481952 and being
overweight respectively. Similarly, the models identified an effect of rs50871 within
XPD, as a main effect, interacting with exercise and interacting with rs2481952.
Results that were only borderline significant included retinol and rs10733118 (within
MTR), the latter as both an independent effect and as a component of the relevant
interaction. Alcohol consumption had a borderline interaction with rs12953717,
which is also found in the coding region for SMAD7.
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8.5 Discussion of Results
It is worth noting that the p-values given in the results are purely in context and not to
be considered conclusive, given the number of pre-selection stages inherent in the
method. A p-value that would normally be considered highly significant is used in the
MTM results as contributing towards evidence there might be an interacting effect
suitable for further study.
CDX 2
The SNP consistently found to have an independent main effect (rs2481952) is
located in the genetic region coding for the intestine restricted transcription factor
caudaltype homeobox2 (CDX2) gene. The CDX2 gene, as other CDX genes, has
homologues across a wide range of species, indicating that it has been evolutionarily
conserved. The CDX genes play a crucial role in the intestinal tract development,
differentiation and maintenance 501. Research has shown that many of the genes
necessary for normal development also have important roles in the process of
carcinogenesis 502; this is due, in part, to the similarities in cell growth and
reproduction in the two processes.
Regarding the role of CDX2 in CRC, there have been a number of different proposed
mechanisms: including effects on the Wnt pathway, an APC target, the Vitamin D
pathway, and a possible target for inactivating mutations in MMR genes 356.
The earliest studies of this role were based on the levels of CDX2 expression, finding
that the expression levels were lower in adenomatous polyps and cancers compared to
normal mucosa, negatively correlating with the degree of dysplasia found 503.
Interestingly, CDX2 expression was absent in most colonic adenocarcinomas, except
for a subset of colon cancer with high levels of microsatellite instability. CDX2
expression has been found in other intestinal tumours and it has been suggested as a
marker in the differential diagnosis of primary versus metastatic adenocarcinomas
with unknown origins elsewhere is the body 504. Similarly, such expression could
reflect the metastatic condition of the CRC patients 505.
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However, the effect on CRC risk and biological role for this gene are not yet well
documented. There are numerous hypotheses including: APC/beta-catenin signalling,
Wnt pathway, Vitamin D pathway, microsatellite instability, relationship with
inflammatory bowel disease (IBD) and insulin production. However, recent research
suggests that CDX2 has a role in sporadic CRC, but is unrelated to any inflammatory
influences 506. The majority of associations assume that CDX2 has a role in the
transcription of other genes, including the VDR gene 507. CDX2 has been found to
directly regulate the Multidrug Resistance 1 (MDR1) gene by binding to regions in
the promoter region 501. Interestingly, one study found co-occupancy of CDX2 and
TCF4 across short genomic regions and evidence that implicates CDX2 in directly
binding intestinal cells 508. One of these regions spans the SNP rs6983267, within the
MYC enhancer region, which is the SNP most often associated with CRC risk.
The other SNPs associated with rs2481952 identified as SNP-SNP interactions were:
rs4779584, which is on the same gene as the SNP found to interact with being
overweight (rs10318); rs50871, which was also found to potentially interact with
exercise; and rs4464148, which was also found during the NSAIDs analysis. The
latter two may indicate either a complex association pathway or simply an increased
risk, occurring by chance, for these two SNPs. The first SNP, however, along with
having the most significant effect, is on the same region as another associated SNP
(rs10318) and might therefore indicate a real SNP-SNP-overweight relationship.
However, there is not enough evidence to generate a specific hypothesis in the role of
CDX2 in CRC other than to keep these potential interactions in mind during further
study.
SMAD 7 and NSAIDs
An interesting finding was that alcohol, NSAIDs and the main gene effect were all
identified with SNPs in the SMAD7 (mothers against decapentaplegic homologue 7)
region of chromosome 18, a gene involved in inflammation and the modification of
both transforming growth factor β (TGF-β) and Wnt signalling pathways. The
association between NSAIDs and CRC risk was particularly strong for those with the
CC genotype at rs4464148, a significance level of 1.87 x10-3, which is extremely high
given the sample size of only 116 people. The cases were significantly less likely to
have taken an NSAID regularly, only 3/52 having done so, compared to 18/64 in the
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control group. The heterozygotes had a slightly smaller and less significant
association (p-value of 1.02 x10-2) and the people homozygous for the TT allele had
no association at all between NSAID intake and CRC risk. This apparent dose
response relationship suggests a co-dominant inheritance model and increases the
likelihood that these results have an underlying biological mechanism.
SMAD7 is a gene which has often been identified as having a relationship with
colorectal cancer, although usually associated with colitis 509. All three SMAD7 SNPs
included in this study have been identified in a previous study as being associated
with adenomas and cancers 480, with similar results being found again, for two for the
three SNPs, in a later study 510. Another study found similar effects but restricted to
women, which could be associated with the different rates of inflammatory disease
between the genders 511. This analysis identified rs4464148 as having both a main
effect and an interaction with NSAIDs, which is similar to findings in another study
where rs4939827 was found to have different risk estimates based on stratification by
NSAID status 509.
There are other roles of SMAD7, potentially associated with CRC, which have been
studied in other biological areas of research, particularly regarding its role in
inflammation. SMAD7 promotes the anti-inflammatory action of the TGF-β pathway
512, by binding to the receptor complexes, thus blocking the downstream signalling
events. The deficiency of TGF-β has been found to lead to increased inflammation 513.
SMAD7 has also been associated with the progression of CRC, with SMAD7
amplification being a selected event during progression of colorectal tumors 514.
The rs1799977 SNP did not demonstrate a main effect but did appear to contribute to
a significant interaction with NSAID use. rs1799977 is found in the β-catenin gene
(CTNNB1) which is an activating compound for the Wnt pathway 515. This SNP has
been previously identified as having a low level, but significant, effect on CRC risk
516 and is also associated with breast and prostate cancers. It is found in MLH1, the
mutations of which are among the most frequent causes of Hereditary Non-Polyposis
Colon Cancer (HNPCC) 517.
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Overall, the role that NSAIDs play in reducing colorectal cancer risk is likely to be
associated with the inflammation, through modification of either the TGF-β or Wnt
pathways. This is both biologically plausible and repeatedly found throughout the
literature. The results of this study combined with the results from previous work
suggest that the hypothesis of NSAIDs interacting with SMAD7 or CTNNB1 is the
most likely and a good area for further study.
UGT1A6 and B vitamins
The SNPs that were implicated in possible interactions with Riboflavin/vitamin B2
and Thiamine/vitamin B1 (rs6761246), Niacin/vitamin B3 (rs4148325), and vitamin
B6 (rs12988520) are found in the coding region for the same gene:
Uridinediphosphate Glucuronosyl Transferase 1A6 (UGT1A6). This gene is more
normally associated with the protective effects of NSAIDs, particularly aspirin 420.
However such a cluster of results for the B vitamins all on the same gene does suggest
a potential area of interest for new work.
A study comparing micronutrient intake with five cancers, including CRC, in women
observed no association between individual B vitamins and CRC 518. A different study
found that increased plasma concentrations of both vitamin B6 and Riboflavin were
associated with decreased CRC risk 519. However, this study found no interactions
between genetic polymorphisms and B vitamins. The gene MTHFR has been found to
interact, in a preventative manner against CRC, with high levels of folate and vitamin
B6 520. This was not replicated in this study but does suggest a possible, if not yet
fully understood, protective association with high levels of B vitamins.
The SNP that may interact with niacin (rs4148325) was also identified as a potential
interacting variable for female energy intake. The same SNP was also identified for
female energy intake, both at fairly low levels of significance, which suggests any
results should be treated with caution and may be simply be an artefact of the data or
a very low significance level main effect. It is also possible that UGT1A6 is an
important gene with strong variations in risk based on SNP combinations. However,
the lack of corroborating work and currently understood biological mechanism make
it difficult to draw any conclusions from these results.
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CYP2C9 and Smoking
There is a possible interaction, with a highly significant effect, between smoking and
rs4086116, which is found in the gene CYP2C9. No main effect was found for the
SNP, and neither was smoking associated with CRC in this study, suggesting an
interaction model where neither factor has a main effect. A more detailed examination
of the results shows that the subgroup that smokes has a very significant association
between rs4086116 and CRC, whereas the non smokers have no association.
A previous study found that the odds of CRC decreased as the level of the CYP2C9
enzyme decreased and a different SNP variant was found to be associated with
decreased CRC risk but increased polyp risk 521. However, other studies have found
no evidence of a relationship between genetic variations in CYP2C9 and tobacco-
related cancers. Kaur-Knudsen et al, did not detect any association between CYP2C9
genotype and CRC 522, and previous research into an interaction found that CYP2C9
activity was not affected by smoking 523.
As CYP2C9 is involved in the bioactivation and detoxification of polycyclic aromatic
hydrocarbons (PAHs) derived from tobacco smoke, the interaction hypothesis is
biologically plausible. There have been studies analysing the different amino acid
change in CYP2C9 in relation to smoking status, but only identifying main effects for
both variables 524. It is possible that the variation in smoke exposure in the different
studies may be confounding the ability to identify the effect of CYP2C9. The possible
interaction between this gene and smoking should be investigated further, both
biologically and statistically.
PIK3R1, Folic Acid and Biotin
The phosphoinositide-3 kinase (PI3K) pathway is involved in cancer cell growth,
survival and resistance to chemotherapeutic agents 525. The results from this study
show a main effect of PIK3R1, a gene on the PI3K pathway, associated with an
increase in CRC risk. However, when this SNP (rs706716) interacted with folate or
biotin, the risk decreased significantly. As folic acid/ folate are involved in DNA
synthesis and methylation and a known target for chemotherapy, this result should not
be dismissed. However, there is no direct evidence of a relationship between folate
and this SNP in currently available research.
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GREM1 and Obesity
GREM1 (gremlin 1), also called CRAC1 or HMPS, was found to have a potential
interaction with being overweight and CRC status. The effect size was relatively large
but not particularly statistically significant. There has been research suggesting that
GREM1 is an important candidate gene for Total Body Lean Mass (TBLM) 157 and
therefore such an association is not entirely implausible. Although the result is not
enough to be conclusive, in this case, there could be scope for further research on
GREM1 within CRC and obesity research. The other marker SNP on GREM1
(rs4779584) was found to potentially interact with the main SNP identified earlier, on
CDX2.
XPD and Exercise
One SNP on XPD, rs50871, was identified as having an independent effect with
increased CRC risk, decreased by an interacting effect with increased exercise. Those
with the CC genotype have a negative association between CRC and exercise with a
p-value of 7.13 x10-3, which is surprisingly strong given the small sample size (297
people with CC genotype). Such an effect was not replicated for the other genotypes.
XPD (xeroderma pigmentosum complementary group D) is a DNA repair gene, also
known as ERCC2 (excision repair cross-complementing rodent repair deficiency,
complementation group 2). This has previously been associated with an increase in
CRC relapse 526 and a target for chemotherapeutic agents 527, and a potential modifier
of alcohol based risk 498. The association between alcohol and CRC only applies for
the carriers of a particular codon, that would result from the amino acid change to the
CC genotype, the same subgroup as this study found as potentially interacting with
exercise. The similarity in mechanisms suggests that the CC genotype, or the Glu/Glu
codon confers increased risk, a risk which may in some way be modified by lifestyle
factors.
Borderline Results
The possible main and interaction effect of rs10733118 with retinol, vitamin A, is
only borderline significant. rs10733118 is found in MTR (Methionine Synthase) a
gene involved in folate metabolism.  However, further investigation showed that both
the homozygous genotypes had no significant difference for retinol consumption
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between cases and controls, with the heterozygous having only a borderline
difference. This is not suggestive of a real effect with a realistic inheritance model and
therefore is quite likely to be a false positive result.
Pantothenic Acid identified a mildly significant main effect for rs12988520, on
MMP2. The low level of significance and the lack of prior evidence and a biologically
plausible hypothesis suggest this is likely to be a false positive result.
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8.6 Summary
From the perspective of the MTM methodology, there are a number of promising
findings from the analysis of the SOCCS data, primarily the ease with which the
method could be applied and the low false positive rate. Although, obviously, it is not
possible to determine exactly which are true or false positive results, the number of
total results and the consistency of results suggest that the false positive rate is lower
than for the simulated studies. This can be explained by the lower levels of statistical
noise, especially when there would be an association between variables but they were
simulated independently, but the results were better than were expected.
A number of the results are candidates for future work, many having biological
plausibility or consistency of findings. There are too many variables, and too few
events per variable, to allow a direct comparison of the results that may be gained
through entering all the potential interaction into logistic regression for comparison.
However, this use of regression following selection is useful in giving a quantitative
estimate of significance, but further statistical research will be required to dictate the





9.1 Conclusions on Research Question
The central tenet of this thesis is that enabling the identification of gene-environment
interactions will expand and complement current epidemiological research on the
aetiology of common complex disease. The research question has had to keep pace
with other scientific advances, especially the increased technology and availability of
data, with such advances moving much more quickly than development of
methodological and statistical approaches required for such analysis.
The Mixed Tree Method takes a first step in resolving this problem, with more
success than comparable methods. Features that suggest wide applicability of MTM
include a lower computational burden and the ability to handle different formats of
data than other current methodolgies. MTM also compared favourably in terms of
successful gene-environment interaction identification for the majority of data models
investigated. Although future work is required to determine the success on GWAS,
the results from the MTM are promising for larger numbers of variables. Even if not
fully applicable in the current format, providing evidence towards a ranking based
approach to results in place of significance or estimation, for large datasets, may be a
useful outcome.
9.1.1 Literature Review
The first aim of the thesis was to assess the methods currently used to identify gene-
environment interactions. Reviewing the literature identified a number of methods
with different strengths and weaknesses. A number of these methods had already been
combined with other algorithms or extended to try and handle greater number of
variables, with differing success. However, tree based methods cover a range of
techniques, easily combined with one another and with very little prior research
looking at interactions. The review selected other analytical approaches that could be
used as a comparison for any new method developed and a potential niche for method
development identified.
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9.1.2 Development of Novel Method
The second aim was the development of a novel method. There is no method
currently available that treats the genetic variables and environmental risks in
different, or weighted, ways to accommodate the differences in their behaviour and
effect sizes. Along with this feature, the specific steps of the method were assessed
through small simulation studies in order to maximise results in the later work. This
stage was also critical for ensuring all the written code was doing exactly as intended
at each step.
9.1.3 Evaluation of Method
The third aim was to adapt the method to different data and evaluate the success of the
method on data under different risk models. In essence there are four areas that need
to be considered for using the MTM, analysing the results and applying any results to
the general population.
(i) Data Input – Are the data used in the analysis appropriate, complete
and accurate?
(ii) Study Designs – For which study designs is this an appropriate
analytical tool?
(iii) Underlying Data Structure – which data characteristics have the
greatest power for interaction identification?
(iv) Application – How well can any results be interpreted and applied to
the general population?
The strength and limitations of this method, with respect to these four aspects are
considered below.
Data Inputs
As statistical analysis is trying to identify particular patterns and effects within the
dataset, any inaccuracies or missing data will have detrimental effects, if analysis is
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possible at all. It is therefore necessary to run some preliminary tests on the data,
remove outliers or variables with large volumes of missing data. If SNP choice is
available, then selection of the allele frequencies most suitable to the potential
inheritance model is essential. Missing data should be well characterised and any
imputations or removals dictated by these features on a case by case basis.
With regards to variable type, environmental variables can be binary, categorical,
ranked or continuous. However binary groups that are very different in size could lead
to a number of problems when the trees are generated and adaptations should be made
to minimise these problems. The majority of variables under investigation were
continuous and therefore the grouping was done by a data driven split, calculated by
the partitioning step. Therefore it is possible to adjust the parameters so that the loss
of information from different group sizes is minimised.
As an environmental exposure rate of 50% is unrealistic, such a decision on
parameters would need to take into account the sample size and the potential loss of
information before deciding how far from 50:50 the grouping could afford to be.
Adaptation was achieved straighforwardly by incorporating simple parameters into
the code to define the data type in advance and treat it accordingly.  Further details of
these changes can be found in Chapter 5. It should be remembered, however, that
prior to analysis it is necessary to define the variable type; binary, categorical, ordinal
or continuous, for each of the environmental variables, as the partitioning step handles
them slightly differently.
One further consideration regarding the quality of data is the SNP selection stage of
any such analysis. As the genes and SNPs selected for this study had all previously
been associated with CRC, there is ascertainment bias present and previously
undiscovered SNPs are less likely to be included in such analysis. However, striking a
balance between ascertainment bias of a SNP panel and the false positive rate for
large numbers of variables is not a problem specific to this method or analysis. In fact,
as this method is more easily comparable to current methodologies that analyse data
with small variable to case ratios, as oppose to GWAS, the results of analyses using
large numbers of variables are reassuring.
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Study Designs
Although designed and tested exclusively on case-control data, there is no reason that,
as long as the case control ratio is not too large, the method could not be used on
cohort data, especially in cases of nested case control studies. As genetic data do not
change over the life course, assigning a retrospective genetic dimension to a previous
cohort study would also be suitable. Although epigenetics would be a natural home to
studies of gene-environmenta interactions, the data gathering is still in its infancy and
would require methodological adaptations.
Without further research it is impossible to gauge the effect of a founder population
on the success of the MTM. However, the SNPs coding for the same gene in the real
dataset did not tend to be identified together in any analysis despite an increased
likelihood that they would be inherited together in the family based controls.
Although in no way definitive, this is reassuring that common ancestry may not
provide an insurmountable obstacle for future work on such datasets.
Underlying Data Structure
The simulation studies had a combination of expected and surprising results. It was
understandable that the identification of a statistically significant association was
highest when the proportion that were exposed and unexposed were roughly
equivalent. In terms of SNP exposure, this equivalency was dictated by the allele
frequency and underlying inheritance model. For environmental variables the power
could sometimes be increased by re-grouping the variables. As would be expected, the
rate of identification increased with effect size and a real interaction effect was
identified more consistently across an increasingly stringent scale of significance
thresholds. For example, an effect with an Odds Ratio of 2 is detected, as either
interaction or SNP main effect, in 75% of cases.
It is debatable whether a factor that is on the causal pathway can be considered an
interaction at all. Assuming that it can be, the MTM shows very poor results at
detecting it. For all the other interaction models, the results are fairly promising, with
the slight differences in some way explainable by the data generation method in this
instance.
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However, the most unexpected and promising result is the relatively low false positive
rate, compared to the most equivalent methods, in the face of increasing SNP
numbers. However, the largest SNP panel simulated contained 300 SNPs, so the
boundaries of this advantage are yet to be fully determined, especially given that
GWAS may identify several hundred thousand SNPs. Although a small step in the
right direction, this result must be kept in context. It is possible that the more general
principal of ranking results against each other to select the most significant candidates
for further work may prove more valuable than the direct application of MTM itself.
Application
The results gained from MTM analysis cannot be directly applied to the general
population. As a data mining technique, even with a significance measuring final step,
any results provide a theoretical basis for further study and not a fully objective
measure of association. It would also be necessary to study data from studies not case-
control in design as the recruitment of such studies prevents them being wholly
representative of the wider population.
In theory, any data containing both environmental variables and a relatively large
sample of SNPs can be analysed using the MTM. As a data mining tool, it is more
appropriate to use this technique when there is little prior information. In situations
where a complex disease has been studied by different groups at the GWAS level,
MTM is a useful way of analysing the different resultant SNPs identified, as the final
stage of a meta-analysis. MTM gives more information than reducing the number of
identified SNPs by means of adjustment for multiple testing.
It is also useful in cases where a risk has been identified in an initial GWAS or case
control study, yet replication cannot reproduce the results. The MTM could be used
with any environmental variables that are markedly different between the populations
to add more information and possibly explain the differences.
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9.1.4 Comparative Methods
Current methodologies evaluated both from the literature and experimentally, have
different strengths and weaknesses. Having too many explanatory variables per
outcome event in regression is a well recognised problem 39, 104. In this particular
scenario under study, with large numbers of variables and unknown interactions,
logistic regression did not perform very well at identifying interactions. Using the
stepwise selection procedure in logistic regression improved the identification rate,
and proved to be the most successful comparable method, yet the false positive rate
continued to be prohibitively high. However, the quantitative nature of the regression
results, both for estimation of the associated risk and significance, provide a very
good summary method and way of identifying the most promising associations from a
smaller dataset. It is therefore a good last step following a parameter selection method
and was used as such in the mixed tree method.
The MDR and ORMDR approaches to identifying interactions were not fully
compatible with the data type in this study. The risk effects did not have absolute
penetrance and there were marginal effects present. The data had been simulated to
imitate an increase in risk, whereas the MDR method is most effective in situations
with complete penetrance.
9.1.5 Analysis of Real Data
Prior to the analysis of real data in chapter 8, there were two main unknown
questions: how the method would handle such data and how easy it would be to
interpret the results? Compared to the simulated data, the overall identification rate
for real data was lower than the expected false positive rate, probably as a result of
decreased statistical noise and suggesting a relatively low false positive rate. One
drawback of the simulation was the presumed independence and separate simulation
of each variable, when in real data there are underlying associations between the
variables. For example, in the simulation it was entirely possible for one person to eat
the most of one nutrient and the least of another, whereas the real data more likely
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represents a spectrum of unhealthy-healthy, with many of the similar risk factors
forming similar population groupings.
The results showed a very likely independent main effect of rs2481952, interpretable
by the importance across a number of environmental variables. Had one of the
variables shown a strong interaction effect with this variable then it may have proven
to be an interaction effect, with the perceived main effect a artefact of the interaction
model. However in this case, it was clearly a main effect, a result that corresponds to
similar findings throughout the literature, and warrants further analysis.
A number of the identified SNPs showed independent and interaction effects, in some
cases with effect estimates in opposite directions, suggesting an increase in risk
associated with the SNP but reduced by interaction with an environmental variable.
The fact that such information was so easily interpretable is reassuring for further
analysis using this approach.
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9.2 Summary
In general, given the number of variables under consideration, in order for a
traditional method to maintain power, extremely large sample sizes are required,
which are expensive and time consuming. The more complex methods also tend to be
very computationally intensive and take time to both set up and run analyses. Finally,
the applicability of results from the study to the general population is a problem often
encountered in eidemiology. As well as the inherent problems in sample selection
prior to a study, the figures and estimated produced by many methods does not easily
convert to an interpretable relationship or risk to the general population.
The importance of identifying gene-environment interactions is becoming more
relevant as different study populations yield varying results from genome wide
association studies (GWAS). More and more potential results are being produced;
some which will turn out to be false, some which will stand up to repeated analysis
and some which need an understanding of the environmental contex to be meaningful.
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9.3 Public Health Implications
Many scientific endeavours are concerned solely with the increase in knowledge of a
particular area, whilst refusing to be drawn on the potential benefits from such
knowledge. However, epidemiological work, both conventional and genetic, usually
has a basis in improving or understanding ill health at a population level, even if the
target population is relatively small.
The benefits in identifying gene-environment interactions are likely to be most
obvious with regard to drug targets. Being able to classify a subgroup that responds
particularly well, or particularly badly, to a drug therapy informs future treatment
options and prescribing decisions. The other benefits include an increased
understanding of the disease and the ability to compare data with different findings to
assess if an underlying interaction effect could be confounding the results. Given that
NSAIDs are protective against CRC, yet can have other gastrointestinal side effects, it
is useful to be able to make a more specific risk estimate with a basis in personal
genetics and drug interactions, before advising daily NSAID intake.
Another area of research where MTM analysis may be fairly straightforward and
provide useful insights is the study of maternal effects. It is relatively easy to follow
up a woman during the nine months of gestation and there is the possibility of
interactions between environmental or lifestyle factors during pregnancy and the
genes of either the mother, or of the resultant offspring.
The identification of gene environment interactions will also help the general
understanding of complex, chronic medical conditions. There are already recognised
risks surrounding lifestyle and family history and the identification of specific risks is
simply a more detailed examination of these risks. The population impact of this
increased knowledge would be dependent on the specific findings, how applicable
they were to the general population, how easy any sort of intervention would be and a
whole host of other variables. In the case of colorectal cancer risk in Scotland, a
number of the identified genes were also risk factors for other cancers, so the
information gained has a wide reaching impact.
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One of the most useful applications of the MTM is for risk factors that are only found
in a proportion of the studies looking for them. Explaining the difference in terms of
interaction, where possible, would mean that conflicting results actually added
information to another study instead of negating its results.
This would be particularly pertinent given the large differences between the countries
and populations being used to assemble genetic databases. Current approaches either
study the within-population effects and then compare the results to see if they match
those found in other populations or combine the samples into a larger population,
where the effects of interaction may actually hide the real effects if not considered
properly. For example, in Asian populations the consumption of dairy products tends
to be lower which would mean a gene-interaction effect dependent on lactose would
not be found within such a population. Combining this population with a European
sample, not Asian in descent, would decrease the estimated Odds Ratio of the effect
of the gene, had it not already been found to interact. This meta-analysis would
effectively lose useful information. Entering such meta-analyses with the additional
hypothesis from an MTM analysis could alert researchers to these complications.
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9.4 Further Work
The results from different analyses of simulated data demonstrate the different
strengths and weaknesses of different approaches to the problem of gene-environment
interactions in large data sets. There are still areas where more work needs to be done
to gauge success under different conditions. There are some results which have
proved beyond the current capabilities of the MTM and there are analyses where the
MTM approach could prove useful.
Method Testing
In order to understand more fully both the uses and limitations of the MTM,
simulation studies could be undertaken to explore more complex underlying data
models, including relatedness between subjects, related variables and sequential
casual pathways (referred to earlier as Type A interactions). It would also be
interesting to create samples with a number of different interactions, some with the
same gene involved in different ways with different environmental variables. There is
increasing use of genotyping large numbers of people within founder populations, so
it is especially important to check the effects of relatedness on the MTM and adapt it
accordingly. Finally, studies containing a model of genetic heterogeneity would be an
interesting addition.
Other testing could include a simulation of larger scale, genome wide association
study to study the scalability of the MTM. This would require substantially greater
computational time, but is a necessary piece of work, considering the pace of
development in molecular genetics.
Potential Adaptations
The method is already fairly adaptable; however, a more detailed analysis of the
necessary significance thresholds would be beneficial. The issue of multiple testing is
a potential area of criticism, when analysing such large numbers of variables in a
single analysis. Although not problematic in the data mining steps of the analysis,
when making statistical estimates on the significance threshold of any findings, it
could be considered statistically invalid to use a threshold as high as 0.05. To confirm
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a more appropriate step, or an accurate threshold may require further work and
statistical development.
Potential Analyses
Ideally the next step would be to use the MTM on a similar dataset, for a different
complex disease. This might include Type 2 diabetes, or an autoimmune condition
which may have a genetic predisposition and an environmental trigger.
From the results on the real data, it would be particularly interesting to follow up the
findings on NSAIDs and the main SNP effect on risk of CRC. It would also be useful
to combine a number of the B vitamin results into a general measure of B vitamin
intake, and repeat the analysis. This would be particularly interesting as the majority
of analysis on dietary variables have been carried out in a univariate fashion.
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9.5 Conclusions
Gene environment interactions are an important part of understanding complex
disease, yet notoriously difficult to identify. The data type and characteristics of the
interaction itself can vary greatly and there are only a few statistical tools capable of
analysing even a few of these possibilities. The development of the mixed tree method
and development of the corresponding software package is a useful and effective way
to detect interactions between genetic and environmental risk factors for complex
disease. This method can be used to analyse interactions between any number of
environmental variables and up to 300 SNPs in populations of between 200 and 3000
people.
The Mixed Tree Method performed very well in particular circumstances and less
well in others. The most obvious examples of variation in performance were found
with the different underlying interaction models, but the variation across different
effect and sample sizes should also be a consideration in any further analysis. The
other results point to a general rule, that exposure of around 50% has the greatest
power for identifying interaction effects.
An important finding however, was the consistency of both the identification rate and
false positive rate as the number of SNPs increased. No other method has performed
as well on similar data. Stepwise regression was unable to handle an increasing
number of variables, even when the data was manipulated in a similar way to MTM
regarding the environmental variables. None of the other methods were directly
comparable. The handling and success of the real data analysis proved that the MTM
is able to cope with real data, in some ways better than the simulated data, and a small
number of potential interactions were identified for further analysis.
In summary, gene-environment interactions are an important part of the puzzle in
complex disease aetiology and the least studied. There is a need to develop methods
to identify interactions and none of the current methodologies are wholly appropriate.
The Mixed Tree Method provides a new way of approaching this analysis, a way that
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Summary of Script File for Data Generation





Creating a variable to translate SEM to sd where necessary
rootn<-sqrt(SampSize)
Restrict function, to remove unrealistic values
restrict <- function(vec, min, max) {
vec <- ifelse(vec <= max, vec, max)
vec <- ifelse(vec >= min, vec, min)}
Male and female, basic characteristics and those that differ by sex are simulated and
then combined along with the gender classification into a data frame. Simulations
then follow for shared characteristics (e.g. BMI) environmental variables and SNPs.
An example of a dietary variables, Vitamin D, is shown below.
FakeVitD<- round(rlnorm(SampSize, meanlog = 1.356,
sdlog = 0.653),digits=1)
Odds Ratio Calculator to Assign Risk:
Define the proportion in the risk groups and the proportion of cases in the sample
p_nsaids <- 0.6634
p_gene <- 0.652
p_int <- p_nsaids*p_gene # 'y'
p_cases <- 0.5  # 'z'
Quadratic solver
A <- OR - 1
B <- (1 - OR)*SampSize*p_int + (1 - OR)*SampSize*p_cases -
SampSize
C <- SampSize * SampSize * OR * p_int * p_cases
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Calculate square root of the "determinant", if determinant is negative, no real solution
sq_det <- sqrt(B*B - 4*A*C)
Define the solutions as more positive (a1) and less positive (a2), then choose the
correct solution (a3). The a, b, c and d refer to the cells of an OR contingency table
a1 <- (-B + sq_det) / (2*A)
a2 <- (-B - sq_det) / (2*A)
a3 <- ifelse(a1 > SampSize, a2, a1)
if (a3 < 0)
a <- round(a3)
b <- round(SampSize*p_int - a)
c <- round(SampSize*p_cases - a)
d <- round(SampSize - SampSize*p_int - c)
Assign the probability of each person being in each cell using the values for a, b, c
and d. In this example the genotypes CC and CT confer an increase in risk when the
person is not taking NSAIDs (n is NSAID intake).
CaseLabel <- c()




if ((n == 0) && (x == "CT" || x == "TT"))
{
CaseLabel <- rbind(CaseLabel,





sample(c("2", "1"),1,replace=T, prob=c((c/SampSize), d/SampSize)))
}
}
Finally, all the variables and the case-control status are combined into a single data
frame. A basic check is done to ensure the population have the desired OR.
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Appendix 4.2
Genes associated with cancer syndromes




rs2431512 G A 46 54
rs2431238 A G 30 70
rs454886 T C 64 36
APC
rs459552 A T 20 80
rs2286681 T G 59 41
rs12112229 G T 67 33
PMS2
rs2345060 A G 76 24
rs1234225 G A 63 37PTEN
rs1234214 G T 62 38
rs10887654 T C 70 30
rs1124482 A C 66 34
rs7922846 T A 75 25
BMPR1A
rs12765929 C A 70 30
rs10502913 C T 76 24SMAD4
rs8096092 G T 62 38
rs3764640 C A 80 20
rs7256801 A G 54 46
rs1978728 G A 63 37
STK11
rs2075608 G A 74 26
rs981959 C A 43 57
rs2017472 A G 49 51
rs759083 G C 58 42
rs6820303 C T 54 46
rs3020821 T C 48 52
rs3134889 A G 35 65
rs4864920 C A 80 20
KIT
rs1008658 A G 34 66
rs6850748 A C 79 21PDGFRA
rs7656613 A G 75 25
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Metabolic Gene Polymorphisms




rs3814309 A G 69 31GSTM3
rs1332018 C A 43 57
GSTP1 rs1695 T C 59 41
rs1476413 G A 69 31
rs1801131 A C 66 34
rs6541003 C T 45 55
rs1801133 C T 69 31
MTHFR
rs11121832 A G 28 72
rs10733118 A G 39 61
rs883396 C T 61 39
rs3768149 T C 56 44
MTR
rs12129440 C T 73 27
rs3776467 G A 22 78
rs326121 T C 75 25
rs326123 G A 37 63
rs1532268 C T 69 31
rs162031 T C 20 80
rs161871 A G 77 23
MTRR
rs10520873 T C 70 30
rs470215 A G 65 35
rs7125062 A G 73 27
rs2071232 A G 79 21
MMP1
rs470358 A G 39 61
rs17301608 G A 62 38
rs243845 C T 63 37
rs2287076 A G 54 46
rs11639960 T C 65 35
rs243836 C T 50 50
MMP2
rs7201 T G 55 45
MMP3 rs591058 A G 56 44
rs2156528 A C 80 20MMP7
rs10750646 C T 25 75
rs3918253 G A 44 56MMP9
rs17576 T C 64 36
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MMP13 rs478927 A G 29 71
rs706208 C T 60 40
rs2124458 A G 67 33
rs4920037 C T 77 23
rs234706 T C 66 34
CBS
rs2851391 A G 47 53
rs2410545 A G 36 64
rs13253389 T C 26 74
rs7003890 A G 48 52
NAT1
rs15561 T G 25 75
rs1390358 A G 63 37NAT2
rs1112005 G A 71 29
rs4767939 A G 80 20
rs2238151 T C 61 39
ALDH2
rs11066028 A C 67 33
rs706713 G A 76 24
rs7713645 T G 52 48
rs12652661 T C 70 30
rs251406 T C 30 70
rs173702 A G 60 40
rs4122269 A G 66 34
rs1823023 T C 38 62
rs173703 C T 79 21
rs706716 G A 74 26
rs13167294 T G 76 24
rs34309 C T 62 38
rs6876003 A G 60 40
rs3815701 T C 80 20
PIK3R1
rs3756668 C T 57 43
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Genes on the Wnt Pathway




rs9813198 T C 46 54CTNNB1
rs4135385 T C 78 22
rs736650 C T 74 26
rs618138 C T 80 20
rs647080 C T 62 38
PPP2R1B
rs4935790 A G 70 30
rs10883655 T C 51 49
rs4451650 C T 34 66
rs4436485 C T 63 37
BTRC
rs9419923 T C 79 21
rs603965 C T 49 51CYCLIN D1
rs649392 C T 41 59
rs3856557 C T 54 46C-MYC
rs37771888 A G 43 57
PS1 rs4213 A C 65 35
rs393521 A C 79 21
rs214249 A C 62 38
rs7200589 C T 74 26
rs214246 T C 54 46
rs8063821 G A 76 24
rs1981492 C T 58 42
rs11649255 A G 74 26
rs3916990 T C 67 33
rs9921222 G A 57 43
rs12719801 G A 70 30
rs370681 G A 44 56
rs2885415 C T 77 23
AXIN1
rs1805105 T C 39 61
rs7591 T A 44 56
rs11867414 A G 35 65
rs4074947 C T 75 25
rs2240308 C T 52 48
rs3923087 A G 27 73
AXIN2
rs3923086 T G 48 52
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rs4541111 G T 51 49
CDX2 rs2481952 G A 52 48
rs3739262 C T 73 27
rs16893344 G A 65 35
rs2977522 G A 59 41
rs2977533 C T 62 38
rs10100792 G A 73 27
rs2929946 T C 39 61
rs4330674 A G 35 65
rs6992383 G A 43 57
rs11774084 T C 58 42
rs6982341 T C 42 58
rs2929965 A G 42 58
rs2929967 G A 52 48
WISP1
rs3739261 A G 62 38
rs6130677 C T 78 22WISP2
rs1230348 T C 34 66
rs6130677 G A 49 51
rs4812858 A G 29 71
rs6094027 T C 42 58
WISP3
rs1061098 G A 65 35
MYH/MUTYH rs3219472 G A 76 24
rs3242 C T 68 32
rs11781990 C T 65 35
rs7843510 T C 58 42
rs6651363 C T 67 33
rs10106678 A G 50 50
rs9694405 C T 51 49
SFRP1
rs968428 T A 59 41
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Other genes with inflammatory or regulatory NSAID effects




rs1604144 G A 67 33
rs12988520 T G 41 59
rs7583278 G A 62 38
rs4663965 A G 55 45
rs4148324 A C 69 31
rs4148328 G A 61 39
UGT1A6
rs10929303 A G 21 79
rs7592624 C T 42 58
rs1604144 G A 67 33
rs6725478 G A 63 37
rs6431628 T C 54 46
rs4148324 A C 69 31
rs4148328 G A 61 39
UGT1A7
rs10929303 A G 21 79
rs2860905 C T 78 22
rs7089580 T A 76 24
rs4918766 C T 64 36
rs1856908 A C 36 64
CYP2C9
rs1934967 G A 76 24
rs5745752 G A 72 28
rs2040968 G A 23 77
HGF
rs5745616 G A 76 24
rs3024498 A G 71 29
rs3024496 T C 48 52
IL-10
rs3024490 T G 22 78
336
Appendix 5.1
Computation Intensity of Analysis
There were a number of hurdles in trying to run so many datasets, each so large in
nature, on a standard computer. The trouble came from saving 1000 datasets in the
short term memory and then trying to run any analysis on them. A number of different
approaches were tried:
1. To generate a single dataset, analyse it, save the results and clear the memory
of the data itself. In practice however this led to the datasets varying depending on
how often a random number generator (RNG) based application was used in the
method. The mixed tree method employs a random forest step, which meant that
when generating the second dataset, the random number generator was a few steps
ahead in sequence than it would be when simply using logistic regression to analyse
the results.
2. Adapt the first suggestion so that after a dataset is generated it is first analysed
using the mixed tree method, then logistic regression, then MDR, saving all the results
appropriately. However the difference in data format required for MDR and the
removal of the MDR function from the more recent version of R made this
impossible.
3. Using a UNIX machine, with compatible code for the simulations steps. This
however, turned out to take longer than the windows version to run comparable runs.
The following table shows the time taken to run the analysis by different number of
datasets and environmental variables. Figure 5.1x shows this relationship in graphical
form.
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Results when 1000 datasets had
been simulated and a selection run.








Similarly 1000 simulated. The faster








Noticeably slower to observe than








The first few variables, particularly
binary ones, were processed quicker
than later variables – showing strain
on the short term computer memory.
338





























Figure 5.1x Computational Intensity, time taken (mins)
There are three factors that influence how long a run takes: number of variables;
number of repetitions; and the number of datasets generated and being saved in the
short term memory of the computer. Once the false error rate has been established
there is no analytical advantage to running large number of variables alongside the
target variable for each run. As long as there is one variable with an effect and one
that doesn’t have a set effect with which to compare, then it is possible to gain a full




When using multiple set seeds, it is important to ensure that the numbers being
generated do not share any sort of common patterns 465. With the size of a number of
simulations exceeding the maximum possible with the available system memory, it
was necessary to divide the simulation into sections and run them separately. In order
to be able to repeat these simulations with other methods, set seeds were used and
recorded for each section. When the simulation was done in four parts, the set seeds
used were: 29, 17, 88 and 63; when two, only 29 and 17. For all other simulations, 29
was used as the set seed throughout.
To check for any potential patterns, each set seed was tasked with generating 100
random numbers between 1 and 10,000 to two decimal places. These numbers were
then plotted on a number of scatter plots, each comparing one set seed with another,
so six in all shown below as figures 6.1x1 – 6.1x6
As can be seen from the scatter plot, there were no repeating patterns across the set
seeds, so using them together will not detract from the random nature of the data
generation.
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Figure 6.1x1 Set seeds 29 and 17 Figure 6.1x2 Set seeds 29 and 88
Figure 6.1x3 Set seeds 29 and 63 Figure 6.1x4 Set seeds 17 and 88
Figure 6.1x5 Set seeds 17 and 63 Figure 6.1x6 Set seeds 88 and 63
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Appendix 6.2: Sample Size by Effect Size
Table 6.2x1 Percentage of Datasets Identifying Interaction at Different Effect Sizes, Sample Size 500
                      Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Effect Size 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5
Target Int
1.6 7.5 8.4 37.5 50.2 0.3 1.7 2.2 13.3 22.7 0.3 1.2 1.3 9.2 17.6 0.1 0.2 0.5 4.8 8.3
Target SNP 7.0 33.5 28.1 86.9 95.1 2.7 19.4 21.1 72.1 85.9 1.9 14.2 18.2 66.7 82.8 0.7 6.6 11.6 51.7 71.9
Neither Int
or SNP
92.8 66.2 71.9 12.8 4.7 97.1 80.0 78.8 27.8 13.9 97.9 85.3 81.7 33.1 17.0 99.2 93.3 88.3 48.1
28.0
Other Int 30.8 25.2 26.9 22.0 21.5 6.3 4.6 4.7 4.7 4.6 3.3 3.0 3.1 2.8 2.6 0.8 0.9 1.1 0.5 0.7
Other SNP 32.6 23.9 8.2 5.5 3.8 9.6 6.3 1.3 1.7 1.2 4.9 3.9 0.9 1.0 0.5 0.9 0.9 0 0.2 0.1
Splitting on environmental variable with no effect (smoking)
Target SNP 2.8 11.9 10.0 47.7 62.0 1.1 5.7 4.4 29.4 41.9 0.7 3.5 3.4 24.0 35.5 0.2 1.1 2.2 12.7 21.7
Target SNP
and smoking
0.7 1.1 0.5 1.4 1.2 0.1 0.1 0 0.3 0.3 0.1 0.1 0 0.1 0.1 0.1 0 0 0 0
Other Int 27.1 25.9 28.5 25.0 22.2 6.3 5.9 3.0 3.7 3.7 3.8 3.8 2.2 3.3 2.7 0.7 1.0 0.5 1.1 0.8
Other SNP 33.9 29.4 13.9 20.0 17.6 10.2 9.4 2.1 5.5 5.5 5.8 5.4 1.7 4.0 3.6 1.3 1.8 0.3 1.1 0.9
342
Table 6.2x2 Percentage of Datasets Identifying Interaction at Different Effect Sizes, Sample Size 2000
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Effect Size 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5 1.5 2.0 2.5 3.0 3.5
Target Int
16.4 64.0 90.1 98.8 99.9 4.9 36.6 72.9 92.1 98.5 3.7 30.4 65.2 88.1 97.8 1.4 19.8 49.4 78.4 93.4
Target SNP 53.8 99.1 100 100 100 35.6 95.6 100 100 100 29.3 94.0 99.9 100 100 18.0 88.9 99.8 100 100
Neither Int
or SNP
45.5 0.9 0 0 0 63.8 4.3 0 0 0 70.1 5.8 0.1 0 0 81.6 10.9 0.1 0 0
Other Int 23.1 22.1 20.7 21.0 21.5 6.7 5.8 5.2 6.0 5.3 4.5 3.5 3.4 3.8 3.3 1.2 1.2 1.1 1.2 0.8
Other SNP 11.9 2.1 1.9 2.2 1.7 4.3 0.2 0.2 0.5 0.2 2.5 0.1 0 0.3 0.1 1.0 0 0 0 0.1
Splitting on environmental variable with no effect (smoking)
Target SNP 23.8 81.0 97.4 99.8 100 11.7 63.1 91.7 98.3 99.9 8.5 57.1 88.2 97.8 99.9 3.4 41.2 80.1 95.2 99.8
Target SNP
and smoking
1.4 1.6 1.7 1.5 1.6 0.1 0.1 0.1 0.3 0.5 0 0 0 0.2 0.2 0 0 0 0 0
Other Int 24.6 24.5 25.4 26.1 27.1 5.6 5.0 4.8 6.4 5.6 3.4 3.6 3.2 3.3 3.1 1.2 1.3 0.9 0.9 1.1
Other SNP 24.0 13.5 17.7 21.5 24.9 6.1 3.3 3.7 5.4 6.2 3.6 1.7 2.0 2.8 3.6 1.4 0.5 0.8 0.4 0.9
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Appendix 6.3: Interaction Type
Table 6.3x1 Percentage of Datasets Identifying Interaction for Interaction Model A
               Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
0 0.2 0.3 0.2 0 0 0 0 0.1 0 0 0 0 0 0 0 0 0 0 0
Target SNP 0 0.1 0.4 0.3 0 0 0 0.1 0 0 0 0 0 0 0 0 0 0 0 0
Neither Int or
SNP 100 100 99.5 99.7 100 100 100 99.9 100 100 100 100 100 100 100 100 100 100 100 100
Other Int 26.0 29.8 30.7 30.9 30.3 5.2 5.8 5.4 7.2 7.3 3.1 5.2 3.2 3.9 4.7 1.2 1.3 1.2 0.8 1.9
Other SNP 34.9 38.1 38.3 37.8 36.6 8.7 9.0 9.5 9.3 10.5 4.5 5.7 4.1 4.3 5.7 0.9 1.3 1.1 0.7 1.5
Splitting on environmental variable with no effect (smoking)
Target SNP 0.7 3.5 4.5 0.3 0 0.7 2.3 1.7 0.1 0 0.7 1.9 1.4 0.1 0 0.7 1.0 0.5 0 0
Target SNP
and smoking
0.2 0.5 1.0 0 0.1 0.1 0.1 0.2 0 0 0.1 0.1 0.1 0 0 0.1 0 0 0 0
Other Int 30.0 30.0 28.3 28.2 30.8 6.3 7.5 5.1 5.8 7.1 3.7 4.5 3.0 3.0 4.0 1.0 0.8 0.4 0.7 0.9
Other SNP 33.5 34.3 31.1 34.5 31.6 9.2 10.1 10.8 8.9 8.2 6.1 6.3 6.9 4.8 4.7 1.4 1.9 1.6 0.9 0.8
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Table 6.3x2 Percentage of Datasets Identifying Interaction for Interaction Model B
                          Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
11.2 80.8 61.8 8.6 0.2 6.8 59.3 36.3 1.6 0.1 5.6 52.1 30.0 1.0 0 4.0 33.7 18.2 0.4 0
Target SNP 13.2 94.8 96.6 29.0 0.7 13.1 93.9 89.8 14.3 0.2 12.9 93.3 86.4 10.6 0.2 12.0 90.0 76.1 4.7 0
Neither Int or
SNP 86.8 5.2 3.4 70.1 99.1 86.9 6.0 9.9 85.3 99.7 87.1 6.6 13.3 88.9 99.8 88.0 9.9 23.7 95.1 100
Other Int 26.1 17.0 18.9 24.8 27.1 6.0 3.7 3.6 5.1 5.3 3.6 1.8 2.4 3.2 2.7 0.9 0.5 0.5 0.6 0.5
Other SNP 31.7 3.5 3.4 21.2 37.9 10.4 0.8 0.9 6.4 10.6 6.5 0.6 0.6 3.6 5.3 1.6 0.2 0.2 1.3 1.7
Splitting on environmental variable with no effect (smoking)
Target SNP 0.8 48.9 63.0 8.4 0.2 0.7 42.2 42.9 3.2 0.2 0.7 37.5 35.9 2.2 0.2 0.7 26.7 22.8 1.1 0.1
Target SNP
and smoking
0.1 0.9 1.6 1.0 0.3 0 0.1 0.3 0.2 0.2 0 0.1 0.2 0.1 0.1 0 0.1 0 0.1 0
Other Int 30.4 25.7 28.3 28.0 30.1 7.6 5.6 5.9 6.8 5.2 4.5 2.8 3.2 3.6 2.7 0.6 0.5 0.8 0.8 0.8
Other SNP 34.1 21.9 18.3 32.3 35.1 9.3 6.7 5.6 8.4 9.3 5.8 3.6 3.9 5.0 5.5 0.9 0.6 1.1 1.1 0.9
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Table 6.3x3 Percentage of Datasets Identifying Interaction for Interaction Model C
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
11.6 83.3 65.7 11.2 0.1 8.1 61.8 37.4 3.1 0 6.1 53.1 30.2 2.2 0 3.2 37.3 17.1 0.4 0
Target SNP 13.9 98.6 98.2 35.7 1.0 13.8 98.5 93.8 15.4 0.6 13.7 98.0 91.7 12.5 0.4 13.6 95.6 80.5 6.7 0.4
Neither Int or
SNP 86.1 1.4 1.6 62.6 98.9 86.1 1.5 6.0 83.8 99.4 86.2 2.0 8.2 87.0 99.6 86.3 4.3 19.5 93.3 99.6
Other Int 17.7 11.9 12.7 10.6 17.0 3.3 2.3 2.1 1.6 3.1 2.4 1.2 1.2 0.7 1.9 0.8 0.4 0.2 0.1 0.4
Other SNP 18.0 1.4 2.7 10.4 20.5 3.4 0 0.9 2.1 3.4 1.6 0 0.6 1.2 2.0 0.4 0 0 0.3 0.5
Splitting on environmental variable with no effect (smoking)
Target SNP 1.2 64.8 73.2 11.6 0.1 1.0 56.8 49.3 4.6 0.1 0.9 53.2 41.2 3.5 0.1 0.7 43.0 27.2 1.5 0
Target SNP
and smoking
0.1 0.5 1.1 0.9 0.4 0 0 0 0 0.2 0 0 0 0 0.1 0 0 0 0 0.1
Other Int 19.3 18.0 20.0 18.3 19.8 3.5 4.0 2.6 3.4 2.9 2.3 1.7 1.1 1.5 2.0 0.4 0.4 0.2 0.1 0.1
Other SNP 21.2 12.1 10.9 15.3 18.6 3.2 3.2 2.7 3.4 3.9 1.8 1.8 1.0 1.6 1.8 0.4 0.4 0.2 0.5 0.4
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Table 6.3x4 Percentage of Datasets Identifying Interaction for Interaction Model E
                                                                                                             Significance Threshold
0.01 0.001 0.0005 0.0001
Splitting on Target Environmental Variable (NSAIDs)
Allele
frequency
0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9 0.1 0.25 0.5 0.75 0.9
Target Int
12.1 59.2 42.9 5.7 0 7.2 33.6 19.0 0.6 0 5.5 27.2 14.6 0.4 0 2.8 15.5 7.1 0.1 0
Target SNP 15.8 89.9 90.6 23.5 0 15.8 87.9 77.3 10.7 0 15.7 86.0 72.2 7.7 0 14.9 78.8 57.9 2.9 0
Neither Int or
SNP 84.2 10.1 9.3 75.8 100 84.2 12.1 22.4 89.2 100 84.3 14.0 27.4 92.3 100 85.1 21.1 42.0 97.1 100
Other Int 28.5 20.1 19.6 23.6 28.5 5.7 4.8 4.4 5.5 3.3 3.3 2.6 3.0 2.4 2.8 0.6 0.7 0.5 0.8 0.5
Other SNP 29.8 4.3 4.8 21.8 38.0 8.1 1.2 1.2 7.0 10.0 4.8 1.0 0.8 4.4 6.4 1.2 0.3 0 1.2 1.6
Splitting on environmental variable with no effect (smoking)
Target SNP 2.0 47.2 35.1 7.1 0.2 1.9 39.2 33.7 2.5 0.2 1.8 35.3 27.4 1.6 0.2 1.5 24.3 14.4 0.7 0.2
Target SNP
and smoking
0.2 1.6 1.3 0.6 0.2 0 0.3 0.3 0.2 0 0 0.1 0.2 0.2 0 0 0 0.1 0.1 0
Other Int 30.0 25.2 25.3 29.0 28.6 6.5 5.3 6.0 5.9 6.1 3.8 2.4 3.3 3.1 4.2 0.8 0.5 1.0 0.9 1.1
Other SNP 31.9 22.1 17.2 31.5 37.4 8.0 6.6 5.1 3.7 8.1 4.9 3.2 2.9 2.1 5.0 0.8 0.5 1.0 1.0 1.0
